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Abstract
Photodynamic therapy (PDT) is a non-invasive treatment method used for treating superficial
skin lesions such as non-melanoma skin cancer (NMSC). The combination of light, a photo-
sensitive molecule and oxygen results in selective tissue destruction. Even though PDT has
resulted in many successful treatment outcomes, the treatment parameters such as required
light dose and preferred light source have not yet been optimised. Since monitoring of the
treatment progress is limited to surface observations, it is difficult to observe what is happen-
ing under the surface of the skin.
In this thesis, the development of complex numerical modelling techniques is considered
with the aim of increasing the understanding of how PDT works within the living skin tis-
sue. In particular, the potential of using daylight as an alternative therapeutic light source is
explored. Daylight PDT is associated with lower experienced pain and has the potential of
reducing pressure on the clinics as well as the number of treatment occasions.
A Monte Carlo radiation transfer (MCRT) model was developed to track photon propaga-
tion during treatment. The first theoretical investigation of daylight PDT is presented where
the results indicate a potential treatment depth of over 2 mm, which is sufficient for treating
superficial skin cancer lesions. Additional models are developed, which consider the drug
interaction and the diffusion of the drug. To include different patient characteristics and
more detailed skin models, multi-layered tissue as well as complex three dimensional tumour
tissues are included within the MCRT model framework.
There is no such thing as a generic patient, making it difficult to generate standardised
treatment protocols. The research performed in this thesis provides further insights into light
interaction with skin tissue for different patient and treatment characteristics, which is a vital
step towards achieving more individualised treatment regimes.
ix
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Introduction
1.1 Thesis outline and objective
This thesis is concerned with the development of advanced modelling techniques for under-
standing how cancer treatment based on photodynamic therapy (PDT) works within living
tissue. The modelling techniques are based on the development of three dimensional (3D)
Monte Carlo radiation transfer (MCRT) codes, which track the propagation of light through
tissue and additional codes to model the light drug interactions and the diffusion of drugs into
the skin.
PDT is a non-invasive method mainly used for treating precancerous and superficial malig-
nant skin tumours [1]. Although it was initially introduced for dermatological purposes it can
today be found in other areas of medicine such as otorhinolaryngology (ear, nose and throat),
ophthalmology (eye), neurology (brain), gastroenterology (digestive system) and urology (ur-
inary tract) [2]. PDT relies upon the activation of localised photosensitive molecules by applic-
ation of a light source. The photosensitiser can be applied systematically, locally or topically
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to the lesion. This is followed by illumination, which in the presence of oxygen molecules,
leads to tissue destruction. The advantages of PDT are its non-invasiveness, the excellent cos-
metic outcome and the selectivity which avoids damaging surrounding tissue. Even though
PDT has been used successfully for many years there are still side-effects associated with the
treatment, including pain during the treatment and long-lasting tissue photosensitivity [3].
This chapter provides an overview of PDT and the background on which this thesis is
based. Firstly the main components of the skin and non-melanoma skin cancer will be in-
troduced, followed by the basic principle behind PDT including the mechanism of action, the
important properties of the photosensitiser, photobleaching and fluorescence. Light penetra-
tion through skin tissue will be discussed followed by an overview of different light sources
adopted for PDT, including daylight PDT. Finally the role of theoretical modelling will be
briefly introduced.
1.2 The skin
With a total weight of approximately 11 kg, covering an area of roughly 1.8 m2, the skin
is the largest organ of the human body [4]. The skin provides a protective barrier against
the external environment including friction and impact wounds, harmful chemicals, bacteria,
viruses and ultraviolet (UV) radiation. The skin prevents water loss, regulates body tem-
peratures, produces vitamin D when exposed to sunlight and contains several nerve endings
making it an efficient sensory organ [5]. The structure and composition of the skin varies
depending on factors such as age, race and gender. This not only results in a variable appear-
ance but also demonstrates functional differences [6]. To effectively study light interaction
with skin tissue, understanding of the structure and composition of the skin tissue as well as
acknowledging the differences between individuals is important.
The thickness of the skin varies depending on the location on the body and can vary from
less than 1 mm (eyelid) to over 5 mm (upper back) [5]. The skin can be divided into two
distinct layers, divided by a base membrane. The outermost layer of the skin is the epidermis
which is typically 100 - 150 µm thick depending on the location and water content. The main
cellular components of the epidermis are different types of keratinocytes which generate a
layered structure. The keratinocytes change function and structure as they move from the
basal layer, where they are produced, towards the outer non-living epidermal layer, referred
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to as the stratum corneum. The keratinocytes are lost from the stratum corneum in the form of
keratin flakes (corneocytes) at the same rate as new cells are produced at the basal layer [4,6].
Figure 1.1 provides a drawing of the skin structure where the different distinct layers of the
epidermis are marked.
The main absorbing molecule in the epidermis is the melanin, produced in the melano-
cytes, mostly located within the basal layer [4]. The main function of the melanin is to protect
against UV radiation. When skin is exposed to UV radiation, the production of melanocytes
increases and the production of melanin is accelerated giving the skin a darker colour. This
is the reason for skin appearing tanned after prolonged sun exposure. The colour of the skin
also depends on genetics, where the melanosomes (containing the melanin) degrade slower in
darker skin compared to lighter skin. For darker skin the melanosomes are located across the
epidermis, while for lighter skin the melanosomes tend to be restricted to the basal layer [5,7].
It is common to group the appearance of the skin and its behaviour to sunlight into six skin
types where skin type I corresponds to the whitest complexion and skin type VI to the darkest
skin type [6,8,9]. This will be discussed further in chapter 5.
The dermis resides below the basal layer (figure 1.1). This layer is much thicker than the
epidermal layer, typically between 1 mm to over 4 mm, and contains mostly fibres, vasculature
and collagen. The dermis can be divided into two sublayers: the reticular dermis and the
papillary dermis [10]. The upper layer of these two sub layers is the papillary dermis which
contains small blood vessels and a fine network of collagen fibres. The second sublayer, the
reticular dermis, contains larger blood vessels and a thicker network of fibres. The main light-
absorbing structure within the dermal layers is the blood which is contained within vessels
and capillaries. The reticular dermis forms a continuous boundary with the third layer of the
skin, the hypodermis which contains a large amount of fat cells. This layer is typically thick
(4 - 9 mm), varying between body location and individuals [6].
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Figure 1.1: Drawing of the main layers associated with human skin. The uppermost layer
is the epidermis which can be divided into several sublayers. The main cell type in the
epidermis is the keratinocytes that are produced on the basal layer. During the turn-over
the keratinocytes gradually travel towards the stratum corneum. During this transition the
function and structure of the cells change and the end product is a non-living flat and hard
cell which forms the stratum corneum. Below the epidermis, the two dermal layers can be
found, the papillary and reticular layer. The hypodermis lies below the dermis [6]. Note that
this is not drawn to scale.
1.3 Non-melanoma skin cancer
Nonmelanoma skin cancer (NMSC) is the most common type of cancer affecting humans;
however it is rarely included in national cancer statistics. The number of new cases of NMSC
per year is estimated to be at least 100 000 in the UK (2005). NMSC is generally thought
to be caused by overexposure to sunlight [11–13] and is typically associated with an older
age group, where 80 % of cases are in subjects aged 60 years or older [14]. Lighter skin
complexions are more commonly affected due to the lower levels of melanin giving reduced
protection against sun exposure. It is also thought that the incidence in men is higher than
that of women [15–17]. Even though awareness of the negative impact of sun on the skin
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has increased, the incidence of NMSC increases annually by 3 - 8 % [16]. This can possibly
be explained by a shift in age in the human population as well as in increased skin cancer
awareness leading to a higher check up rate. It is also estimated that the risk of developing
additional lesions after the primary lesion is 40 - 50 % [17]. The increasing incidence in
combination with the high recurrence rate makes NMSC a concern for both the public health
as well as medical costs [11, 13, 18, 19]. The two most common types of NMSC are basal
cell carcinoma (BCC) and squamous cell carcinoma (SCC), both originating from cells in the
epidermis [4,5,20]. Mortality as a result of NMSC is rare and most commonly associated with
SCC [11,17].
Some of the environmental factors which increase the risk of developing NMSC are sum-
marised in table 1.1. Even though factors such as sun exposure have been shown to be
important in pathogenesis, there are also complex genetic factors that affect the risk of devel-
oping NMSC. Body sites that are affected are typically areas exposed to sun such as the head
and neck area. The relationship between sun exposure and occurrence is further supported
by the variations of incidence with geographic location, where countries closer to the equator
receiving large levels of UV radiation, are associated with an increased incidence of skin can-
cer among light-skinned Caucasians. For an example, Australia has a considerably higher rate
of incidence than Europe. It has been suggested that different lesion types are associated with
different exposure patterns. It is thought that SCC is caused by a cumulative lifetime sun
exposure, while BCC is more commonly thought to be due to intermittent exposure to the sun
as well as sun exposure during childhood [11,12,17,21,22].
The most dangerous carcinogenic part of the solar spectrum is the ultraviolet (UV) radi-
ation which can be divided into UVA (315 - 400 nm) and UVB (280 - 315 nm). UVB causes
direct damage to the DNA and RNA while UVA causes indirect damage through the formation
of reactive oxygen species [23]. The damage caused by the UV radiation requires complex and
efficient DNA repair. However if the systems responsible for the DNA repair are insufficient,
there are possibilities that NMSC or other skin cancers develop [17].
80% of BCCs are located on the head and neck area and even though metastasising is
rare, they can spread deeply and cause substantial local damage and disfigurement [19,24].
There are several subtypes of BCC, such as nodular, superficial and pigmented BCC (figure
1.2 a - c), all with different characteristics, so clinical diagnoses tend to be straightforward.
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Table 1.1: Table of environmental factors increasing the risk of developing NMSC. The table
has been modified from [17]
Environmental impact Type of NMSC
Solar radiation [12] BCC, SCC
UVB radiation [27] BCC
PUVA (psoralen +UVA) [28] SCC, (BCC)
Ionising radiation [29] BCC
Photosensitising drugs [30] SCC, BCC
Human papillomavirus (HPV) [31] SCC
HIV/AIDS [32] SCC, BCC
Arsenic [33] SCC, BCC
Unlike BCC, SCCs have precursor lesions that are generally considered as precancerous. These
include actinic keratoses (AK) (figure 1.2 g - i) and Bowen’s disease (BD) (figure 1.2 d - f).
SCC (figure 1.2 j - l) is the most aggressive type of NMSC and although the precancerous
lesions have a small possibility of developing into the more aggressive type [20], these should
be removed to avoid tissue destruction and metastasis.
For cases where the diagnosis is ambiguous, a sample of the lesion tissue can be removed
and examined further [17, 25]. It is not always convenient to biopsy all lesions of interest
hence non-invasive devices have been developed to try and aid the diagnosis of different skin
lesions. These include dermoscopy, optical coherence tomography [25] and fluorescence life
time imaging [24,26].
There are clear medical problems associated with NMSC. There are also cosmetic disad-
vantages, since most lesions are located in visible areas commonly exposed to the sun such as
the highly visible head and neck region. Therefore there is an incentive to develop treatment
methods that have a satisfactory cosmetic outcome as well as an efficient lesion eradication.
Conventional treatment methods include cryosurgery (freezing), curettage (light scraping),
surgical excision and radiotherapy [34]. The treatment method that is chosen depends on
lesion properties such as type, size and location as well as the available facilities [17]. The
treatment method that will be discussed in this thesis is photodynamic therapy (PDT), which
provides a non-invasive treatment method with excellent cosmetic outcome.
1.4 Photodynamic therapy
Examples of the use of light therapy have been found from more than 3500 years ago, where
civilisations in China, Egypt and India used light to treat various skin diseases. In the early
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twentieth century, Niels Finsen received the Nobel prize (1903) for his achievements in suc-
cessfully treating cutaneous tuberculosis using light. The concept of PDT was first developed
in 1900 when Oscar Raab reported how the combination of light and a specific dye caused
cell destruction. In the following decade Hermann von Tappeiner and Albert Jesionek further
proved the importance of oxygen and developed the concept of PDT by being first in applying
PDT to humans [2,35–40]. Dougherty et al later carried out extensive work by expanding the
clinical use of PDT to treat cutaneous cancers and malignancies which laid the foundations
for the current applications of PDT [37]. In recent years many developments have been made
both with regards to the photosensitiser that is used, as well as developing user friendly light
sources [3]. This thesis will focus on topical PDT, where PDT is used to treat NMSC (BCC) or
precancerous NMSC (AK or BD).
The selection of an appropriate photosensitiser has been a challenge throughout the de-
velopment of PDT. Protoporphyrin IX (PpIX) naturally occurs in the human body and provides
a good balance between tumour selectivity and fast clearance from the body. The PpIX can
be produced from externally applied prodrug containing either 5-Aminolevulinic acid (ALA)
or its methyl-ester, methyl aminolevulinate (MAL) (section 1.5) [42, 43]. Figure 1.3 shows
the progression of a typical treatment. Before the treatment, a light curettage removes the
upper crust of the lesion, to increase penetration efficiency of the applied cream. After the
surface preparation, the prodrug (in the form of a cream) is applied to the lesion, after which
the lesion is covered with an occlusive dressing. The occlusive dressing excludes ambient
light from interacting with the photosensitive molecule. The dressing is typically applied for
3 hours, during which the cream diffuses through the skin and the prodrug molecules (MAL
or ALA) are converted into the photosensitive molecules PpIX (section 1.5). After the three
hours the occlusive dressing is removed and any excess cream is removed from the lesion.
The lesion is then exposed to the light source of choice (section 1.8). After the appropriate
illumination time a dressing is applied and the patient is advised to avoid direct sunlight due
to the risk of photosensitivity. After 7 days all of the treatment steps are typically repeated, a
typical response after the first treatment can be seen in figure 1.3 b. 30 days after the second
treatment, the lesions can be expected to be fully cleared, similar to figure 1.3 c. The slight
depigmentation shown in the figure is common, but will in most cases recover with time.
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Figure 1.2: Photographs of different types of non-melanoma skin cancer (NMSC). a) su-
perficial basal cell carcinoma (sBCC) b) nodular basal cell carcinoma (nBCC) c) pigmented
basal cell carcinoma (pBCC) d) Bowen’s disease (BD) e) BD f) BD g) actinic keratoses (AK)
h) AK i) AK j) squamous cell carcinoma (SCC) k) SCC l) SCC. All images are taken from [41]
with permission.
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Figure 1.3: Figure showing the development of the lesion (BCC) during treatment. a)
picture of the lesion prior to initial treatment. A light curettage removes some of the crusty
surface prior to cream application to increase the cream penetration. b) Picture of the lesion
one week after the initial PDT session, when the treatment is repeated. c) Picture of the
response a month after the treatment. The lesion is cleared and the slight depigmentation
will recover with time.
The recommended guidelines suggests that only lesions 2 mm or thinner should be treated
with PDT [44,45]. For topical PDT the response rate for AK is typically reported to be around
89-92 % at the three months follow up. This is on average slightly lower than cryosurgery
however the cosmetic outcome is significantly superior for PDT [46, 47]. After one year the
typical sustained clearance has been reported to be 63-78 % [48]. BD typically has a response
rate of 86-93 % at the three months follow up with a sustained clearance after the 12 months
follow up of 68-71 % [49,50]. For BCC the response rates reported range from 92 - 97 % at the
three months follow up, where superficial lesions were more successful than nodular lesions.
A typical recurrence rate of 9 % has been reported at the one year follow up [49, 51, 52].
Even though PDT is an established treatment method, there are still aspects of PDT that are
not yet fully understood and there is room for further development and optimisation [53].
Treatment parameters such as level of curettage, light source and amount of delivered light
differ for different institutes. Differences between individuals contribute to the difficulty in
determining optimal treatment parameters and point to the requirement for individualised
treatment regimes.
1.5 Photosensitiser
The efficacy of PDT is highly dependent on the properties of the photosensitiser. Engin-
eering of appropriate photosensitisers has been one of the main challenges associated with
PDT. There are many features desired of an ideal photosensitiser including high absorption
at longer wavelengths, providing deeper penetration and hence improved treatment efficacy.
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It is also desirable to develop a photosensitiser that has a strong localising potential where
the accumulation within the tissue is sufficient. To achieve time efficient treatment it is ad-
vantageous for the concentration of the photosensitiser to reach a peak value shortly after the
administration of the substance. To avoid prolonged photosensitivity it is also favourable for
the photosensitiser to have a fast clearance rate. If the photosensitiser has a high probability
of generating singlet oxygen which is responsible for the tissue destruction, the efficacy of the
treatment is improved. See section 1.6 for a more detailed description of the production of
singlet oxygen and its role in PDT. The desirable features of the photosensitiser mentioned
above have led to major efforts into developing new and improved substances [37,38].
When von Tappeiner and Jesionek first conducted PDT in humans, eosin was topically
applied and used in combination with visible light to treat skin tumours, condylomata lata
and lupus vulgaris [54]. However eosin did not selectively accumulate in tumour tissue and
resulted in undesirable healthy tissue damage. Therefore it was concluded that eosin is not
an optimal photosensitiser. The realisation that porphyrin-based photosensitisers on the other
hand, have strong tumour localising properties was the origin of the developments of the
photosensitisers used for PDT today. It was found that the application of hematoporphyrin
derivatives (HPD) selectively accumulated in the tumour [37]. HPD is now available under
the commercial name Photofrin (Axcan Pharma, Canada) and was the first photosensitiser
to receive approval. Even though Photofrin has resulted in many successful treatments it is
associated with several undesirable side effects. The clearance of the drug is long which can
leave the patient photosensitive for up to eight weeks. It was also found that the localising
properties were not as good as initially thought and in combination with low absorption
properties at the desired longer wavelengths, Photofrin has been determined to be a sub-
optimal substance for many applications [3,38,39].
There are now many different photosensitisers available for different clinical and exper-
imental applications. Most of these are derived from naturally occurring tetrapyrroles, the
main building block for porphyrias. Tetrapyrroles typically have a large absorption peak
called the Soret band at around 400 nm with several smaller absorption bands at longer
wavelengths, referred to as Q bands. For porphyrin the longest wavelength absorption band
is around 630 nm, however the absorption peak at this wavelength tends to be small. The
absorption spectrum for protoporphyrin IX, which is a naturally occurring porphyrin within
the human and the main component of hemoglobin, is plotted in figure 1.4. For topically ap-
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Figure 1.4: Absorption spectrum of Porphyrin IX (PpIX) [55,56].
plied photosensitisers it is common to use precursors to PpIX such as the naturally occurring
amino acid 5-Aminolevulenic acid (ALA) or its methyl ester methyl aminolevulinate (MAL).
ALA occurs naturally in the heme biosynthetic pathway. MAL is a methylated version of ALA;
it is approved for the use in PDT and is commercially available in Europe. Following the ap-
plication of MAL, it is converted to ALA in vivo. Figure 1.5 shows the molecular structure
of ALA, MAL, PpIX and heme (one of the main components of hemoglobin). MAL has been
expected to result in deeper penetration within the tumour tissue due to its increased lipo-
philicity; however little significant difference in the response has been reported between the
two substances [42,44,57].
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Figure 1.5: Figure showing the chemical structure of ALA and MAL, PpIX as well as heme
[38].
When additional ALA is exogenously added to the tumour cells, rate limiting steps within
the heme bio-synthetic pathway are bypassed which result in selective accumulation of PpIX
within tumour cells. Figure 1.6 shows the most important steps in the heme biosynthesis.
ALA is normally produced from glycine and succinyl-CoA. Through conjugation of several
ALA molecules PpIX molecules are produced within the mitochondria. The final step of the
heme biosynthesis is the addition of iron (Fe2+) into PpIX to produce heme, catalysed by the
enzyme ferrocelatase (FECH). The two most important bypassed rate-limiting steps are firstly
the negative feedback loop regulating ALA production and secondly the production of heme
from PpIX. The amount of naturally occurring ALA will be regulated by the amount of heme
in the cell. By exogenously adding ALA this feedback loop will be bypassed which leads to
an accumulation of PpIX within the cell. The accumulated PpIX will not automatically be
converted into heme due to the rate limiting FECH. The additional selectivity within tumour
cells can be explained by the difference between the heme biosynthesis in malignant and
non-malignant cells. A decreased activity of FECH as well as a limited amount of available
iron within tumour cells is thought to be the reason for the additional accumulation of PpIX
within tumour cells. It has also been reported that the levels of enzymes responsible for the
conjugation of ALA into PpIX are higher in tumour cells [3,38,42,43,58].
12
1.6. Mechanism of action
Figure 1.6: Figure showing the heme pathway for ALA (and MAL) induced PpIX. This is nat-
urally occurring in all human cells but the exogenous addition of ALA (or MAL) disrupts the
biosynthesis of heme which leads to accumulation of PpIX in the target tissue cells. Eight ALA
molecules are conjugated to generate PpIX through various enzyme activated steps. When
ALA is exogenously added to the tumour lesion rate limiting steps are bypassed, which results
in accumulation of PpIX within the cells. The PpIX is produced within the mitochondria, but
quickly diffuses to other part of the cell [3,58].
1.6 Mechanism of action
Cell death is caused by light-induced activation of the photosensitiser which generates reactive
oxygen species. As previously mentioned, the prodrug used for topical PDT contains ALA or
MAL molecules which are converted to PpIX molecules (section 1.5). Figure 1.7 shows the
Jablonski diagram for the PpIX molecule containing only a subset of the discrete energy levels.
The photosensitising mechanism is initialised by the absorption of a photon. This causes an
excitation of the PpIX molecule from its singlet ground state (S0) to an excited single state
(S1), associated with a short life time (10 8 to10 9 seconds) [59]. The excited molecule
can decay back to its ground state through dissipation of energy through heat or emission of
a fluorescence photon. An alternative route is by intersystem crossing and conversion to a
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triplet excited state (T1) through a spin flip. This state is a more stable state and has a longer
life time (10 3 seconds) due to the forbidden transition between T1 and S0. The triplet state
is responsible for the generation of the cytotoxic species. The long life time makes the PpIX
molecule in the triplet excited state more likely to react with the surrounding environment.
The probability of the different pathways is determined by the composition of the molecule
and engineering of the molecule can increase the likelihood of intersystem crossing.
The photodynamic reaction can be split into two processes known as Type I and Type II.
Type I reactions involve direct interaction with a surrounding substrate. Through electron
or proton (hydrogen) transfer, free radical or superoxide ions can be produced. This can be
expressed as a reaction between the photosensitiser in its triples state, 3PS and a molecule M.
For electron transfer:
3PS+M ! PS·–+M·+
3PS+M ! PS·+ +M·–
And for hydrogen atom transfer:
3PS(H)+M ! PS· +MH·
3PS+M(H) ! PSH· +M·
Here the dot indicates that the species are radicals, hence that they have an uneven num-
ber of electrons. The signs (+/-) indicates the net charge of the molecule. PS(H) indicates
that it is only one (of many) of the hydrogen atoms (H) in the PS molecule that is involved
in the transfer reaction. The same applies to M(H). In the final two reactions PS· and M· are
the original molecules minus one of its hydrogen atoms. These radicals (with one unpaird
electrons) tends to be very reactive (in comparison to molecules with even paired electrons)
and can react with oxygen to produce reactive oxygen species.
Type II involves an interaction with molecular oxygen in its first step, where the outcome
is singlet oxygen, 1O2. This process can be expressed as:
3PS+O2(
3⌃) -> PS + O2 (1 )or(1⌃)
14
1.6. Mechanism of action
where (3⌃) corresponds to the triplet state of O2, (
1 ) corresponds to the fist excited
singlet state and (1⌃) corresponds to the second excited singlet state. In the case when
O2(
1⌃) is produced, a fast decay will result in a rapid conversion to O2(
1 ) (responsible for
a the type II reaction).
The ratio between Type I and Type II depends on the photosensitiser and the available
concentration of oxygen; however Type II is thought to be the main cytotoxic agent involved
in PDT [37,59–61].
The different oxygen species induced by the light absorption can lead to destruction of
multiple cellular structures. Both proteins and lipids are targeted which leads to functional
and structural changes to the cells which finally leads to apoptosis and/or necrosis [62]. It
is believed that the different oxygen species only diffuse small distances ( ⇠ 10 µm) which
emphasises the importance of the localisation of the photosensitiser. If the photosensitiser is
efficiently and selectively accumulated within the tumour region, only tumour tissue will be
affected by the photodynamic reactions [63,64].
Figure 1.7: Figure demonstrating the main photodynamic reactions through a simplified
Jablonski diagram of the photosensitive molecule. S0 represents the ground state level and
S1 and S2 represents two singlet excited states. T1 corresponds to an excited triplet state of
the photosensitive molecule. The different arrows demonstrates different energy transitions
during photon absorption. a) Excitation, b) Internal Conversion / vibrational relaxation, c)
Fluorescence, d) Intersystem Crossing, e) Phosphorescence f) Excitation of oxygen by energy
transfer.
1.6.1 Photobleaching
Ideally the photosensitive molecule (here PpIX) would act as a catalyst for tissue destruction
without actually being destroyed itself. By generating singlet oxygen molecules, the energy in
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the photosensitiser is transferred to the oxygen which results in a ground state photosensitiser.
This way the photosensitiser is fully recycled (figure 1.7). However, during the photodynamic
process the sensitiser is used up, which results in photobleaching. During the process of
developing the reactive oxygen species, the photosensitiser can be destroyed or chemically
modified. This results in a dysfunctional photosensitive molecule. It is also possible that the
produced singlet oxygen can react with the photosensitiser itself. Again this would change
the properties associated with the molecule and result in reduction of available photosensit-
iser [59, 65]. The photobleaching results in decay of the photosensitiser, which is typically
expressed by an exponential decay and will be further discussed in chapter 2 (section 2.6)
and chapter 3 (section 3.3.2 ).
1.6.2 Fluorescence
One of the options for a molecule in its singlet excited state S1 is to emit a fluorescence photon
(figure 1.7). The fluorescence spectrum of a photosensitiser is always shifted towards longer
wavelengths and the PpIX has a characteristic fluorescence peak at 635 nm. This can be
experimentally useful since it provides an indirect indication of the quantity of PpIX within
the measured tissue. The fluorescence properties allow for the edges of the tumour to be
determined using e.g. a Woods lamp. The drug delivery efficiency can also be investigated
by measuring the fluorescence signal at different time points [59]. In addition, the fluores-
cence signal produced by accumulated PpIX can be used to aid the diagnosis of some skin
diseases that are more difficult to diagnose by eye [3]. Indirectly it is thought that the fluor-
escence signal indicates the singlet oxygen production, this is typically referred to as implicit
dosimetry [66]. Since the fluorescence signals can reveal important information, develop-
ing a photosensitiser with strong fluorescence characteristics appears to be of interest [67].
The fluorescence spectrum of PpIX and techniques of measuring the spectrum will be further
discussed and illustrated in chapter 7.
1.6.3 Oxygen
Oxygen plays a key role in PDT, mostly due to the production of singlet oxygen which is
thought to be the main contributor to the photodynamic effect. The level of oxygenated
blood will also affect the penetration of light since oxygenated and deoxygenated blood have
different optical properties which effect the light propagation at certain wavelengths. The
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level of available oxygen within the tumour will deplete due to singlet oxygen production
(as well as other reactive oxygen species) and vessel damage as a result of long exposure
times [68]. For this reason, it has been suggested that fractionated treatment would allow the
oxygen levels to recover in-between light bursts. Delivering the light in smaller fractions with
a pause in between bursts, allows the oxygen concentrations to recover. The frequency of the
pulses vary from multiple illumination periods where the light source is turned off/on every
60 seconds [69] to fractionation with only two periods of light illumination with a pause of
2 hours in between [70]. Both in vitro and in vivo studies suggest that using a fractionated
treatment results in an improved PDT outcome [71]. Optimised treatment regimes and il-
lumination patterns have not been established and fractionated PDT is not yet a commonly
adopted technique.
1.7 Light propagation through skin tissue
The photodynamic effects are dependent on the light interaction with skin tissue. As the light
travels through the skin it is either scattered or absorbed as the photons interact with the skin
tissue. This will be discussed in more detail in chapter 2. The optical properties of the skin
tissue determine the propagation of the light through skin. The values and implications of
these properties will be discussed further in chapter 5.
It is common to refer to light dose when comparing different light based therapies. The
light dose describes the amount of light delivered to the tissue and is expressed in units of
J cm 2. The light dose is defined as,
Light dose = I · t (1.1)
where I is the irradiance of the source light at the surface of the skin (Wcm 2) and t is the
total irradiation time (seconds). This allows for different light sources of varying intensities
to be compared for the same delivered light dose, corresponding to different treatment times.
Light doses between 37 and 540 Jcm 2 have been shown to result in effective PDT treatment.
The total light dose delivered does not consider the differing spectral contributions during
PDT. Different wavelengths contribute to different levels of absorption of the photosensitive
molecule. An alternative way to consider the light dose is therefore by weighting it by the
absorption properties of the photosensitive molecule [72]. A typical light dose (non-weighted)
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delivered during conventional PDT treatment at Ninewells Hospital in Dundee is 75 J cm 2
[56], and is therefore the light dose considered and compared for many of the simulations in
this thesis.
The different light sources that have been proven to result in effective PDT differ not only
in wavelength but also in intensity and uniformity. The irradiance of the applied light sources
is recommended to not be higher than 150 mWcm 2 since a high irradiance can lead to
unwanted hyperthermic damage [72].
1.8 Light sources
When choosing an appropriate light source for PDT there are several aspects to consider.
Firstly, the wavelengths have to match the absorption bands of the photosensitiser so that a
sufficient amount of singlet oxygen is produced. The illumination area has to be sufficient to
treat the selected region and the irradiance has to be high enough to provide a good treatment
response without causing too much pain. There are also aspects of the equipment that have to
be considered such as cost and user friendliness. The type of light source chosen is often dic-
tated by the location of the lesion, the light dose that is required as well as the photosensitiser
that is used.
To enable deep penetration within the skin tissue, the absorption properties of tissue have
to be considered. Figure 1.8 shows the absorbance of the main chromophores in skin tis-
sue. Melanin and hemoglobin are strongly absorbing in the shorter blue wavelength range
while water is strongly absorbing at longer wavelengths. Wavelengths between these two re-
gions ensures deeper penetration within biological tissue. This wavelength range is typically
referred to as the therapeutic window. The targeted wavelength range for PDT is however
between 600 nm and 800 nm. Longer wavelengths do not provide enough energy for triplet
state conversation to subsequently excite oxygen molecules. When using the photosensitiser
PpIX, it is common to target the absorption peak at 630 nm to ensure the deepest possible
penetration [1,3].
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Figure 1.8: Figure showing the absorbance of the main absorbing chromophores in tissue
which demonstrates the therapeutic window in which deeper tissue penetration is achieved.
The main absorbers are melanin, hemoglobin and water. Reproduced with [73]
Three main classes of light sources have been adopted for PDT: lasers, filtered lamps and
light emitting diodes (LED). Even though lasers provide a monochromatic high powered light
source, they are not optimal light sources for topical applications when treating larger lesions
due to the requirement of expanding the beam, which requires the addition of optical in-
struments. In addition the lasers tend to be expensive and associated with additional safety
requirements. In addition, the requirement for technical support makes these less attractive
for topical PDT applications; however, successful results have been reported for internal PDT
application where the laser has been coupled to an optical fibre. Different lamps have the ad-
vantage of being cheap and easy to maintain as well as providing a portable device. However
due to the wide spectrum, more care is required to calculate the desired light dose. Coupling
lamps into optical fibres tends to limit the output power which limits lamps to topical applic-
ations such as to treat skin lesions. Currently, LED-based light sources are commonly adopted
in PDT with the main advantage of being cheap and versatile with a reliable power output.
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They provide a portable device with the flexibility of arranging the LEDs in different geomet-
ries for different body locations [1,74]. Valentine et al (2011) performed a theoretical study
comparing different non-laser light sources, demonstrating the importance of an appropriate
choice of light source [75].
The light source adopted for clinical treatment at Ninewells Hospital in Dundee is the
Aktilite, which is an array-based red LED light source. The arrangement of LEDs can be
adjusted so that the illuminating region is appropriate relative to the size of the lesion. An
image of the device is shown in figure 1.9.
Figure 1.9: Image of Aktilite, which is the light source adopted at Ninewells Hospital [72].
By delivering the light during a longer period of time at a lower irradiance, it is thought
that the oxygen consumption is also slower. This is therefore considered to be as effective, if
not more so, compared to the conventional high-dose PDT using e.g. Aktilite [69]. The lower
levels of pain reported for the low-dose PDT has shown a clinical advantage. Successful results
have been reported using a portable LED low irradiance light source (Ambulight; Ambicare
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Health Ltd, Scotland). The Ambulight provides a convenient wearable source associated with
a lower experienced pain [76, 77]. Unfortunately, these devices are still limited in size and
therefore not appropriate for treating larger affected areas, typically associated with AK. The
same theory of delivering light during a longer period at a lower irradiance supports the
investigation of daylight activated PDT, where daylight is used as the excitation light source
[76,78,79].
1.8.1 Daylight activated PDT
One of the limitations with many light sources used in PDT is the restriction in the size of
the possible treated area. By using daylight, the only restriction is in the ability to expose the
affected region to daylight. With conventional treatment modalities, only a few lesions can be
treated during the same hospital visit. Utilising daylight as the therapeutic light source would
lead to a reduction in the number of treatment sessions for patients with extensive coverage
of lesions. Efficient daylight PDT would lead to a more convenient treatment modality for
both patient as well as the treating clinic, leading to a higher throughput of patients.
The first clinical study of daylight PDT took place during the summer of 2006 in Denmark
(Copenhagen). 29 patients with AK of the face and scalp were included in the study. Each pa-
tient received both daylight PDT and conventional PDT (using a red LED) on separate lesions.
This allowed the patients to compare the two treatment methods. During the conventional
PDT the area was occluded for three hours after the application of the cream (containing
MAL) after which a total light dose of 37 J cm 2 was delivered. For daylight PDT the area was
occluded for only 30 minutes after which the area was treated with daylight for 2.5 hours.
The weather conditions varied although most patients were treated on days with no or few
clouds. The study showed no significant difference in the treatment response between the
two treatment protocols (79 % vs. 71 %). Treatments using daylight PDT resulted in a sig-
nificantly lower pain score compared to conventional treatment modalities. The study also
successfully demonstrated that daylight PDT was the preferred choice of treatment for 62%
of the patients [80].
Since this first study, several supporting studies on AK have been published in Europe
[81–88], Australia [89], North America [90] and Latin America [91] with response rates
between 70 - 89%. All studies show no inferior response rates to conventional PDT with lower
recorded pain scores and better skin reactions such as reduced erythema. Daylight PDT has
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also been shown to be the preferred choice of treatment by patients. The European consensus
recommends 2 hours of daylight exposure, 30 minutes after application of MAL cream. The
treatment is suggested to be possible in all weather conditions however a minimum temperat-
ure of 10  C is recommended for the comfort of the patient (it is also recommended that the
temperature should not be too high to cause discomfort or danger to the patient). A shorter
exposure is thought to result in an insufficient amount of PpIX produced within the lesion
and for a longer exposure the probability of extensive erythema (without improved treatment
results) is increased [78]. The recommended effective light dose is typically suggested to be
8 J cm 2 (weighted by the normalised absorption properties of the photosensitiser) [92]. To
protect patients from damaging UV radiation, a sunscreen should be applied to all exposed
areas. Typically sunscreens only overlap the absorption spectrum of PpIX by a small amount
and are not thought to reduce the penetration of the light, and thereby not affect the efficacy
of the treatment [93].
The reason for the reduced pain is not only due to the lower irradiance, but also due to
the continuous build-up of PpIX. During conventional PDT the PpIX builds up during 3 hours
after which the region of interest is exposed to a light source of high irradiance during a short
period of time [94]. This results in a high concentration of reactive oxygen species (including
singlet oxygen) shortly after the start of the illumination, thought to be one of the reasons for
the high levels of experienced pain. During daylight PDT the PpIX is produced continuously
during the illumination resulting in a continuous production of reactive oxygen species and
considerably lower levels of pain [78].
So far it is only common to treat AK of grade I and II [95] using daylight PDT; however
a study in Denmark reports successful results using daylight PDT to treat BCCs. The response
rate at the 3 months follow up was 90 % [34], again comparable to results achieved using
conventional PDT [51, 96]. The response was reduced to 74% after 12 months and the high
recurrence rate has been speculated to be due to the thickness of the lesion making this
treatment less suitable for thicker lesions such as BCC [78].
Unpredictable weather conditions altering the treatment conditions as well as the lack
of supervision during the treatment are the main limitations with daylight PDT. In northern
Europe daylight treatments can only be scheduled for the summer months of the year and in
warmer climates the heat of direct sunlight is an additional restriction. If the treatment is per-
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formed during unsupervised conditions, the full exposure time is not guaranteed. Discomfort
can be achieved if the region of interest is exposed to varied degrees of daylight. For example,
prolonged time in dark shadowy areas can increase the production of PpIX, leading to in-
creased pain when subsequently exposed to daylight [78]. Daylight PDT has recently become
very popular with both patients and clinics. Even though there are treatment guidelines, there
is little evidence for the justification of treatment time and treatment conditions. To fully ex-
plore the potential and limitations of using daylight PDT further studies on treatment depths
and treatment times should be explored.
1.9 Role of theoretical simulation
Theoretical approaches are useful when establishing links between measurements and the
properties of skin tissue. They also aid further development of new treatment techniques
since theoretical simulations can reveal important information about the interaction between
light and tissue. For example PDT requires knowledge of the photodynamic dose and pen-
etration depth [97], which are difficult to measure. Through theoretical simulations, these
properties can be easily determined and subsequently aid the development and comparison of
new treatment modalities [98]. This thesis focuses on the implementation of Monte Carlo ra-
diation transfer (MCRT) modelling of PDT, where photons are followed through their random
walk through skin tissue. Due to the flexibility and accuracy associated with MCRT modelling,
this technique is thought to be the gold standard in radiation transport modelling.
MCRT has been used for over two decades to simulate light propagation through skin
tissue [99] and has since then been used multiple times to simulate PDT [97, 100–102]. In
the work presented here we use MCRT as a tool to compare different treatment modalities
and different treatment conditions. Many previously published studies simulate reflectance
and fluorescence measurements [103–105] however here we focus on simulating daylight
PDT and how different treatment parameters such as PpIX concentration and different optical
properties affect the treatment outcome. These are properties that cannot be directly meas-
ured and therefore theoretical modelling provides a tool to work towards a more personalised
treatment. Chapter 2 will discuss the theory behind MCRT modelling and also discuss the
benefits and limitations of theoretical models further.
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1.10 Synopsis and thesis objectives
This thesis focuses mainly on topical PDT during different treatment conditions. Treatment
conditions vary between different institutes where, for example, the total delivered light doses
vary significantly. By investigating light interacting with skin tissue during different treatment
conditions the aim of this thesis is to increase the understanding of PDT and work towards
finding optimised treatment parameters. Due to the non-invasive nature of the treatment the
monitoring of the treatment progress is limited to surface measurements and observations.
The challenges associated with these limitations can be assisted by implementing theoretical
techniques. By developing appropriate simulations information about the light distribution
and photo-toxicity within the skin tissue during the treatment can be established. A major fo-
cus of this thesis is to investigate appropriate properties and skin models to achieve accurate
results. Patients with different tissue properties respond differently to treatment. Therefore
there is incentive to develop a more personalised treatment plan. To develop current treat-
ment plans the effects of different types of skin (with regards to for example age and skin
colour) and different tumour shapes during PDT are investigated for the first time. A further
aim of this thesis is to investigate new treatment modalities such as theoretically exploring
the potential and limitations of using daylight as a potential light source.
Chapter 2 discusses the importance of theoretical modelling of PDT as well as the devel-
opment of the Monte Carlo radiation transfer (MCRT) model adopted in the majority of the
subsequent chapters. A thorough validation is presented where both experimental and pre-
viously published theoretical results are reproduced successfully. Chapter 3 demonstrates a
theoretical model for daylight PDT during different weather conditions in comparison to con-
ventional treatment modalities where an artificial light source is adopted. The toxicity during
daylight PDT is determined as a function of depth for different weather conditions indicating
sufficient treatment depths for superficial lesions after only 30 min of daylight illumination.
Chapter 4 considers the production of the photosensitiser within the tumour as it changes
with depth from the surface as well as time since application of the prodrug. The properties of
the production of the photosensitiser are investigated and explored and compared to clinical
data. Chapter 5 discusses the importance of the allocation of appropriate optical properties,
where the effect of different optical properties is demonstrated through the investigation of
different ages and skin types. It will be shown that light propagates deeper through lighter
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skin complexions and older skin. Chapter 6 explores the importance of including three di-
mensional (3D) structures in the MCRT model. By redistributing the mass of the tumour in
a clustered way, keeping the total mass constant, it is found that the light penetrates deeper
through heterogeneous tissue. This supports further development of 3D heterogeneous skin
phantoms.
Chapter 7 presents a clinical study performed in Brazil, where the PpIX fluorescence signal
was recorded during the occlusive treatment phase prior to light illumination. The fluores-
cence signal can be used as an indication of the amount of PpIX present within the skin tissue.
The results from the study suggest a linear build-up of PpIX during the three hour long oc-
clusive treatment. This indicates that the light treatment could be initialised later to ensure
that the PpIX penetrates deeper into the skin. Chapter 8 presents overall conclusions and
suggestions of future work based on the results obtained in this thesis.
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Monte Carlo radiation transfer modelling, code
set-up and validation
2.1 Summary
Monte Carlo Radiation Transfer (MCRT) is a flexible and robust technique for studying light
propagation through turbid media. Due to its ability to accurately simulate light interactions
with different tissue types, it is a useful tool for assisting photodynamic therapy (PDT) dosi-
metry and treatment planning [106,107]. This chapter describes the fundamentals of MCRT
modelling and the development of the code that will be used in subsequent chapters to sim-
ulate different treatment conditions. For any established code, validation is essential. The
code that was developed here was rigorously validated by successfully reproducing both ex-
perimental observations and theoretical predictions from independently produced codes. The
experimental validation reproduced the fluorescence signal generated by Coproporphyrin III
in various aqueous concentrations of the fat emulsion Intralipid 20 %. The theoretical valida-
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tion successfully reproduced MCRT results generated by Jacques et al in 1993 [97].
2.2 Introduction and background
By simulating the light propagation through the skin tissue during the light treatment, further
information about the potential and limitations for different PDT treatment conditions can
be explored. This chapter discusses different alternative methods of studying light propaga-
tion through a turbid medium, with a focus on MCRT modelling. The majority of the work
presented in this thesis uses MCRT modelling to investigate different aspects of PDT. This
chapter provides a detail description of the development and validation of the code used for
subsequent chapters.
2.2.1 Benefits of theoretical modelling
The number of light applications in medicine is growing, which increases the need of the-
oretical models that link the measurable properties with tissue characteristics. From surface
measurements alone (e.g. reflected light and fluorescence) it is impossible to study light
interaction under the surface of the skin and thereby the treatment progress during illumin-
ation. For PDT the simulated light distribution helps to determine optimal light sources and
wavelengths. By considering the properties and dynamics of the skin, additional information
and knowledge can be acquired from surface observations such as the generated fluorescence
signal [98, 108]. In addition to allowing more information to be gained from surface ob-
servations, theoretical simulations also allow investigation and exploration of features of the
treatment impossible to observe from the surface [107, 109]. Simulations of PDT allow for
different treatment modalities to be investigated and compared and provide a useful tool
when developing new techniques [110]. By adopting a sufficient and appropriately validated
model, scattering, absorption, treatment depths, energy deposition and fluorescence signal
can be thoroughly studied during a simulated light treatment.
2.2.2 Limitations of theoretical modelling
Theoretical models rely on appropriate and reasonable input parameters to generate accurate
results. Only when realistic input parameters are adopted is it possible to generate useful
information. When simulating PDT it is not only crucial to include all the important features
and processes involved, but also to represent accurately the optical properties of the simulated
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tissue region. Unfortunately the available in vivo data necessary for accurate representation
is relatively limited [111,112]. The optical properties are very different between and within
individuals which makes the allocation of appropriate optical properties challenging as dis-
cussed in chapter 5. With more assumptions and approximations the result tends to be a less
accurate model. However, a model with fewer assumptions typically results in a too simple
model. The balance between these factors is important to as accurately as possible, represent
the desired situation. Therefore it is imperative, when adopting a theoretical model to con-
sider the associated assumptions and approximations where the limitations only allows the
results to be used as a guide under the circumstances stated by the simulations.
2.3 Light propagation through tissue
The radiative transfer equation (RTE) describes the distribution and propagation of light
through any medium. The RTE can be derived from the energy conservation principles of
the energy flow, dP, through a cylindrical volume element, within the solid angle d⌦, in the
direction sˆ, per unit time (figure 2.1) [106, 113]. The energy conservation equation is de-
scribed as:
dP =  dPdiv  dPext+ dPsca+ dPsrc (2.1)
Where dPdiv is the energy lost due to divergence of the photon beam, per unit time. dPext is
the energy lost per unit time due to absorption and scattering. dPsca is energy gained (per unit
time) due to scattering from any other direction sˆ0 into sˆ and dPsrc is the energy contribution
from the sources per unit time. These different contributions will be separately discussed and
finally combined to derive the RTE (Boltzmann equation).
The overall change in energy per unit time in the volume element (figure 2.1) can be
expressed as
dP =
1
c
@ L(~r, sˆ, t)
@ t
dV d⌦ (2.2)
where L(~r, sˆ, t) is defined as the radiance of the light at position ~r, travelling in the direc-
tion, sˆ, at time t . L has the units Wm 2 sr 1 and in equation 2.2, c represents the speed of
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Figure 2.1: Figure showing the cylindrical volume element. The energy flow through the
volume element is used to derive the radiative transfer equation [113].
Figure 2.2: Figure demonstrating the energy flow through area dA in direction sˆ. ✓ in
equation 2.3 is the angle between the unit outwards direction sˆ and the normal unit vector
nˆ [113].
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light. The radiance is defined as the specific intensity over a narrow frequency range. The
radiance is what describes the light distribution through the medium and the end goal with
the RTE is to determine L(~r, sˆ, t) since this contains all the important and relevant information
to describe additional physical properties.
The radiance, L(~r, sˆ, t) can be used to determine the energy flow through the small area
dA, within solid angle d⌦ during dt by:
dE = L(~r, sˆ, t)cos✓dAd⌦d t (2.3)
Where ✓ is the angle between the unit outwards direction sˆ and the unit normal vector of
dA (figure 2.2). The radiance can also be used to determine the fluence rate, which is defined
as the energy flow per unit area and time independent of flow direction and has the units
Wcm 2. The fluence rate is therefore generated by integrating the radiance over the 4⇡ solid
angle:
 (~r, t) =
Z
4⇡
L(~r, sˆ, t)d⌦ (2.4)
To determine the radiance, the losses and contributions in equation 2.1 have to be con-
sidered. The two losses of energy (per unit time) in the equation are due to divergence and
extinction. First of all, the energy diverging out of the photon beam (per unit time), can be
expressed as,
dPdiv =
@ L(~r, sˆ, t)
@ s
dsdAd⌦ =
@ L(~r, sˆ, t)
@ s
dV d⌦ (2.5)
and describes the energy flow out of the volume element dV and the solid angle d⌦ (per
unit time). The second loss, the extinction, is expressed by,
dPext = (µtds)L(~r, sˆ, t)dAd⌦ = µtL(~r, sˆ, t)dVd⌦ (2.6)
where µt = µs +µa, is the total attenuation coefficient (length 1), defined as the probab-
ility of being either scattered or absorbed per unit distance. Light that is scattered into the
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volume element and into the solid angle d⌦ from any other direction, sˆ0 (figure 2.1) contrib-
utes to the total dP by,
dPsca = (NsdV )
ñZ
4⇡
L(~r, sˆ0, t)Ph(sˆ0, sˆ) sd⌦0
ô
d⌦ = (µsdV )
ñZ
4⇡
L(~r, sˆ0, t)Ph(sˆ0, sˆ)d⌦0
ô
d⌦
(2.7)
where Ns represented the density of the number of scatterers, hence NsdV represents the
number of scatterers within the volume element.  s is the cross section of the scatterer, where
Ns s = µs. Since L(~r, sˆ0, t) sd⌦0 describes the energy flow (per unit time) through area  s and
solid angle d⌦0, this denotes the energy interacting with a single scatterer per unit time. The
phase function, Ph(sˆ0, sˆ), describes the distribution of scattering angles, which depends on the
angle  , between sˆ and sˆ0. The phase function is a probability distribution which equals to
one when integrated over all angles. The phase function can therefore equally be written as,
Ph( ), since the new scattering angle is related to the original direction of propagation.
The second contribution to the energy (per unit time) in the volume element in equation
2.1, is the energy produced by the source (per unit time),
dPsrc = S(~r, sˆ, t)dVd⌦ (2.8)
Here S, is the volume emissivity generated by the source, with units Wm 3 sr 1. Hence
dPsrc describes the energy in the volume element within d⌦, per unit time due to the source.
Putting all of these contributions and losses together, the RTE becomes,
1
c
@ L(~r, sˆ, t)
@ t
=  @ L(~r, sˆ, t)
@ s
 µtL(~r, sˆ, t)
+µs
Z
4⇡
L(~r, sˆ0, t)Ph( )d⌦0+ S(~r, sˆ, t)
(2.9)
This is the equation that analytically describes the light propagation through biological
material and any turbid media. The RTE is however difficult to solve analytically, therefore
approximations are typically applied to more easily describe the light propagation [106,113,
114]. The two most obvious approximations are either the assumption that scattering or
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absorption is dominating the light interaction.
2.3.1 Beer-Lambert law
For a mediumwhere the absorption is much larger than the scattering, the intensity of the light
is attenuated exponentially with distance z (figure 2.3). The irradiance, I(z) can therefore be
expressed only as a function of distance travelled:
I(z) = I0e µaz (2.10)
where µa is the absorption coefficient within the media, and µaz is the optical depth of the
slab of depth z. The optical depth refers to the level of absorption over a certain depth. This
is known as the Beer-Lambert law, which is appropriate to use in a highly absorbing medium
where it can be assumed that there is no scattering. However, tissue is highly scattering,
therefore this approximation is not appropriate when considering light propagation through
tissue [106].
Figure 2.3: Description of light travelling through a medium where absorption is domin-
ating. The transmitted light depends on the thickness of the medium and the absorption
coefficient within the medium. The strength of the intensity of the light exponentially atten-
uates as it travels through the slab [106].
2.3.2 Diffusion approximation
For a medium where the scattering is dominant, i.e. a medium with a high albedo, and
where the scattering is nearly isotropic, the radiance can be expanded in terms of spherical
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harmonics. This approximation is less valid for an anisotropic media, such as skin tissue,
which is highly forward scattering. In particular it is not valid close to the surface when
simulating illumination of the skin surface [115]. Another issue with diffusion theory is the
required uniformity of the tissue type [101]. The tissue has to have uniform optical properties
throughout the simulated region. It is therefore a challenge in diffusion theory to include
different tissue types such as tumour tissue in a three dimensional fashion [101].
Studies by for example Flock et at (1989) [98] and Wang and Jacques (2000) [116]
have compared diffusion theory to more exact solutions to the RTE. These studies show that
diffusion theory produces accurate results deeper into the surface for isotropic scattering.
However, determining the light distribution close to the surface boundary is associated with
large errors. This is not a desirable effect, since it is close to the surface where a lot of the
intense light-tissue interactions, important for light treatment in medicine, occur [116]. The
Diffusion approximation is an attractive method due to its simplicity and the fact that it is not
computationally expensive.
2.3.3 Monte Carlo radiation transfer method
Monte Carlo Radiation Transfer (MCRT) is a numerical simulation to the RTE, where no as-
sumptions of the levels of absorption or scattering are required. MCRT is a stable, yet flex-
ible technique which allows accurate information about the light distribution within tissue
phantoms to be generated. MCRT is a computer based solution to the light transport prob-
lem which utilises the probabilistic nature of the photon interactions. The random walk of
the photons is simulated, and by following each photon’s trajectory the description of the
distribution of the light is built up. Scattering and absorption events are tracked until the
photons are either absorbed or exit the simulation region. By repeating this process for many
several photons, or energy packets, the light distribution and energy depositions start to ap-
proach their true values. Due to the sophistication of the technique, MCRT is an appropriate
method of describing light based therapies, such as PDT. The more accurately the tissue is
described in terms of optical properties, the more accurate the computed MCRT results will
be [101,107,117].
The term ’the Monte Carlo method’ was first introduced as a way of investigating neut-
ron propagation through different media in 1949 [118] and since then it has been used for
a variety of applications. Modelling light interaction with skin tissue using MCRT was first
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introduced by Wilson and Adam in 1983 [99]. Wilson and Adam determined the light at-
tenuation through a homogenous tissue considering only isotropic scattering. Keijzer later
(1989) introduced anisotropic scattering and propagation of photons through a system using
cylindrical coordinates [119]. This was further extended to Cartesian coordinates by Prahl
(1989) making the results easier to interpret [117]. Wang and Jacques developed a multi-
layered Monte Carlo (MCML) model, which has subsequently been made publicly available
and been utilised frequently to simulate light distribution through skin tissue [107,120–122].
Several additional MCRT models adopt a layered approach to represent different tissue types
in skin [123] in liver [101] and heart [124]. There have also been several simulations where
tumours have been included to represent diseased tissue. These tumours have typically taken
the form of different geometrical shapes such as squares [125], spheres [126] and cylin-
ders [100, 101, 127]. MCRT modelling has also been used to simulate light propagation
through brain tissue [128–132] where complex three dimensional (3D) brain tissue has been
used as the propagating medium [128]. MCRT has frequently been used to calculate optical
properties by comparing simulations and experimental measurements [104,105,123], to sim-
ulate fluorescence spectroscopy [103, 124] as well as comparing different illumination geo-
metries and wavelengths [121, 126]. Extensive work studying treatment of port wine stains
have used MCRT modelling to investigate the effects of the position, diameter and number
density of blood vessel in tissue [123,133,134].
The drawback with MCRT modelling is that it tends to be computationally expensive com-
pared to using for example the diffusion approximation [116]. However, approaches have
been made to speed up the computation time [107] such as mesh based grid systems [131],
combining MCRT with diffusion theory [125,135] and computer parallelising [132].
2.4 Method
The MCRT model presented here was originally developed for astronomy research, but has
been adapted for this project where the light propagation through skin tissue is simulated
[136, 137]. In general terms, the MCRT model tracks photons as they enter a grid contain-
ing multiple voxels. The photons travel through the simulated region undergoing scattering
events. These interactions are tracked until the photons are absorbed (or escape the simulated
region), and the locations of the absorption events are recorded. The scattering and absorp-
tion events are determined by the optical properties of the medium in which the photons are
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propagating, which can be varied on a voxel by voxel basis. The step size as well as angular
distribution are sampled from probability distribution functions (PDFs) using random number
generators. The developed code described here simulates a three dimensional (3D) Cartesian
grid with the voxel dimensions 100 x 100 x 100 voxels (note that chapter 5 adopts different
voxel dimensions) with a variable grid size (figure 2.4).
z 
y 
x 
Incident Photons 
Figure 2.4: Representation of the Cartesian grid adapted in the developed MCRT model.
The voxel based system allows for optical properties within each individual grid cell to be
defined independently. This allows for structures and layers of different tissue types to be
included in a three dimensional fashion.
2.4.1 Code details
A photon simulated within the MCRT model, is described as an energy packet and is related
to the number of ’real’ photons, N , by,
N  =
Ei
h⌫i
(2.11)
where Ei is energy per MCRT photon, h is Plank’s constant and ⌫ is the frequency of the
photon. The energy per MCRT photon, Ei depends on the total amount to energy delivered
to the simulation as well as the total number of MCRT photons (here after referred to as
photons) simulated, N :
Ei =
IA t
N
(2.12)
here I is the irradiance (Wcm 2) of the incident light sources and A is the area of the
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illuminating region (cm2) and  t is the time of illumination (s). The amount of energy per
unit time that is simulated is divided into small energy packets. It would not be convenient to
simulate individual photons due to the large number of photons emitted per second from the
simulated light source (of the order or 1017 photons per second). Instead the energy packets
are traced on their random walk through the simulation grid. By ensuring that the results
from the simulations are not affected by an increase number of simulated packets an appro-
priate number of packets can be established. Typically 106   107 photons were simulated. A
flowchart and overview describing photons movement from launch to termination is shown
in figure 2.5. The different steps in the flowchart and the build-up of the photon propagation
through the medium is described below.
Figure 2.5: Flowchart demonstrating the movement of the photons through the MCRT grid.
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Step size
The propagation of the photons through the medium is, as previously mentioned, determined
by the optical properties of the medium.
The probability of the light beam interacting (scattering or absorption) over distance ds is
µtds (equation 2.6). The probability of a photon travelling distance ds without an interaction
is therefore given by, 1 µtds. The length S can be divided into A segments, such that ds=S/A.
Hence the probability of the photon travelling the whole distance S without interaction can
be expressed as,
P(S) = lim
A!1 (1 µtS/A)A = e µtS = e ⌧ = P(⌧) (2.13)
Here ⌧ is the optical depth, defined as the number of mean free paths over a given dis-
tance. The mean free path, is the average distance a photon travels between interactions and
is given by 1/µt. As the optical properties (µt) may change over the distance the photon
travel, the optical depth can be translated to a physical distance S by,
⌧=
Z S
0
µtds (2.14)
Within MCRT many parameters are generated through random sampling from PDFs. Since
the repetition of the sampling reproduces the PDF, this is an appropriate way of randomly
sampling parameters to accurately represent reality. To randomly sample the optical depth,
the PDF, P(⌧), (equation 2.13) has to be normalised over all ⌧ to generate the cumulative
distribution function (CDF). This is the probability of the variable taking a value less than or
equal to a specific ⌧,
CDF=
Z ⌧
0
P(⌧)d⌧=
Z ⌧
0
e ⌧d⌧ (2.15)
From this we can then sample an optical depth by generating a random number between
0 and 1, ⇠, which is sampled from a uniform distribution.
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⇠=
Z ⌧sample
0
e ⌧d⌧ (2.16)
Where it is assumed that 0 is the lower limit of the range at which ⌧ is defined and ⌧sample
is the sampled optical depth. The solution for this equation is,
⌧sample =  ln(1  ⇠) (2.17)
This sampled optical depth ⌧sample, is thereafter converted to a physical distance S, using
equation 2.14.
Equation 2.14 determines the physical distance travelled before an interaction within a
continuous medium. For the situation considered here, the photons travel through an spatial
grid containing small voxels where the optical properties can be different in each individual
voxel. Therefore the optical properties within the medium are not continuous and step size is
determined by,
⌧=
X
i
µt si (2.18)
where,  si, is the step size within voxel i, with total attenuation coefficient µt. Figure 2.6
shows a simplified example where the calculation of the physical distance is demonstrated.
Figure 2.6: Representation of the step size calculation within the MCRT grid. This shows a
one dimensional case, however the same technique is used for three dimensional grids.
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Interaction event
After travelling a physical distance S, the photon is either scattered or absorbed. The probab-
ility of the photon being scattered is determined by the albedo,
a =
µs
µa+µs
=
µs
µt
(2.19)
where the scattering coefficient, µs and absorption coefficient µa, are the local optical
properties at the interaction site (in the units of length 1). The interaction event is determined
again by random number generating. If the randomly generated number ⇠ is less than or
equal to the albedo, the photon is scattered and given a new direction and a new optical
depth. When determining the scattering angle, both the polar angle, ✓ (0  ✓   ⇡), and the
azimuthal angle   (0      2⇡) have to be determined. The azimuthal angle is assumed to
have a isotropic distribution and hence is sampled by,
  = 2⇡⇠ (2.20)
The most common way of describing the polar scattering in tissue is through the Henyey-
Greenstein phase function. The phase function was originally introduced to describe scatter-
ing of light from distant galaxies by dust in our galaxy. The phase function, Ph(✓ ) [138],
describes the probability of a photon travelling in direction sˆ scattering into the direction sˆ0
and is expressed as follows,
Ph(✓ ) =
1  g2
4⇡(1+ g2  2gcos✓ )3/2 (2.21)
Here ✓ is the angle between the direction of travel (sˆ) to the direction after scattering (sˆ0).
g is the anisotropy factor, which is defined as the average of cos✓ ,
g = hcos✓ i=
Z ⇡
0
Ph(✓ )cos✓2⇡sin✓d✓ (2.22)
The phase function allows for scattering that is not symmetric relative to the direction
of travel. g takes a value between -1 and 1, where g=0 for photons that are isotropically
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scattered. Skin tissue is however very forward scattering and therefore a typical value for g is
in the range 0.7 - 0.9 [139]. To sample the scattering angle from the probability distribution
(equation 2.21), the CDF has to be generated in a similar way as the optical depth. The CDF
equals to one when the the phase function (equation 2.21) is integrated over all sold angles
such that
Z 2⇡
0
d 
Z ⇡
0
Ph(✓ )sin✓d✓ = 2⇡
Z ⇡
0
Ph(✓ )sin✓d✓ = 1 (2.23)
The angle ✓ can therefore be sampled such that,
2
Z ✓sample
0
Ph(✓ )sin✓d✓ = ⇠ (2.24)
Hence,
cos✓sample =
8<: 12g
⇢
1+ g2 ⇣ 1 g21 g+2g⇠⌘2  , g 6= 0.
2⇠  1, g = 0.
(2.25)
The sampled angle will be in relation to original direction of the photon. Hence to translate
the new angle to the global Cartesian coordinate system, the following transformations are
applied [113],
n0x =
sin✓ (nxnzcos    nysin )p
1  n2z
+ nxcos✓
n0y =
sin✓ (nynzcos  + nxsin )p
1  n2z
+ nycos✓
n0z =  
∆
1  n2z sin✓cos  + nzcos✓
(2.26)
Where n0x, n0y andn0z corresponds to the new directions and nx, ny andnz are the original
directions. To avoid division by small numbers, trajectories close to alignment along the z-axis
( i.e. | nz | close to 1), the following compotents of a unit vector are adopted,
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n0x = sin✓cos 
n0y = sin✓ sin 
n0z = sgn(nz)cos✓
(2.27)
This approximation is adopted when | nz | is larger or equal to 0.999. The reason for
adopting these approximations is to avoid division by small numbers and thereby round-off
errors.
Reflection and refraction
To take into account for the reflection and refraction at the surface boundary (both from
above and below) Fresnel’s equations and Snell’s law were implemented. The probability that
a photon is reflected at the boundary (figure 2.7) between two different media R(✓i,✓t) can
be expressed using the following equation [140],
R(✓i,✓t) =
1
2
24    nicos✓i  ntcos✓tnicos✓i+ ntcos✓t
    2+     nicos✓t  ntcos✓inicos✓t+ ntcos✓i
    2
35 (2.28)
where ni is the refractive index of the incident medium and nt is the refractive index of
the second medium. ✓i is the incident angle that the photon hits the boundary and ✓t is the
refractive angle determined by Snell’s law,
nisin✓i = ntsin✓t (2.29)
Again, a random number, ⇠, is generated to determine if the photon is reflected or refrac-
ted between the boundary. If ⇠ > R(✓i,✓t), the photon is reflected and does not cross the
boundary.
Other important parameters
When a photon is absorbed, an amount of energy is deposited in the tissue. Instead of counting
each individual absorption event, the energy absorption per cubic centimetre per second is
computed by,
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Figure 2.7: Representation of the reflection and refraction of light at the interface of two
media of different refractive indices. The angle of refraction, ✓t, is determined by Snell’s law
(equation 2.29) and the probability of refraction (1-R) and reflection (R) is determined by
Fresnel’s equation (equation 2.28 ).
Q =
IA
N V
X
i
µasi (2.30)
Here µasi is the probability of absorption over the photon path si in voxel i. I is the
irradiance (Wcm 2) of the light, A is the area of the top of the grid ( cm2), N is the number
of simulated MCRT photons and  V is the volume of each grid cell. The fluence rate  
(Wcm 2), which describes the light distribution (equation 2.4) within the tissue, is computed
through similar techniques,
 =
IA
N V
X
i
si (2.31)
Here
P
i si is the sum of photon path length within a cell i. This technique of computing
the light distribution and energy deposition within the simulated region drastically improves
the signal to noise ratio due to the scattering dominating the interaction events. If each
absorption event was counted this would result in poor statistics [141]. A further discussion
on the path length summation can be found in appendix A.
As previously mentioned the photon paths are tracked until they are either absorbed or
exit the simulation region. If the photons exit the grid through the top or the bottom (i.e.
z-faces) of the grid their paths are terminated. For photons exiting the sides of the simulation
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grid (i.e. x- and y-faces), their paths are not terminated if repeated boundary conditions are
adopted (adopted in all chapters except for simulations performed in section 2.5.2). When
repeated boundary conditions are adopted, the photons that exit one side of the grid are re-
launched on the opposite side of the simulation region. Figure 2.8 demonstrates how the
repeated boundary conditions are adopted. The photons that exit the grid through the x- or
y-face will continue its projection on the opposite side of the grid. If the photon for example
left the simulation grid through its y-face at (x, ymax, z), it will continue in the same direction
from location (x,0, z). This results in the representation of a semi-infinite tissue slab where
the light source is assumed to be larger than the simulation grid and thereby considering light
contributions from a larger area. The code that was used for the simulations in this thesis
was written in FORTRAN on a contemporary computer (MacBook Pro, 2.9 GHz processor). A
typical simulation in this thesis where 106 photons is simulated at 405 nm takes less than 20
seconds to run (serial, single processor (not parallelised)). This might to some present-day
readers appear to be fast. However, I hope that those reading this thesis in several years time
will consider this slow.
Figure 2.8: Figure demonstrating the principles behind repeated boundary conditions.
Photons exiting the simulation region from the sides (x- or y-face) will continue their tra-
jectories in the same direction on the opposite side of the grid as demonstrated here. This
results in the representation of a semi-infinite tissue slab.
2.5 Experimental validation
The MCRT model describes the photon propagation through a turbid medium and can be
used to determine optical properties of the medium by comparing the experimental results
to theoretical results. The aim with the experimental validation was to both determine the
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concentration dependent optical properties of Intralipid as well as successfully reproduce the
experimental measurements.
2.5.1 Experimental design
The solutions that were prepared contained Coproporphyrin III with varied concentrations of
Intralipid 20% (Fresenius Kabi, Germany) and distilled water. Intralipid is highly scattering
and is frequently used for studying light propagation through turbid media [142]. Copropor-
phyrin III is a stable fluorescing standard (stable compared to for example protoporphyrin IX).
Due to the stability of Coproporphyrin, it is ideal for comparing the fluorescence signal in dif-
ferent solutions. The different solutions were added to a 10 mm x 10 mm cuvette which was
placed in a cuvette holder (figure 2.9). The fluorescence signal was measured using an optical
biopsy system (OBS). The OBS operates on the principles of fluorescence spectroscopy [143].
It houses a low powered 405 nm laser diode (approximate 1mW output) and can be used
for in vivo, non-invasive monitoring of tissue fluorescence. The blue light is coupled to a
fibre probe (inner diameter of 600 µm), which is both used for excitation light as well as
collecting the resulting fluorescence light. The probe has to be in contact with the subject of
measurements, which in this case was one of the cuvette sides. This is however equally valid
for measurements in contact with skin tissue (chapter 7) [103]. A bifurcated fibre (Avantes
FCB-UV400-2) 455 nm long-pass filter is introduced to allow the excitation light and collected
signal to be separated and the backscattered light from the excitation to be eliminated from
the recorded spectra. The collected light was recorded using a compact grating spectrometer
interfaced with a PC (figure 2.10) [144].
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Figure 2.9: Experimental set of where the cuvette was placed in the cuvette holder. The
fluorescence signal was acquired through the probe which was assured to be in contact with
the cuvette surface. In the laboratory experiment, the cuvette replaced the skin in figure
2.10.
Figure 2.10: Schematics of the optical biopsy system (OBS) where all components, except
for the laptop computer are eclipsed within a box to prevent any stray light effecting the
measurements. The multimode fibres has a core diameter of 600 µm and a outer (cladding)
diameter of approximately 2 mm.
5 ml of each concentration of Intralipid 20 % was made up to generate concentrations of
0.2, 0.5 and 0.8 % of Intralipid 20 %. To each 5 ml solution, 1 ml of Corpoporphyrin III was
added, the volume concentration of Intralipid 20 % was therefore adjusted according to table
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2.1.
Table 2.1: Intralipid solutions used for the experimental validation .
Volume measurements (ml)
Intralipid 20% H2O Coproporphyrin III Intralipid 20 % concentration
0.04 4.96 1 0.67%
0.03 4.98 1 0.42%
0.01 4.99 1 0.17%
2 ml of each solution in table 2.1 was added to a cuvette and the fluorescence signal was
recorded (by the OBS). In addition the fluorescence signal from a cuvette containing only
Coproporphyrin III as well as from an empty cuvette. The reason for the fluorescence signal
being recorded for the Coproporphyrin only was to determine the fluorescence signal when
there were no scatterers present. This generated the fluorescence emission spectrum for PpIX
which was subsequently used for the simulations (see below). The background effect from
the cuvette was determined through the empty cuvette. The fluorescence signal acquired from
the cuvette containing distilled water was subtracted from the other solutions to remove the
background signal generated by the cuvette. The same cuvette was used for all measurements
to ensure consistency. The absorption properties of the Coproporphyrin III (100 %) were
measured using a spectrophotometer and the total attenuation coefficient can thereafter be
determined through Beer-Lambert’s law (equation 2.10) [113].
2.5.2 Simulation design
The aim with the theoretical simulations was to generate a computer model which success-
fully reproduced the experimental measurements. Two species were included in the model
and were assumed to be uniformly distributed throughout the simulated region. The first
species was the solution containing Intralipid 20 % and the second species represented the
Coproporphyrin III. The optical properties for these two different species had to be determined
and included within the simulation. Intralipid is highly scattering and therefore the albedo
was assumed to be 0.999 [144]. The anisotropy factor was assumed to be 0.7 following work
from Flock et al [145]. Coproporphyrin is highly absorbing and therefore it was assumed that
the scattering associated with Corporporphyrin was negligible (i.e. the albedo is assumed
to be zero). The refractive index was set to be 1.33 (water). The scattering coefficient for
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Intralipid 20 % is previously known [142] (figure 2.11), however the scattering properties
do not scale linearly with Intralipid concentration in aqueous suspensions [146]. Previous
work at Ninewells hospital, Dundee [144] determined the total attenuation coefficient for the
concentrations 0.2, 0.5 and 0.8 % of Intralipid 20 % at only three wavelengths (632, 532
and 405 nm). For the work presented here a larger wavelength range was required since the
Coproporphyrin fluorescence signal covers a wavelength range between approximately 550
and 700 nm. In an attempt to scale the optical properties associated with the investigated
concentrations, a power law was fitted to the concentration dependent attenuation coefficient
previously determined. The power law function was used to scale the scattering coefficient
for Intralipid 20% (figure 2.11). To ensure that these coefficients are correct, the relationship
between the change in fluorescence signal due to change in concentration of scatterers have
to be the same for the experimental measurements as well as the MCRT simulations. The
absorption properties adopted for the Coproporphyrin is displayed in figure 2.12 a.
The Cartesian grid was given the dimension 10mm⇥ 10mm⇥ 10mm, to represent the
same dimensions as the cuvette. It was assumed that the light from the OBS was emitted
at 405 nm, through a circular region with a diameter of 600 µm. 109 photons were simu-
lated to ensure good signal to noise. The fluorescence quantum yield was assumed to be 1
and the fluorescence photons were assumed to be isotropically emitted from the absorption
location. A new wavelength sampled from the Coproporphyrin fluorescence spectrum (figure
2.12 b) was given to the fluorescence photon. The fluorescence photons were samples from
the fluorescence spectrum such that the probability distribution function of the spectrum was
reproduced. In reality the fluorescence yield is considerably lower than 1, however the results
are linearly scalable with the fluorescence yield. Only fluorescence photons exiting the sur-
face of the grid at an angle corresponding to a numerical aperture of 0.22 were collected and
binned according to wavelength.
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Figure 2.11: Scattering coefficient for Intralipid 20% [142].
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Figure 2.12: a) Absorption coefficient for Coproporphyrin III b) Fluorescence signal gener-
ated by sample of pure Coproporphyrin III
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2.5.3 Results, experimental validation
The scaling power law function determined from the properties already known from previous
work, is displayed in figure 2.13. The fitted function B scales the optical properties µs( , 20%)
in figure 2.11 such that µs( , 20%) = Bµt( , Concentration). B is determined to be 6.98⇥
x 0.96 where x is the concentration in % of Intralipid 20 %. µt was determined instead of µs
since µa is small (the albedo is set to be 0.999). By scaling the optical properties in figure
2.11 by B, the optical properties for the different concentrations were determined.
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Figure 2.13: Power law fitted between three scaling factors between Intralipid 20 % and
lower concentrations of Intralipid 20 %. The fitted function has the form B = 6.98x 0.96
where x is the concentration of Intralipid 20 % [144].
The fluorescence signal recorded through the described experimental set-up, and the the-
oretically generated fluorescence signal from the MCRT code, are both shown in figure 2.14.
The experimental measurements (solid line) showed that the fluorescence signal reduced
with increasing Intralipid concentration. This was also demonstrated successfully with the
MCRT model using the scaling of the optical properties described above. The change in signal
strength can be explained by the increasing concentration of scatterers resulting in a more
dispersed fluorescence signal. This results in a reduction of the collected light through the
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small probe region. It was important to include the restricted collection region for the probe
to accurately represent the smaller amount of collected light.
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Figure 2.14: Figure showing the fluorescence signal generated both experimentally and
theoretically for varied concentrations of Intralipid 20 %. The solid lines corresponds to the
experimentally measured fluorescence signal using the OBS. The dashed lines corresponds to
the theoretically determined fluorescence signal through the MCRT modelling. The varied
concentrations for Intralipid 20 % was a) 0.2 %, b) 0.5 % and c) 0.8 % (concentration
before Coproporphyrin III was added).
2.6 Theoretical validation
To ensure the accuracy of the code it is important to be able to reproduce previously generated
results at any point during the code development. Jacques et al [97] presented results from a
MCRT code where several of the important parameters that are used in subsequent chapters
were discussed [97]. Jacques fitted functions to data generated from MCRT simulations, to
describe several properties associated with light propagation through skin tissue during PDT
treatment. The MCRT model adopted uniform illumination of the surface of the simulated
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region. The absorption and scattering events were determined using the optical properties
presented in table 2.2. The reflection and refraction from the upper boundary was considered
(equation 2.28). The fluence rate (equation 2.4),  (z), through skin tissue of known optical
properties (table 2.2) as a function of depth was described through the following equation,
 (z) = 0(C1e k1z/    C2e k2z/ ) (2.32)
where C1, k1, C2, andk2 are the fitting parameters specific for different wavelengths (table
2.2).  0 corresponds to the incident irradiance of the light source. Jacques also modelled PDT
where the light sensitive molecule protoporphyrin IX (PpIX) was introduced within the simu-
lated region. The simulated region was assumed to have an initial homogeneous distribution
of the PpIX. The escaping fluorescence emission, E(z), was suggested to follow the function,
E(z) = C3e k3z/  (2.33)
The escaping fluorescence emission is the proportion of the fluorescence photons that
escape the simulated region originating from a specific depth (z). The simulated region was
assumed to have optical properties as suggested by table 2.2. The escaping fluorescence signal
(equation 2.33) describes the fluorescence signal generated at 705 nm after being excited by
630 nm light. The MCRT model assumed that each absorbed photon (by the PpIX) resulted
in a fluorescence photon, isotropically re-emitted at 705 nm. Equation 2.33 was fitted to the
MCRT result generated by Jacques with C3, k3 and  corresponding to the established fitting
parameters (table 2.2) [97].
Table 2.2: Tissue optics parameters for equation 2.32 and 2.33 as well as the MCRT model
[97].
 
[nm]
µa
[cm 1]
µs
[cm 1]
C1 k1 C2 k2 C3 k3  
[cm]
420 1.8 82 5.76 1.00 1.31 10.2 0.290
630 0.23 21 6.27 1.00 1.18 14.4 0.290
705 0.23 17 0.771 0.994 0.290
During the light illumination the distribution of PpIX is reduced due to the photobleaching
(section 1.6.1, chapter 1). Therefore, when simulating the PDT treatment, photobleaching is
a very important property to include. It is typically assumed that the photobleaching follows
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first order kinetics where the local distribution of PpIX, C(z, t) reduces with time as follows
[147],
C(z, t) = C0e  (z)t/  (2.34)
Here C0 is the local initial concentration prior to illumination.   is the photobleaching
constant (J cm 2) which is defined as the light dose required for the fluorescence signal gen-
erated by the PpIX to be reduced to 1/e (37 %) of its original value [56].   is unique for
the excitation wavelength (section 3.3.2) and will be discussed further in chapter 3. t is the
total treatment time, hence a time dependent simulation is required. When the concentration
of PpIX is reduced, the optical properties associated with the PpIX are also affected, since
µt = n  = C". Here " is the extinction coefficient (cm 1(µg/ml) 1),   is the cross section
(cm2), C is the local concentration (µg/ml) and n is the number density of scatterers (cm 3).
As the amount of the photosensitiser reduces the resulting fluorescence signal will also re-
duce. The function explaining the reduction of the observed fluorescence with time that was
fitted to the MCRT results generated by Jacques et al was expressed by the equation,
F(t) =
Z 1
0
 ex(z)"C(z, t) E(z) f dz (2.35)
where   is the fluorescence yield which was assumed to be 1, in order to improve signal
to noise (section 2.5.2). f is the collection efficiency which was also assumed to be 1,  ex(z)
refers to the excitation fluence rate (equation 2.32).
Jaques also introduced photodynamic dose (PDD), which is defined as the number of
absorbed photons (by the sensitiser) per cubic centimetre. The accumulation of the PDD was
expressed as,
@ PDD(z, t)
@ t
= b (z)"C(z, t) (2.36)
Hence,
PDD(z, t) = b"C0 (1  e  (z)t/ ) (2.37)
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where b is the conversion from energy to number of photons,
b =
1
h⌫
=
 
hc
(2.38)
where h is Planck’s constant, ⌫ is the photon frequency, c is the speed of light and   is the
wavelength of light.
The initial concentration of PpIX was assumed to be 0.2 µgml 1. The photobleaching con-
stant   was assumed by Jacques to be 105 Jcm 2 and the extinction coefficient was assumed
to be 0.0265 cm 1(µg/ml) 1 at 630 nm and 0.105 cm 1(µg/ml) 1 at 420 nm. These are the
properties used in both the equations above as well as the MCRT model described below. The
irradiance was set to be 0.1 Wcm 2.
2.6.1 Simulation design
The equations outlined here (equation 2.32 - 2.37) are the ones presented by Jacques et al
describing the light propagation through tissue of known optical properties. The equations
were developed from fitting equations to results generated by a MCRT model. As a validation
of the developed model presented in this thesis, the equivalent results were generated using
the MCRT model developed and described previously in this chapter.
The code that was used for this validation was given the dimensions 2mm ⇥ 2mm ⇥
2mm (100⇥ 100⇥ 100 grid cells). The grid was assumed to be uniformly illuminated over
the top surface of the grid (figure 3.2). By adopting the optical properties in table 2.2 the
fluence rate was generated in the developed MCRT code using the techniques described above
(equation 2.31). To determine the escaping fluorescence, similar techniques described above
were adopted. The excitation light was assumed to be 630 nm, and all absorption events were
assumed to result in a isotropic reemission of a photon at 705 nm. The fluorescence emission
was recorded for those photons that escaped the simulated grid through the top surface.
To incorporate the photobleaching, a time parameter had to be included in the developed
code. This was done by adding an iterative time loop where the time was increased stepwise.
For each time iteration the same number of photons were simulated and a new concentration
of the sensitiser was determined (equation 2.34).The length of each time step was adjusted
appropriately. At the start of the treatment, the photobleaching results in large reductions
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of PpIX, hence the time steps have to be small (seconds). After the first couple of simulated
minutes the majority of the PpIX at superficial layers have been bleached and the reduction of
PpIX concentration at deeper layers is slower and therefore larger time steps can be adopted
(minutes).
As with the escaping fluorescence, when determining the fluorescence evolution with time,
the number of escaping fluorescence photons during each time step was recorded. This simu-
lation was performed for both excitation wavelengths 420 nm ad 630 nm.
The PDD, which is an important parameter when determining the photo-toxicity within
the skin tissue as it changes with time, also required the time iterations described above. This
quantity will be utilised in subsequent chapters and therefore it is especially important to
validate this.
During each time step the amount of absorbed energy per second  Q was determined
(equation 2.30). This quantity was thereafter converted into the number of real photons
(equation 2.38) and multiplied by the time step t. This way the number of photons absorbed,
per cubic centimetre during  t was calculated,
 PDD = Qb t (2.39)
The accumulated PDD over the full illumination period t, was calculated by summing all
the individual contributions over the total illuminated timed
PDD(t) =
X
t
 PDD (2.40)
For the simulations of PDD a toxic threshold is included. The toxic threshold is an approx-
imation of the number of photons required to be absorbed for an effective PDT outcome. The
value of 8.6⇥ 1017 photons cm 3 is based on Photofrin in liver tissue, where Photofrin is an
alternative photosensitiser [148]. The same threshold will be adopted throughout the follow-
ing chapters since it allows for comparison between the different conditions investigated as
well as providing quantitative results. Typical values stated for a toxic threshold are in the
regions of 1017 1019 photons cm 3 [1,148,149], therefore the toxic threshold applied is an
approximation of the required dose.
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2.6.2 Results of the theoretical validation
The four different quantities: fluence rate  (z), escaping fluorescence E(z), observed fluor-
escence F(z) and PDD, were computed from the fitted functions introduced by Jacques et
al [97] as well as through the MCRT model developed here. As displayed in figures 2.15-
2.18, all four quantities showed good agreement between the predictive equations and MCRT
results. Figure 2.15 shows the normalised fluence rate for 630 nm and 420 nm, where the
optical properties in table 2.2 were adopted within the MCRT model. The normalised fluence
rate,  / 0 is defined as the fluence rate divided by the incident irradiance of the light source.
The escaping fluorescence at 705 nm when excited with 630 nm light is shown in figure 2.16.
The results from the model of the observed fluorescence is displayed in figure 2.17 where
both 420 nm and 630 nm were used as excitation wavelengths. When simulating the PDD,
figure 2.18 was produced where the MCRT modelling and predicted equations are compared
showing excellent agreement. Here the same time points during illumination were displayed
for the theoretical predictive model as well as from the MCRT model.
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Figure 2.15: Figure showing the fluence rate (normalised) generated using equation 2.32
(solid) as well as the fluence rate generated by the MCRT simulation (dashed). The optical
properties adopted in the simulations are reported in table 2.2. The fluence rate for 420 nm
(blue) and 630 nm (red) are represented in the figure.
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Figure 2.16: Figure showing the proportion of the fluorescence emission that escapes the
tissue originating at depth z (x-axis). Both the predicted escape fluorescence (equation 2.33;
solid) and MCRT simulations (dashed) are displayed. The figure was generated from emis-
sion of 630 nm where the fluorescence signal isotropically re-emitted at 705 nm.
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Figure 2.17: Figure representing the fluorescence observed as it changes with elapsed expos-
ure time where both 420 nm (blue) and 630 nm (red) are used as excitation wavelengths
for isotropic re-emission of 705 nm. The observed fluorescence is defined as the proportion of
fluorescence photons escaping the top of the simulated grid relative to the initial fluorescence
(fluorescence observed at time zero). The observed fluorescence is plotted as a function of
t/⌧ where ⌧ =  / 0 where  0 is defined as the irradiance of the light source and   is
the photobleaching dose constant. The observed fluoresce predicted by equation 2.35 (solid)
is plotted together with the results generated by MCRT simulations using the appropriate
parameters (table 2.2 ; dashed)
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Figure 2.18: Figure showing the photodynamic dose (PDD) in the presence of photobleach-
ing as a function of depth and time elapsed. The initial concentration of the photosensitiser is
assumed to be uniformly 0.2µgml 2 and the irradiance is assumed to uniformly illuminate
the top surface of the simulating grid at 0.1Wcm 2. Both the prediction based on equation
2.37 (black) as well as MCRT simulations (red) are displayed at time 1-10 min in steps of 1
min as well as 10 - 60 min in steps of 10 min. The horizontal line corresponds to the toxic
threshold which is assumed to be 8.6⇥ 1017photons cm 3.
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2.7 Discussion
MCRT is a recognised technique for studying light distribution through a turbid medium. This
chapter describes the technique and the developed code that will be used in chapters 3 - 6.
The aim with the developed code is to study light interaction with skin tissue during PDT.
By rigorous validation of the code, the accuracy of subsequent simulations is supported. It is
important to revisit the same simulations during further code developments to ensure that the
same results are generated. By adopting a voxel based approach, errors due to the boundaries
between voxels as well as issues arising at the edge of the simulating envelope can arise,
which are important to consider when analysing simulation output [109].
The experimental validation demonstrates the potential of using MCRT to determine op-
tical properties of a turbid medium. Similar surface measurements can be used to determine
optical properties of skin tissue by using a diffuse reflectance measurements technique and re-
lating the observations to specific optical properties using a MCRT model [105,150,151]. By
successfully simulating the observed fluorescence, other simulations of the fluorescence signal
are supported (chapter 4). It was clear during the development of the fluorescence code that
it was important to represent accurately the collection region of light. Only by implementing
the small collection region and the correct angle corresponding to a numerical aperture of
0.22, could the observed fluorescence be reproduced accurately. The importance of including
the reflectance from upper boundary was also introduced as a feature to include within the
model to enable both the experimental and theoretical validation.
The theoretical validations demonstrate the successful reproduction of predictive equa-
tions of many parameters important to light distribution through skin tissue. The PDD will be
used extensively in the remaining chapters in this thesis to determine the toxicity caused by
different light sources and different treatment conditions. The same toxic threshold will be
adopted since this allows for comparison between different treatment conditions.
The code utilises a three dimensional grid system, which allows for complex geometrics
of different species within the simulation region. This is an advantage compared to many
other developed MCRT models where a 1D layered representations is most commonly adopted
[107]. The grid system allows for 3D representation of different skin features such as blood
vessels, tumours and melanin content. The possibility of adding 3D structures with different
optical properties will be explored further in chapter 5 6.
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2.8 Conclusion
The MCRT technique utilises the probabilistic nature of photon interactions, and due to this
statistical nature a large number of photons are required to achieve accurate information
about the photon propagation. This results in a fast and accurate technique (on contempor-
ary computers) which accurately yields information about reality. This chapter discusses the
key features of the MCRT technique and the development of the code that is utilised in the re-
maining chapters of this thesis. To ensure that the developed code generates accurate results
and is appropriate for applying to PDT, rigorous validations were performed. Due to the cap-
ability of accurately representing scattering, absorption, reflection, transmission, fluorescence
and PDD within skin tissue and other turbid media this technique is shown to be suitable for
simulating PDT and other light based therapies.
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3
Monte Carlo radiation transfer modelling of
daylight activated photodynamic therapy
3.1 Summary
The treatment of superficial skin lesions via daylight activated photodynamic therapy (PDT)
has been explored theoretically using three dimensional (3D) Monte Carlo radiation trans-
fer (MCRT) simulations. For similar parameters and conditions, daylight activated PDT was
compared to conventional PDT. Under reasonable assumptions for the optical properties of
the tissue, protoporphyrin IX (PpIX) concentration, and a treatment dose of 75 Jcm 2, it was
found that during a clear summer day an effective treatment depth of over 2 mm can be
achieved after 30 min of daylight illumination at a latitude of 56 degrees North. The same
light dose would require 2.5 h of daylight illumination during an overcast summer day where
a treatment depth of just under 2 mm can be achieved. For conventional PDT the developed
model suggests that 15 min of illumination is required to deliver a light dose of 75 Jcm 2,
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which would result in an effective treatment depth of about 3 mm. The model developed here
allows for the determination of photo-toxicity in skin tissue as a function of depth for differ-
ent weather conditions as well as for conventional light sources. Our theoretical investigation
supports clinical studies and shows that daylight activated PDT has the potential for treating
superficial skin lesions during different weather conditions.
The work presented in this chapter contributed to the publication "Monte Carlo model-
ling of daylight activated photodynamic therapy" in "Physics in medicine and biology" (2015)
[127].
3.2 Introduction and background
PpIX absorbs light over a wide range of the visible spectrum and therefore a range of dif-
ferent light sources are suitable for treatment. Daylight-PDT removes the need for artificial
light sources, results in less pain during treatment [152], and in clinical studies was the
preferred choice of treatment for many patients [80]. In addition to the reduced pain, pa-
tients have been found to have equally efficient treatment outcomes compared to conventional
PDT [34,81–83,92,93]. Due to these recent clinical studies indicating the successful applica-
tion of daylight-PDT, it is of interest to further investigate the potential and limitations of this
treatment modality. To my knowledge, there have not been any theoretical investigations of
daylight PDT and in this chapter results from a 3D Monte Carlo radiation transfer (MCRT)
model which simulates daylight PDT are presented. The methods used in this work allow the
determination of the photo-toxicity at different depths in the simulated skin and tumour tissue
for different light sources and, in the case of daylight-PDT, for different weather conditions.
The model adopts the same conditions for daylight PDT as for conventional PDT, where the
PpIX is already accumulated before the tissue is exposed to the light source. The parameters
investigated include initial distribution of PpIX and delivered light dose. In chapter 4, time
and depth dependent distribution of PpIX is discussed and compared with the uniform initial
distribution. The main aim with this chapter lies in the code development and methodology
to allow for further development of the code where more parameters can be considered in
subsequent chapters.
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3.3 Methods
A MCRT model was developed to simulate the transport, scattering and absorption of light
through the skin tissue during illumination. The MCRT, using the probabilistic nature of
the photons, generates accurate information about the light distribution and energy depos-
ition during light illumination [108,117,153]. The different light sources were simulated by
sampling wavelengths from the corresponding light spectra. Different ratios of the diffuse and
direct daylight contributions allowed for different weather conditions to be represented.
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Figure 3.1: Wavelength dependent optical properties of tumour and skin tissue. The black
curves correspond to the scattering coefficients (solid line corresponds to healthy skin tissue
and dashed line corresponds to nodular BCC tissue). The red curves, plotted on the right axis,
indicate the absorption coefficients for both healthy (solid) and nodular BCC tissue (dashed).
The optical properties for healthy skin tissue are based on a modelling approach developed
by Yudovsky et al [154, 155] which takes into account different contributions of different
chromophores. The scattering coefficients for tumour tissue are based on the interpolation of
data extracted from Salomatina et al [156] using the approach developed by Jacques [112].
3.3.1 Optical properties
The MCRT code developed here can incorporate optical properties representing different types
of tissue, determined from theory or experiment. For the simulations presented in this chapter,
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the wavelength dependent scattering (µs) and absorption coefficients (µa) for skin tissue and
tumour tissue shown in figure 3.1 were adopted [154–156] . Many studies report a wide
range of values for the optical properties of human skin and are summarised in recent review
papers by Lister et al [111] and Jacques [112].
In this work, the model developed by Yudovsky et al [154, 155] was employed. This
model is based on in vivo measurements, and determines the optical properties for healthy
skin tissue over the wavelength range required for daylight PDT modelling. The scattering
coefficients for the tumour tissue (nodular basal cell carcinoma, nBCC) were taken from the
model developed by Jacques which is based on the data from Salomatina et al [112, 156].
The absorption coefficients for the tumour tissue are based on data determined by in vitro
measurements of nBCC [156]. For further discussion on optical properties, see chapter 5.
The angular scattering phase function was modelled using the Heyney-Greenstein phase
function (chapter 2, section 2.4.1) where the wavelength dependent anisotropy factor g =
0.62+0.29⇥10 3 (nm)was adopted. Polarisation is not considered and the reflectance at the
air/tissue interface was determined using Fresnel reflectance assuming a uniform refractive
index of 1.38 for the skin surface (equation 2.28).
An initial uniform distribution of PpIX was assumed where the absorption properties of the
PpIX affect the photodynamic dose (PDD) and thus the efficacy of different PDT treatments.
The wavelength dependent absorption of the photosensitive chemical PpIX is shown in figure
1.4 (chapter 1). The absorption spectrum is measured using a spectrophotometer and was es-
tablished from previous work in the group [55,56,100]. The absorption properties of the PpIX
are important to the outcome of the treatment since it affects the amount of energy absorbed
by the photosensitiser and thus the efficacy of the PDT treatment. To explore this feature fur-
ther different initial concentrations of the PpIX were explored in this chapter. By increasing or
alternatively reducing the initial concentration of PpIX, a wider range of potential absorption
coefficients for the PpIX were investigated.
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Figure 3.2: The MCRT simulation employs a 3D Cartesian grid (101 grid cells on a side)
which is illuminated from above. The optical properties are determined in each individual
grid cell. A cylindrical tumour is added in the centre of the grid, where the PpIX is accumu-
lated and assumed to be of uniform density. The dimensions of the grid are 10 mm on a side
and the tumour diameter is 6 mm.
3.3.2 Coding implementation
For the model presented here the dimensions of the simulated region was set to be 10 mm
x 10 mm x 10 mm where a cylindrical tumour was positioned in the centre of the grid with
a diameter of 6 mm (figure 3.2). The tissue outside the tumour was assumed to be of a
single tissue type (dermis) with a smooth uniform structure with different optical properties
compared to the tumour. The PpIX was restricted to the tumour tissue and was assumed to
have a uniform initial distribution within the cylindrical tumour corresponding to a number
density of 7.84⇥1013 cm 3. Repeated boundary conditions were adopted to simulate a semi-
infinite tissue slab. Source photons were launched from the top of the grid and assigned an
initial direction and wavelength depending on the source being simulated (e.g. daylight or an
artificial light source). They were followed until they were either absorbed or scattered out of
the simulation grid (top or bottom of the grid) as described in chapter 2.
A time dynamic was added to the code to take into account the photobleaching that
changes the spatial distribution of PpIX throughout the treatment. At each time step 5⇥ 106
photons were launched and the photobleaching was determined before the simulated time
was increased and the process was repeated. The time dependent photobleaching of the PpIX
was considered as described in chapter 2 (section 2.6)). However to take into account for
a wide wavelength range (as in the case for Daylight-PDT) a wavelength dependent pho-
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tobleaching constant can be adopted [97,143]. Therefore the previous photobleaching equa-
tions discussed in chapter 2 (equation 2.34), can be modified in the following way,
C(x , y, z, t) = C0(x , y, z)e  (x ,y,z)t/ ( ) (3.1)
where again C(x , y, z, t) is the time dependent PpIX concentration at location (x , y, z)
at time t, C0(x , y, z) is the initial concentration, and  (x , y, z) is the local fluence rate in
Wcm 2. In the model described in chapter 2 (section 2.6) the fluence rate was kept constant
for all simulated time steps. For the work presented here the fluence rate was updated for
each time step to take into account the change in PpIX concentration due to photobleaching.
As mentioned in chapter 2, the photobleaching constant,   , is defined as the light dose
(J cm 2) required to reduce the fluorescence signal from the photosensitiser by 37% (1/e).
The value for   has previously been established to be 14 Jcm 2 for 630 nm irradiation [100].
To my knowledge there is no information about how the photobleaching constant changes
with wavelength. The assumption that has been made here to make   wavelength dependent
is an inverse proportionality between   and the absorption of the photosensitiser. This allows
the photobleaching equation to include the difference in absorption for different wavelengths
and to account for the different energies carried by photons of different wavelengths. Since
clinical data verifying the photobleaching constant is only available at 630 nm, for the simula-
tions presented here the following wavelength dependence was applied to the photobleaching
constant
 ( ) =
 630 µa630  630
  µa 
(3.2)
where  630 = 14 Jcm 2 (clinically determined [100]), µa630 is the absorption coefficient of
PpIX at 630 nm,  630 equals 630 nm,   is the wavelength of the simulated photon in nm and
µa  is the absorption coefficient for PpIX at that wavelength. The photobleaching equation
(equation 3.1) [97, 100] assumes an exponential decay, an unlimited oxygen supply and is
assumed to be applied over the wavelength range 350 - 750 nm.
The reason why the proportionality in equation 3.2 was assumed is motivated by the max-
imum achievable photobleaching. When the PpIX is fully photobleached the PDD is saturated
and therefore there is a maximum number of photons that can be absorbed by the photo-
sensitiser before it is fully photobleached and this level is assumed to be the same for all
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wavelengths. By adopting the wavelength dependency discussed above, the saturated PDD
level is equal for all light sources and treatment conditions and is therefore believed to be
plausible.
The value for  630 has, as previously mentioned, been clinically determined to be 14
Jcm 2. A range of values have been reported [147, 157–159] which encourages a further
exploration of this parameter. For this reason the photobleaching dose constant  ( ) was
multiplied and divided by three in equation 3.2 to further explore the range of possible values.
The PDD was computed in the same way as described in chapter 2 (section 2.6.1) and the
same toxic threshold was applied (8.6⇥1017 photons cm 3). Although this threshold is based
on measurements of Photofrin in liver tissue it was adopted for illustrative purposes, allowing
for comparison with previously published models [97, 100]. For most of the simulations
presented here the maximum light dose delivered was 75 Jcm 2 since this is a typical light
dose delivered during conventional PDT treatment. This allows for comparison between light
sources under the same conditions. To simulate longer treatment times for daylight PDT, a
larger light dose was computed.
Figure 3.3: Daylight consists of both direct and diffuse light. Direct photons in the MCRT
simulation are assigned a single angle of incidence. Diffuse light isotropically illuminates the
surface of the skin phantom and consists of photons that have been scattered from particles
and aerosols in the atmosphere. On sunny days the proportion of direct light will be larger
and on an overcast day 100% of the daylight is assumed to be diffuse light.
3.3.3 Natural and artificial light sources
The light distribution under the surface of the skin depends on the incident light field which
in the case of daylight PDT consists of both direct and diffuse sunlight (figure 3.3). Due to
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the differences of the spectral and angular illumination between the diffuse and the direct
light, it is important to decompose their relative contributions [160]. The light distribution
during daylight illumination also depends on weather conditions, time of the day and month
of the year [161]. In the simulations it was assumed that the direct sunlight enters the
skin at a constant angle depending on the latitude on Earth (and time of day). The diffuse
radiation, which was assumed to illuminate the skin isotropically, comprises sunlight that has
been scattered by molecules and particles in the atmosphere but still reaches the surface of
the Earth. The intensity of daylight is often measured in lux and is referred to as illuminance
which is a measure of the irradiance weighted by the luminosity function, which takes into
account the sensitivity of the human eye. The illuminance for daylight (at midday) varies
from about 120 000 lux for a very clear sunny day to around 20 000 lux for an overcast day
during summer, to considerably lower (<7500 lux) in the middle of winter (overcast) [93].
In this study weather conditions in the middle of summer were considered, where the solar
zenith angle was assumed to be 30  at 56 degrees North [162], appropriate for the latitudes
of Copenhagen in Denmark and Dundee in Scotland. It is possible to extend the spectrum
to different latitudes, different time of years and also different time of day. However this is
beyond the scope of this chapter.
The direct and diffuse spectra used in the simulations were generated from a model of
the solar spectrum reaching Earth [161]. The total spectral irradiance IT  at wavelength  ,
incident on a horizontal surface is given by,
IT  = Id cos✓ + Is  (3.3)
where Id  and Is  are the direct and diffuse (scattered) contributions, and ✓ is the angle from
the normal to the surface to the incident light. The direct component is dependent on the
solar zenith angle and is expressed by,
Id  = Ho  DTr  Ta  Tw  To  Tu  (3.4)
where Ho  is the extraterrestrial irradiance at the mean sun-earth distance. D is the correction
parameter that takes into account the distance between the sun and the earth which depends
on the day of the year. The remaining components correspond to transmittance function of
the atmosphere at different wavelengths. Tr  takes into account the molecular or Rayleigh
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scattering, Ta  the aerosol attenuation, Tw  the water vapour absorption, To  the ozone ab-
sorption and Tu  takes into account the uniform mixed gas absorption.
The contribution from diffuse sunlight is
Is  = Ir  + Ia  + Ig  (3.5)
where Ir  is the Rayleigh scattering component, Ia  is the contribution from aerosol scattering,
and the third component, Ig , takes into account the reflection of sunlight between the ground
and the air. A more detailed description of the algorithm and model can be found in Bird et
al (1986) [161]. The exposure will vary between different people and different body sites
depending on orientation [163,164]. To take this into account different surface orientations
were investigated which will alter the intensity of the irradiance according to equation 3.3.
The direct and diffuse spectra that were input to the Monte Carlo simulations (figure
3.4) represent conditions for midday on a clear summer day. In this model the direct light
represents 80% of the total illuminance of about 100 000 lux. For daylight PDT simulations of
an overcast day, the spectrum was assumed to be 100% diffuse light, corresponding to about
15 000 lux. Daylight PDT was compared to conventional PDT by simulating illumination
by an Aktilite lamp (Photocure ASA, Hoffsveien 48, Norway) [72] which is a red LED light
source, typically used for conventional PDT treatment (chapter 1, section 1.8). The spectral
irradiance for the Aktilite is plotted in figure 3.4. Also shown in figure 3.4 is the spectral
shape of the PpIX absorption spectrum, showing the strong absorption around 405 nm and
the smaller absorption peak coincident with the Aktilite spectrum.
69
Chapter 3. Monte Carlo radiation transfer modelling of daylight activated photodynamic
therapy
Direct Daylight
Diffuse Daylight
Aktilite
PpIX absorption
350 400 450 500 550 600 650 700
Wavelength [nm]
0.0000
0.0001
0.0002
0.0003
0.0004
Sp
ec
tra
l Ir
ra
dia
nc
e 
[W
/cm
2 /n
m
]
0.000
0.001
0.002
0.003
0.004
Sp
ec
tra
l Ir
ra
dia
nc
e 
[W
/cm
2 /n
m
]
Figure 3.4: Illuminating spectra adopted for the MCRT simulations for daylight [161]
and the Aktilite [72]. The indicative absorption curve for PpIX is shown in blue and is
provided as a guide to the eye only to highlight the dominant absorbing features. The
Aktilite spectrum targets a small absorption peak around 630nm while the daylight utilises
the whole absorption spectrum of PpIX which results in more energy being absorbed from the
daylight even though the spectral irradiance is lower.
3.4 Results for Monte Carlo modelling of daylight PDT
Daylight may be absorbed by PpIX over a wide wavelength range, while the Aktilite targets
the smaller PpIX absorption peak around 630 nm (figure 3.4) to ensure a deeper light penet-
ration [73]. This means that the total absorbed energy (by PpIX) is roughly 5 times greater
for daylight compared to the Aktilite . This is determined by calculating the overlap between
the light spectra and the PpIX absorption spectra. By multiplying the light spectrum by the
absorption spectrum and integrating, the total absorbed energy can be compared for the dif-
ferent light sources. The dominating absorbing wavelengths for daylight and conventional
PDT are 405 nm and 630 nm respectively. In figure 3.5 results from two separate Monte Carlo
simulations for the PDD, assuming normal illumination by monochromatic light, at 405 nm
and 630 nm of an irradiance 82 mWcm 2 are shown. Results are displayed for four different
light doses of 10, 20, 40 and 75 Jcm 2. As one would expect, due to the deeper penetra-
tion, the 630 nm light achieves higher PDD at greater depths compared to the 405 nm light.
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Although not penetrating as deeply, the 405 nm light achieves the same PDD at superficial
layers.
The results of Monte Carlo simulations of the depth dependent PDD using the daylight
spectrum (on clear and overcast days) and the Aktilite are shown in figure 3.6 for light doses
of 10 and 75 Jcm 2, with a PpIX absorption coefficient at 630 nm obtained from figure 1.4
of 0.06 cm 1. To investigate the full range of published values [159], a higher and lower
PpIX concentration were also investigated. Figures 3.7 and 3.8 show the resulting PDD for
daylight PDT when the PpIX absorption coefficients at 630 nm are 0.18 cm 1 and 0.02 cm 1,
representing higher and lower concentrations of PpIX compared to the results in figure 3.6.
So far, equal light doses have been compared with a maximum light dose corresponding to
75 Jcm 2. During Daylight-PDT a standard illumination time (1.5-2.5 h) is typically applied
instead of a specific light dose. To investigate the effect of an extended illumination time, a
light dose corresponding to 2.5 hours was simulated for Daylight-PDT (during clear weather
conditions). This is equivalent to a total light dose of approximately 370 Jcm 2 (assuming an
irradiance of 41 mWcm 2). To display the effect of this increased illumination both 75 Jcm 2
(30 min) and 370 Jcm 2 (2.5 hours) are plotted in figure 3.9.
The absorbed photons (by PpIX during daylight PDT) were binned according to both
wavelength and absorption location to investigate the contribution from different wavelengths.
First of all absorption wavelengths were grouped into two blocks, the first (300-500 nm) rep-
resenting the shorter wavelength range and the second (500-700 nm) representing the longer
wavelengths. In figure 3.10 the total absorption was calculated for four different time blocks
during the initial 75 J cm 2. In figure 3.11 the absorption was compared for the initial 75
J cm 2 to the prolonged treatment section (75-370 Jcm 2). For both figure 3.10 and 3.11 the
absorption was normalised by the number of bf absorbed photons during the treatment time
represented in each figure.
To more specifically investigate different wavelength contributions to the absorption, the
absorption distribution for the different wavelengths were plotted at different depths. Here
the contribution at different depths were grouped to display how the absorption distribution
changes with depth at different points in the treatment during daylight PDT (figure 3.12).
Figure 3.6 - 3.9 show simulations for the case where direct daylight is incident at ✓ = 30 
from the normal to the skin surface. The results of different surface orientations are shown
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in figure 3.13. For the clear daylight situation the PDD has been simulated for additional ✓
in equation 3.3, of 0 , 60  and 80 . All of the scenarios investigated assumed that the patient
would orient the lesion being treated, towards the sun. For this reason only one angle of
rotation was considered.
When the photobleaching dose constant was scaled to explore the range of possible values
the maximum light dose of 75 J cm 2 was compared for the three different light conditions.
The PDD for both the higher and lower value for  ( ) was compared to the case previously
explored (figure 3.6) and plotted in figure 3.14. A lower value for  ( ) results in a fast
photobleaching and a fewer number of absorption events before the PpIX is photobleached.
This results in a lower PDD at the surface and also a lower effective treatment depth. The
opposite is true for a higher value for  ( ), when the slower photobleaching allows for more
absorption events to occur. This results in a higher PDD which stretches deeper into the skin
tissue.
72
3.4. Results for Monte Carlo modelling of daylight PDT
630 nm
405 nm
0 1 2 3 4 5
Depth [mm]
0.1
1.0
10.0
Ph
ot
od
yn
am
ic 
Do
se
 [1
01
8  p
ho
to
ns
 /c
m
3 ]
a b c d
a b c d
Figure 3.5: Photodynamic dose for two separate wavelengths at normal incidence on the
tumour. Four different light doses are plotted: 10 (a), 20 (b), 40 (c) and 75 (d) J cm 2,
where both light sources are assumed to have a total irradiance of 82 mWcm 2. The hori-
zontal line corresponds to the toxic threshold which determines the number of photons that
have to be absorbed for necrosis to occur.
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Figure 3.6: Photodynamic dose for conventional PDT treatment (red), and for daylight PDT
for both a clear summer day (solid black) as well as an overcast summer day (dashed black).
The photodynamic dose is plotted for two light doses, 10 and 75 J cm 2. The irradiance for
the Aktilite is assumed to be 82 mWcm 2, while the irradiance for a clear summer day is
determined to be 41 mWcm 2 and for an overcast summer day the irradiance is determined
to be 8 mWcm 2. Corresponding treatment times are displayed in the plot.
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Figure 3.7: Photodynamic dose for the situation where the concentration of PpIX has been
increased by a factor of three. This corresponds to an absorption coefficient at 630 nm for
PpIX of 0.18 cm 1. Light doses of 10 and 75 Jcm 2 are plotted and correspond to the same
treatment times as indicated in figure 3.6.
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Figure 3.8: Photodynamic dose for the situation where the concentration of PpIX has been
reduced by a factor of three. This corresponds to an absorption coefficient at 630nm for PpIX
of 0.02 cm 1. The light doses and treatment times are equivalent to those plotted in figure
3.6 and 3.7.
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Figure 3.9: Photodynamic dose for a longer treatment time. Here the difference between 30
min (75 J cm 2) and 2.5 hours (370 J cm 2) of simulated treatment time during daylight
activated PDT during clear treatment conditions is demonstrated.
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Figure 3.10: Wavelength distribution of the absorption of a total light dose of 75 J cm 2
divided into four time sections. As the treatment progresses the longer wavelength range
contributes more and more. The photon absorption events are recorded and represented
for daylight PDT (during clear weather conditions). Each curve is normalised by the total
number of photons absorbed during the first 75 J cm 2.
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Figure 3.11: Proportion of the photons being absorbed in different wavelength ranges at
different depths through the tumour during daylight PDT. Normalised by total number of
absorbed photons (by PpIX) during the 150 minutes that was simulated.
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Figure 3.12: Proportion of the photons being absorbed at different wavelengths at different
depths during daylight PDT. Normalised by total number of absorbed photons (by PpIX) in
each treatment block: a) 0-30 min which corresponds to 0-75 J cm 2 and b) 30-150 min
which corresponds to 75-370 J cm 2.
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Figure 3.13: Effect of different illumination angles during daylight PDT. The four different
angles that have been investigated are ✓ = 0 , 30 , 60 , and 80 , where ✓ is the angle
between the incident light and the normal to the surface. In each case it is assumed that the
person being exposed to daylight faces the sun.
Figure 3.14: The photodynamic dose comparing different values for the photobleaching dose
constant  ( ) which was multiplied and divided by three to explore the range of possible
values. The PDD at the light dose 75 J cm 2 is compared for the different light conditions:
a) conventional PDT where the Aktilite is used as the illuminating light source b) Daylight
PDT during clear conditions and c) Daylight PDT during overcast conditions. A higher
 ( ) (dotted) results in a slower photobleaching and therefore a higher PDD. A lower  ( )
(dashed) results in a faster photobleaching and therefore a lower PDD.
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3.5 Discussion
Due to the Soret band of PpIX (the broad absorption peak around 405 nm in figure 3.4) and
limited penetration depth at these wavelengths, the PDD caused by daylight will be closer
to the surface. This results in rapid photobleaching at the beginning of the treatment that
then slows as treatment progresses since the concentration of PpIX is reduced. Figure 3.6
indicates that on a clear sunny day it would take about 30 minutes to deliver a light dose of
75 Jcm 2 with an effective treatment depth of over 2 mm. The same light dose would take
about 2.5 h to deliver on an overcast day with approximately the same effective treatment
depth. The Aktilite delivers the same light dose after about 15 min of irradiation, yielding
an effective treatment depth of about 3 mm. The wavelength distribution of the absorption
for daylight PDT (clear) (figure 3.10) show how the absorption changes with time. During
the initial 10 J cm 2 the shorter wavelengths dominate the absorption. Gradually as more
light is delivered to the skin tissue the ratio between the shorter wavelength contribution
and the longer wavelength contribution change. For the last 30 J cm 2 (40 - 75 Jcm 2) the
longer wavelength range dominates the absorption. Throughout, the longer wavelength range
contributes to deeper absorption.
Figure 3.6 suggests that the treatment depth is limited by the light penetration. To in-
vestigate this, figure 3.9 was produced. This result shows that prolonging the daylight treat-
ment time, deeper efficient treatment can be achieved. Figures 3.11 and 3.12 show how the
wavelength distribution of the absorption changes with time. As shown in figure 3.11, during
the initial 75 J cm 2 of the treatment the absorption is dominated by shorter wavelengths.
However during an extended treatment after the first 75 J cm 2, the absorption is dominated
by longer wavelengths. Due to the longer wavelengths penetrating deeper they have the po-
tential of activating the PpIX deeper in the tissue while the shorter wavelengths are restricted
to the superficial layers which will be photobleached before the deeper layers. Figure 3.12
shows how the absorption is shifted towards the red part of the spectrum for different parts of
the treatment, where the initial 75 J cm 2 shows a larger proportion of the absorption in the
blue compared to the second treatment block (30-150 min). This figure also shows how at
the start of the treatment more photons are absorbed at the top of the tumour while at later
times the absorption is dominating in deeper layers of the tumour.
Exploring the range of values for the photobleaching dose constant  ( ) shows that the
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rate of photobleaching effects the penetration and thereby the treatment depth that is achiev-
able. This indicates that an extended investigation of this rate is necessary for further im-
provements of theoretical models. This would require a clinical study where the PpIX pho-
tobleaching properties are explored in vivo. This can be achieved by measuring how the PpIX
fluorescence signal changes during illumination [100].
The adopted skin phantom is a simplified model, where the well defined layered structure
has not been taken into account. The shape of the tumour is not an exact replica of those
found in patients but shows the discrepancy between healthy tissue and diseased tissue. The
optical properties are assumed to be uniform within the tissue and future developments could
include different structures such as blood vessels that may affect the spatial distribution of
absorbers and scatterers [165, 166]. In chapter 6 more complex tumour structures will be
considered with the aim to explore the importance of including three dimensional affects in
theoretical simulations of PDT.
A further complication in clinical treatment is the time dependent build-up of PpIX prior to
the commencement of irradiation. In this work a uniform distribution of PpIX was assumed,
although treatment depth may also be limited by the distribution of PpIX [167, 168]. This
will be discussed in chapter 4 where the difference between treatment protocols for daylight
and conventional PDT are considered. However from the initial models presented in this
chapter it is clear from figure 3.7 and 3.8 that the concentration, and therefore the uptake
and accumulation of PpIX in the tumour, will have a large effect on the treatment outcome.
Even though studies have shown that oxygen is depleted during treatment, the model
presented here assumes an unlimited oxygen supply. To accurately take into account the
oxygen supply [169–171] both oxygen consumption as well as perfusion would have to be
considered. This phenomenon is not well understood and further investigation is required
[169].
It is well known that optical properties vary for patients with different skin types and may
be a reason for the different treatment outcomes. Other optical properties will be discussed
and investigated further in chapter 5. In our simulations, apart from the time dependent
effects of photobleaching on the concentration of PpIX, all other optical properties remain
constant during treatment.
A patient undergoing daylight PDT will not constantly orient the area of interest perpen-
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dicular to the direct sunlight since this will sometimes be inconvenient. Figure 3.13 shows
that a steeper angle to the sun results in a lower irradiance and therefore a slightly lower
effective penetration depth of the treatment light. Here we only investigate one angle of rota-
tion, however this study validates the principle that a steeper angle results in a more shallow
treatment depth.
3.6 Conclusions
A MCRT model has been developed for the simulation of conventional and daylight activated
PDT. It was used to investigate the potential and limitations of treating superficial skin lesions
with artificial and natural light. The model determines the toxicity (PDD) within the tumour
as a function of depth during different weather conditions. Adopting optical properties appro-
priate for healthy and diseased tissue, simulations show that for a clear summer day it would
take around 30 minutes to deliver a light dose of 75 Jcm 2, which is comparable to the light
dose used in conventional PDT treatments. The simulations predict an effective treatment
depth for daylight PDT of over 2 mm, making it ideal for treating superficial skin lesions,
though limiting its efficacy for deeper lying tumours. The effect of PpIX concentration was
also investigated, finding that a higher concentration yields a greater effective penetration
depth. The results of our MCRT simulations support the clinical findings that daylight PDT
can be an effective alternative to conventional PDT for appropriate tumour types. Different
parameters were investigated in this chapter such as different lesion orientations and initial
PpIX concentrations.
80
4
Theoretical determination of continuous
protoporphyrin IX production
4.1 Summary
Most existing models of photodynamic therapy (PDT) assume a uniform initial distribution of
the photosensitive molecule, protoporphyrin IX (PpIX). This is an adequate assumption when
the prodrug is systemically administered; however for the situation which is considered in
this thesis, this is no longer valid. Topical application and subsequent diffusion of the prodrug
results in an inhomogeneous distribution of PpIX at the start of the light treatment. In this
chapter, a model that takes into account a PpIX distribution that depends on the incubation
time and the treatment modality is described. Three steps of the PpIX production are con-
sidered. The first is the distribution of the topically applied prodrug, second is the conversion
from the prodrug to PpIX. Thirdly the light distribution which affects the PpIX distribution
through photobleaching is considered. The results show that prodrug diffusion and PpIX con-
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version properties are vital for accurate determination of the spatial and temporal distribution
of PpIX. The work presented here suggests that treatment depths are not only limited by the
light penetration but also by the PpIX distribution.
4.2 Introduction and background
Traditionally PDT dosimetry is based on a systemic injection of the drug where it is appropriate
to assume that the photosensitiser is uniformly distributed throughout the region of interest.
When this situation is considered the treatment depth is only limited by the penetration of (the
treatment) light. Topically administered sensitisers are commonly used for PDT to treat non-
melanoma skin cancer (NMSC) and dysplasia. In this situation it is not appropriate to assume
that the drug is uniformly distributed through the tumour tissue when the light treatment
is started. The distribution of the drug will depend on the distance from the surface and
the total time since application. For topical PDT it is therefore important to include this
inhomogeneous distribution (in the vertical plane) of the photosensitiser for a more accurate
dosimetry model [167,172].
During conventional PDT, the prodrug is topically administered to the lesion 3 hours before
the light illumination. During this occlusive treatment phase, the prodrug diffuses through
the skin and is subsequently converted within the mitochondria of the tumour cells to the
photosensitive chemical PpIX [53, 58, 65, 173]. These two processes are discussed further in
section 4.3.1 and 4.3.2. For daylight PDT however this occlusive treatment phase is typically
(only) 30 minutes. When introducing the model developed in this chapter, it is possible to
consider the differences in treatment protocol.
It is of interest to develop topically applied prodrugs which give deep penetration and
a high PpIX accumulation, since this results in maximally efficient treatment depth. Due
to the variation in tumour tissue and between individuals there is some dispute about the
penetration of the prodrug. Studies in mouse tumours show diffusion of the prodrug to a
depth of several mm however most prodrug molecules are confined to the top 2 mm of the
tumour [53, 69, 174–176]. The most common prodrugs used for topical PDT contain either
ALA (aminolevulinic acid) or its methyl ester MAL (methyl-aminolevulinate) [53] where 5-
ALA is licensed in the US and MAL is the only commercially available prodrug in Europe.
Both molecules are converted within tumour tissue to PpIX, however MAL is required to first
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be converted to ALA before finally producing PpIX. See section 1.5 in chapter 1 for a more
detailed description of the production of PpIX. It is thought that prodrugs containing MAL
result in a deeper penetration of the photosensitiser since it is more lipophilic, however few
studies support this theory [42, 43, 177–179]. Previous studies also indicate that the surface
fluorescence using ALA-based creams is higher [180], indicating that there might be both a
difference in diffusivity as well as conversion rate between ALA and MAL.
Previous studies have considered topical application of the prodrug to theoretically de-
termine the distribution of the PpIX after the occlusive treatment phase. These different
studies have used slightly different approaches [167, 168, 181, 182]. The study by Star et al
included the most complicated conversion model between the prodrug and the PpIX, however
a maximum penetration depth of 0.5 mm was assumed [168]. This contradicts other stud-
ies where a deeper penetration is indicated [53,69, 174–176]. The model developed for this
chapter combines ideas demonstrated in several of these earlier studies. Previous work has
explored different exponential distributions of PpIX in a light distribution model [183–185].
However this does not combine a molecular diffusion model with Monte Carlo radiation trans-
fer (MCRT) modelling (chapter 2) using an appropriate model of the PpIX distribution. The
work presented here attempts to extend current theoretical models by including a more ap-
propriate representation of the PpIX distribution.
The aim of the work presented here is to combine the light distribution model (chapters 2
and 3) with a modelled distribution of PpIX where both temporal and spatial dependence is
considered. This allows for not only light penetration limitations to be investigated but also
drug penetration limitations, resulting in a more accurate representation of PDT for different
treatment conditions. The developed model invites discussion regarding the appropriateness
of the length of the occlusive treatment phases and the effect of prolonged daylight exposure.
The model developed in this study is primarily based on basic molecular diffusion theory in
combination with a simple rate equation. Properties and characteristics of diffusion through
skin and the conversion of PpIX are not well understood. Therefore in an attempt to improve
knowledge of PpIX production characteristics, the aim was also to generate a theoretical simu-
lation of fluorescence during the incubation time to better understand and explain the clinical
data collected in chapter 6.
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4.3 Methods
The production of PpIX from topical administration of a prodrug is a complex procedure with
multiple steps. The model presented here contains only the most relevant parameters, thus
the number of required assumptions and approximations is reduced. A one dimensional case
was considered where the concentration of PpIX was assumed to only vary in the vertical
direction (from the surface of the tissue).
The addition of the PpIX distribution model will affect the light distribution model through
the concentration dependency of the optical properties associated with the PpIX. Hence the
absorption coefficient for PpIX (µa( )) will depend on the local number density of PpIX mo-
lecules as follows,
µa( ) = nPpIX ( ) (4.1)
where nPpIX is the number density of PpIX molecules (cm 3) and  ( ) is the PpIX cross
section (cm2) (figure 4.1).
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Figure 4.1: Figure showing the PpIX cross section as a function of wavelength. The absorp-
tion coefficient is generated by multiplying the cross section (displayed in the figure) with
the PpIX number density of PpIX molecules present [181].
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The set-up of the code is similar to that described in chapter 3 where a simulated region of
10mm⇥10mm⇥10mm was considered. Repeated boundaries were applied with a centrally
located cylindrical tumour with a diameter of 6 mm. The PpIX molecules were restricted
to the areas occupied by the tumour tissue. The optical properties of the tumour as well as
surrounding tissue were the same as adopted in chapter 3.
4.3.1 Prodrug diffusion
Since the distribution of the MAL (or ALA) molecules dictates the distribution of PpIX mo-
lecules, the first step of the procedure that is considered is the diffusion of the prodrug. Mo-
lecular diffusion, where molecules diffuse from a region of high concentration to a region of
lower concentration is described by Fick’s (first) law,
J =  D@M(z, t)
@ z
(4.2)
In this equation, J corresponds to the flux which describes the flow of substance (mo-
lecules) through a unit area per unit time (m 2s 1). The magnitude of J is proportional to the
gradient of the concentration M(z,t) (m 3). In this case, M(z,t) corresponds to the number
density hereafter referred to as concentration of MAL (or ALA) molecules. D (m2 s 1 ) is the
diffusivity, or diffusion coefficient, which describes the speed at which a substance diffuses
through another substance.
By applying the continuity equation for mass conservation [167],
@ J
@ z
+
@M(z, t)
@ t
= 0 (4.3)
and combining with equation 4.2, the equation that describes how M(z,t) changes with
time is,
@M(z, t)
@ t
= D
@ 2M(z, t)
@ z2
(4.4)
Equation 4.4 is a partial differential equation that requires boundary conditions to be
solved.
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By assuming that the initial concentration, C0 is introduced at t=0 and z=0 and thereafter
kept constant at C0 (at the surface) the following solution satisfies equation 4.4 [186]:
M(z, t) = C0(1  erf
✓
zp
4Dt
◆
) (4.5)
where the Gaussian error function (erf) is defined as
erf(u) =
2p
⇡
Z u
0
e t2d t (4.6)
These boundary conditions were assumed due to the excess cream still present on the le-
sion after 3 hours of occlusive treatment, acting like a reservoir and the concentration of MAL
(or ALA) molecules was therefore kept constant at the surface. Since the diffusion problem
described here can be compared to a plane source with an extended initial distribution, the
standard solution (equation 4.5) was believed to be an appropriate description of the prodrug
diffusion. Similar assumptions have previously been argued for and applied in other studies
where similar models were developed [167,168,181,182,186].
4.3.2 PpIX production
The PpIX is produced from ALA molecules (section 1.5, chapter 1). In the work presented
in this thesis, a prodrug containing MAL molecules was considered, however the conversion
from MAL to ALA was not separately included. Hence only the conversion from MAL to PpIX
was considered in the equation describing the production of PpIX. The rate equation that was
considered here is expressed as follows [167,168],
@ PPIX(z, t)
@ t
=  PPIX(z, t)
⌧p
+ "p
M(z, t)
⌧ap
(4.7)
This rate equation includes the two main features that contribute to the resulting con-
centration of PpIX , PPIX(z,t). The source term in the equation (term furthest to the right)
corresponds to the conversion from MAL molecules to PpIX molecules. This depends on the
distribution of MAL molecules, M(z,t), the yield, "p, which determines the proportion of MAL
molecules being converted to PpIX, as well as the relaxation time, ⌧ap. The relaxation time,
⌧ap determines how fast this conversion happens and is defined as the time it takes for the
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concentration (M(z,t)) to reduce to 1/e (37 %) of its original concentration due to PpIX pro-
duction. The sink in equation 4.7 is the first term to the right of the equal sign. This term
corresponds to the clearance of the PpIX (mostly due to heme production). The rate at which
the clearance mechanism happens is dictated by the relaxation time, ⌧p.
The rate equation described here does not include any light interaction and only considers
the production of PpIX. When PpIX interacts with light, the concentration of PpIX molecules
reduces with time due to photobleaching. This type of reduction of concentration was con-
sidered within the MCRT model however, it was not included in the rate equation (equation
4.7). Therefore it was assumed that the concentration reduction due to photobleaching did
not affect the diffusion of the prodrug molecules or the production of PpIX.
The solution to equation 4.7 has previously been established [167] to be ,
PPIX(z, t) =
"p
⌧ap
Z t
0
e
  t t0
⌧p M(z, t 0)d t 0 =
C0"p
⌧ap
Z t
0
e
  t t0
⌧p (1  erf
✓
zp
4Dt 0
◆
)d t 0 (4.8)
This is the equation that was used in the work presented here to calculate the distribution
of the PpIX as it changes with time and depth.
4.3.3 Different treatment modalities
During the occlusive treatment phase of conventional (using an artificial light source) PDT
the region of interest is covered with an occlusive dressing. Before the light irradiation, the
dressing and any excess cream is removed from the lesion. When daylight is used as the
alternative light source there is no occlusive dressing applied and any excess cream is left on
the lesion for the duration of the treatment. Since the amount of exposure will be different
for different patients during daylight PDT, for the work presented here it was assumed that
the occlusive treatment phase during daylight PDT was similar to conventional PDT. The light
interaction during the occlusive treatment phase was therefore assumed to not occur.
Different treatment modalities had to be considered when modelling the different scen-
arios and are shown in table 4.1. The most important difference is the continued accumulation
and production of PpIX during the light treatment for daylight PDT. This is due to the cream
being kept on the lesion during the light application.
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Table 4.1: Description of the different treatment modalities where the PpIX is assumed to
continue to build-up during the light interaction phase of the treatment during daylight PDT
but not during conventional PDT. These values are based on established clinical practice [78].
Concept Conventional PDT Daylight PDT
Occlusive treatment, no light 3 hours 30 minutes
PpIX build-up during illumination NO YES
Photobleaching during illumination YES YES
4.3.4 Determination of constants
For the method described above, the parameters: D, C0, "p, ⌧ap and⌧p, determine the distri-
bution and production rate of PpIX. There is limited knowledge about the exact values of
these parameters, however using educated assumptions based on previously published data
an initial set of parameters was adopted (set 1, table 4.2). This set of values were believed to
be the most relevant and appropriate; however, it is important to acknowledge that there is a
large variability in the published literature.
Star et al [168] developed a similar model to the one discussed here where the relaxation
times, ⌧ap and ⌧p were assumed to be: ⌧p = 1.3h and ⌧ap = 2.4h. The magnitude of these
relaxation times agree with those suggested by Aalders et al (2001) [173] . Another related
model, developed by Salas Garcia et al [181,182], suggested that ⌧p = 84ms and ⌧ap = 24h.
However, it can be argued that these values are less reasonable, especially since 84 ms is the
non radiative relaxation time of the PpIX molecule [187], which is irrelevant to the clearance
rate of the molecule. Additionally, considerably longer clearance rates of the photosensisiters
from the human body have been identified [53, 188]. It can also be argued that the value
for ⌧ap should be shorter, otherwise a longer incubation time would be introduced. Although
they seem unreasonable, the parameters suggested by Salas Garcia et al [181,182] were also
included in this investigation (set 2, table 4.2).
There are no experimentally determined values published for the diffusion coefficient, D,
for ALA/MAL diffusion through skin tissue. Svaasand et al [167] suggested that the mag-
nitude of the diffusion coefficient of 5-ALA can be determined by comparison to molecules
with similar molecular weight through human tissue. Assuming that the diffusion properties
for MAL is not widely different to ALA, this suggest that values of the diffusivity should be
in the region of 10 10 to10 9m2 s 1 [167] where a value of 0.69 ⇥ 10 10m2 s 1 has been
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applied by others for MAL diffusion [181].
Table 4.2: Parameter exploration for PpIX production model.
Set C0 "p ⌧ap A ⌧p D
cm 3 s cm 3 s 1 s m2 s 1
Initial guess, Set 1 6⇥ 1016 0.5 8640 3.82⇥ 1012 4680 0.69⇥10 10
Set 2 [181] 6⇥ 1020 0.5 86400 3.82⇥ 1015 84⇥10 3 0.69⇥10 10
Set 3 3.47⇥ 1010 4680 0.69⇥10 10
Set 4 3.47⇥ 1014 4680 0.69⇥10 10
Set 5 3.47⇥ 1012 46.80 0.69⇥10 10
Set 6 3.47⇥ 1012 468000 0.69⇥10 10
Set 7 3.47⇥ 1012 4680 10 12
Set 8 3.47⇥ 1012 4680 10 8
The initial concentration of the MAL molecules is also an important parameter to consider.
A typical molecular density of MAL molecules in the cream is typically considered to be around
1020 cm 3 [181]. Previous simulations presented in this thesis (chapter 3) assumed a uniform
number density of around 1014 cm 3 (figure 1.4). By assuming that the concentration at the
most superficial layers will be considerably lower than the cream concentration itself, a value
of C0 was assumed in this work to initially be somewhere between the two extremes discussed
above. As an initial guess, C0 was therefore suggested to be 6 ⇥ 1016 cm 3. The conversion
from MAL molecules to PpIX molecules is also affected by the yield, "p, where values between
0.03-0.5 have been suggested. Following the work by Salas Garcia et al, this was initially set
to be 0.5 (50 %) [168,181].
The limited knowledge about these important parameters invites for parameter explora-
tion, where the contribution of different parameters can be determined. The parameters of
interest can be grouped together to reduce the unknown constants from five to three such
that,
PPIX(z, t) = A
Z t
0
e
  t t0
⌧p (1  erf
✓
zp
4Dt 0
◆
)d t 0 (4.9)
The first three constants in equation 4.8,
"pC0
⌧ap
were grouped into one constant A (equation
4.9). It is clear from A that reducing the initial concentration C0 has the same effect to the
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distribution model as an increased relaxation time, ⌧ap, or indeed a reduced yield, "p. These
three parameters (A, ⌧p and D) were first adjusted independently to determine the individual
contribution to the PpIX distribution. Table 4.2 displays the different values for the parameters
that were explored. Subsequently the parameters were logically adjusted to match the linear
fluorescence model describing the clinical data in chapter 6. See section 4.3.5 for further
detail of this implementation.
The concentration and treatment depth was explored for different sets of parameters ap-
plied to equation 4.9 (table 4.2). Longer treatment times up to 2.5 hours (370 Jcm 2) were
also explored as well as the effect of different incubation times during daylight PDT.
4.3.5 Fluorescence code implementation
In an attempt to further gain knowledge about the parameters that are under consideration a
MCRT model was generated to represent the situation described in chapter 6. By simulating
the fluorescence signals that were measured during the occlusive treatment and by adjusting
the parameters discussed above, the simulation was matched to the clinical results. This
results in determination of a set of parameters that reproduce the experimental results.
The fluorescence spectrum generated in the model was sampled from an experimentally
measured fluorescence spectrum (figure 4.2). Similarly to the experimental validation (sec-
tion 2.5.2) the excitation photons were launched through a small area (diameter of 600 µm)
representing the optical biopsy (OBS) fibre probe (section 2.5.1) and the resulting fluores-
cence signal was collected through the same region with a numerical aperture of 0.22. It was
assumed that each absorption event (by the PpIX) resulted in an isotropic fluorescent photon,
i.e. the fluorescence yield was assumed to be one. Due to the narrow spectrum of the OBS it
was also assumed that the illuminating light was of a single wavelength (405 nm).
The strength of the recorded signal by the OBS is arbitrary since it depends on the irra-
diance of the light source and the sensitivity of the measuring equipment. The fluorescence
MCRT model is also arbitrary since the strength of the resulting fluorescence signal depends
on the number of simulated photons as well as the fluorescence yield (assumed to be 1). As
a consequence it is only appropriate to explore the normalised fluorescence signal (generated
by the MCRT model) with a linear trend where the signal increases from 0 to 1 over 180
minutes.
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Figure 4.2: Fluorescence signal generated by the PpIX, normalised by the total fluorescence
signal.
Figure 4.3: Graphical representation of the fluorescence modelling. The PpIX is excited with
blue light (405 nm) (left) and re-emits red fluorescence light (figure 4.2) (right)
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The parameters (table 4.2) that were used to generate different spatial and temporal
distributions of PpIX, were also used to generate the fluorescence signal. The peak of the
fluorescence signal was plotted as a function of time and compared to the linear model. By
determining the effect that the different sets of parameters (table 4.2, equation 4.9) had on
the evolution of the fluorescence signal, values of the parameter that fit the linear model better
could be determined. To establish if this results in reasonable effective treatment depths, the
photo-toxicity during the light treatment phase was subsequently generated.
4.4 Results
By applying the different sets of parameters, shown in table 4.2, to the PpIX distribution model
derived from equation 4.9, a range of different distributions were achieved. The results after
30 min, 1 hour and 3 hours of incubation are illustrate in figure 4.4. The 30 minute time point
is, as previously discussed, a typical incubation time for daylight PDT following application
of the cream, while 3 hours is the incubation time adopted for conventional PDT. The same
distribution of PpIX is assumed in the horizontal plane throughout the tumour area, illustrated
in figure 4.5. All sets of parameters are compared to the reference set (set 1, table 4.2) since
they have been adjusted accordingly. When A is increased simultaneously as ⌧p was reduced
(set 2), the resulting concentration profile is comparable to the reference set. However the
rate at which the PpIX builds up within the tissue is slightly faster and the differences between
the two concentrations profiles increases with time. When A, in equation 4.9 is reduced (set 3)
or increased (set 4), the concentration profile is scaled accordingly. For increased and reduced
⌧p, the concentration profile is not scaled linearly due to the nature of the model. A reduced
⌧p (set 5) results in a lower overall concentration of PpIX compared to set 1. The reduction
of ⌧p results in a small increase in overall PpIX distribution over three hours of occlusive
treatment. An increase (set 6) in the parameter results in a concentration of PpIX comparable
to set 1. A reduced diffusion coefficient (set 7) resulted in shallow drug diffusion, with low
concentrations of PpIX only present within superficial skin layers. Conversely, an increased
diffusion coefficient (set 8) resulted in a more uniform distribution of PpIX. Overall, with time
the PpIX distribution reached deeper layers within the tumour tissue which is shown in figure
4.4.
92
4.4. Results
1 2 3 4 5
Depth [mm]
0.1
1.0
10.0
100.0
1000.0
10000.0
Nu
m
be
r d
en
sit
y [
10
14
 cm
−3
]
1 2 3 4 5
Depth [mm]
0.1
1.0
10.0
100.0
1000.0
10000.0
Nu
m
be
r d
en
sit
y [
10
14
 cm
−3
]
1 2 3 4 5
Depth [mm]
0.1
1.0
10.0
100.0
1000.0
10000.0
Nu
m
be
r d
en
sit
y [
10
14
 cm
−3
]
30 min 1 h
3 h
a b
c
N
um
be
r d
en
si
ty
 [1
01
4 
cm
-3
 ] 
N
um
be
r d
en
si
ty
 [1
01
4 
cm
-3
 ] 
N
um
be
r d
en
si
ty
 [1
01
4 
cm
-3
 ] 
Depth [mm] 
Depth [mm] Depth [mm] 
Figure 4.4: Figure showing the number density of PpIX molecules as a function of time
for different sets of parameters (table 4.2). Results for three different incubation times are
plotted, a) 30 min, b) 1 hour and c) 3 hours. This assumed no light interaction during the
production of PpIX and these times are a measure from the time of drug application.
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Figure 4.5: Contour plot of the cross section of the distribution of PpIX after 3 hours of
occlusive treatment where the parameters in table 4.2 (set 1) were adopted.
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The concentration of PpIX is reduced during treatment due to photobleaching. However
during daylight PDT (for both clear and overcast conditions) the concentration simultaneously
increases as a significant reservoir of the prodrug remains on the surface of the skin. For the
uniform case described in chapter 3, the initial concentration of PpIX molecules was assumed
to be 7.84⇥ 1013 cm 3, where the concentration only reduces due to photobleaching, for all
different light sources. The change in concentration during the treatment from 0 - 75 Jcm 2
for both the uniform (where the initial concentration of PpIX was assumed to be uniform) and
the non-uniform case (where the initial concentration of PpIX was assumed to follow equation
4.8) were compared for the three different light conditions and the results are displayed in fig-
ure 4.6. For the uniform case, the concentration reduction with increased light dose is similar
in all light conditions. For the non-uniform case there is a larger difference between the light
conditions. Where for example daylight PDT during overcast conditions resulted in overall
larger concentrations of PpIX within the tumour tissue compared to treatment during clear
conditions. For daylight PDT, PpIX is produced during the light treatment which generates a
different reduction in PpIX distribution compared to the conventional PDT situation.
Figure 4.6: Graphical representation of the change in PpIX distribution during the light
treatment (set 1 in table 4.2 is adopted) . Daylight PDT for overcast (c) and clear (b)
conditions as well as conventional PDT (a) is compared for the uniform and non-uniform
case. The uniform case is discussed in chapter 3, while the non-uniform case represents the
model developed here using basic diffusion theory.
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Figure 4.9: Photodynamic dose for different initial starting points (for daylight PDT during
clear conditions). The black curves correspond to the situation where the lesion was exposed
to the daylight simultaneously to the cream application while the blue curve corresponds to
60 min of incubation time before the lesion was exposed to the light source. The red curves
corresponds to an incubation time of 30 min, which corresponds to the typical incubation
time applied in the clinic and also the incubation time adopted for all other results (daylight)
in this chapter.
When the initial set, set 1 in table 4.2, was compared to the uniform case, similar treat-
ment depths were achieved as shown in figure 4.7. After a delivered light dose of 75 Jcm 2
treatment depths of approximately 3 mm were reached during conventional PDT conditions.
After the same delivered light dose for daylight PDT during clear conditions, treatment depths
of just under 1.5 mm were reached. Daylight PDT, during overcast conditions however
reached treatment depth of approximately 2 mm. When the lesion of interest was simulated
to be exposed to daylight for 2.5 hours (equivalent to 370 Jcm 2 during clear conditions)
treatment depths of over 2.5 mm were reached. The results for this are illustrated in fig-
ure 4.8. The light doses 75 and 370 Jcm 2 were compared for different total incubation
times for daylight PDT (clear conditions) and the results are displayed in figure 4.9. A dif-
ference in treatment depth of just under 1 mm was achieved after a delivered light dose of
75 J cm 2 between occlusive treatment times of 0 minutes (cream applied simultaneously to
light source) and 1 hour. After 370 Jcm 2 the difference reduced to approximately 0.5 mm.
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Figure 4.7: Photodynamic dose as a function of depth where the initial distribution of PpIX
non-uniform (solid) and the uniform (dashed) are compared. The toxicity corresponding to
a light dose of 75 J cm 2 is displayed for three light conditions: conventional PDT (Aktilite),
daylight PDT (clear) and daylight PDT (overcast).
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Figure 4.8: Photodynamic dose as a function of depth for daylight PDT (clear) for 75 J cm 2
(30 min) and 370 J cm 2 (150 min).
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The photodynamic dose (PDD) was generated for the different sets of parameters in table
4.2 where both daylight PDT (clear and overcast) as well as conventional PDT was investig-
ated. The results from the simulations show that the deepest penetration is achieved from
set 4 and 8. The more shallow penetration depths were achieved by adopting parameters in
set 3 and 7. The results are summarised in table 4.3. For further discussion and graphical
representation see Appendix B.
Table 4.3: Summary of the results from the toxicity and fluorescence signal when adopting
different sets of parameters from table 4.2. Parameter exploration allowed for the sets B1
and B2 to be determined. It is clear from the summary that the shape of the fluorescence
signal as it changed with time is not directly correlated with the effective treatment depth.
The treatment depths are summarised when the toxic threshold is adopted for the different
light conditions, Daylight (clear) (DC), Daylight (overcast) (DO) and Aktilite (A).
Set Adjustment Treatment depth (mm) Fluorescence
DC DO A
1 - 1.5 2 3 steep initial increase
2 reduced ⌧p 1.5 2.5 3.2 similar to 1
increased A
3 reduced A 0.5 1 1.3 reduced initial steepness
4 Increased A 1.8 2.5 3.8 increased initial steep-
ness
5 reduced ⌧p 0.9 1.3 1.7 similar to 1
6 increased ⌧p 1.4 2 3 similar to 1
7 reduced D 0.2 0.4 0.4 reduced initial steepness
8 increased D 3.3 3.8 N/A similar to 1
B1 reduced A 0.1 0.4 0.4 best fit
reduced D
B2 reduced ⌧p 0 0 0 best fit
For the initial set of parameters (set 1, table 4.2) the change in the peak of the fluores-
cence signal with time was compared with the linear model established in chapter 7 (shown
in figure 4.10). The fluorescence signal increased rapidly before plateauing after approxim-
ately 50 min. The fluorescence signal for the other sets of parameters (sets 2-8, table 4.2)
were compared to the fluorescence signal generated by this reference set. The results from
the fluorescence modelling are summarised in table 4.3. The most noticeable change in the
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fluorescence signal was noticed for sets 3 and 7, where the initial increase in the signal was
reduced. For further discussion and graphical representation see Appendix B.
Table 4.4: Parameters that best match the fluorescence data collected for chapter 6.
Set A ⌧p D
cm 3 s 1 s m2 s 1
Set B1 3.47⇥ 1010 4680 5⇥ 10 12
Set B2 3.47⇥ 1012 0.47 0.69⇥ 10 10
4.4.1 Clinical study
The fluorescence signal was measured during the occlusive treatment in chapter 7. The char-
acteristic red light produced as a result of blue excitation light was collected every 20 minutes
for a total of three hours. Statistical modelling showed a linear trend between the fluores-
cence signal and the occlusive time. A more detailed description of the study can be found in
chapter 7. To be able to gain more understanding of the production of PpIX within the tumour
lesions the parameters in equation 4.9 were adjusted to generate the set of parameters that
best fit the linear model (table 4.4). The peak of the fluorescence signal (from the theoretical
results) as it changed with time for these sets (set B1 and B2, table 4.4) and the statistical
model compared successfully as shown in figures 4.11 and 4.12. To determine if these sets
of parameters are plausible further investigations were carried out. Using parameters B1 and
B2 in table 4.4, the light treatment was simulated and the PDD was determined. For set B1
treatment deaths of less than 0.5 mm were achieved, which can be seen in figure 4.13. For set
B2 the treatment PDD is displayed in figure 4.14, where the applied threshold is higher than
the achieved PDD. The concentration profiles generated by sets B1 and B2 (table 4.4) at 30,
60 and 180 min after cream application are displayed in figure 4.15. The results indicate that
the distribution of PpIX reached only superficial layers where the overall concentration is low
compared to sets 1-8 in table 4.2.
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Figure 4.10: Figure showing how the fluorescence signal (red) changes with time for the
first set of parameters (set 1) in table 4.2. The linear model (black) corresponds to the
clinical results.
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Figure 4.11: Figure showing how the fluorescence signal (red) changes with time for the
first set of parameters (set B1) in table 4.4. The linear model (black) corresponds to the
clinical results. This shows one of the best combination of parameters that were found to
match the clinical results.
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Figure 4.12: Figure showing how the fluorescence signal (red) changes with time for the
second set of parameters (set B2) in table 4.4. The linear model (black) corresponds to the
clinical results. This shows one of the best combination of parameters that were found to
match the clinical results.
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Figure 4.13: Figure showing the photo-toxicity as it changes with depth after 75 J cm 2
of delivered light dose where the parameters in set B1 (table 4.4) were adopted. The figure
shows the same light conditions as previously been investigated. The figure shows a relatively
low penetration compared to the uniform case investigated in previous chapter (chapter 3).
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Figure 4.14: Figure showing the photo-toxicity as it changes with depth after 75 J cm 2
of delivered light dose where the parameters in set B2 (table 4.4) were adopted. The model
presented indicates that this set of parameters results in a reasonable treatment depth, how-
ever the validity of the relaxation time ⌧p could be argued.
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Figure 4.15: Figure showing the concentration after 30, 60 and 180 min of incubation
time (no light interaction) for set B1 and B2 from table 4.4. These parameters produced the
fluorescent signal from the MCRT model that matched the clinical set most favourably.
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4.5 Discussion
It is clear from the investigation performed here, that without accurate knowledge of the
different parameters: A, ⌧p andD in equation 4.9, it is difficult to generate an appropriate
distribution. Therefore the parameter exploration is important in terms of determining the
contribution from the different parameters. During the light exposure the concentration re-
duces due to photobleaching, as demonstrated in figure 4.6. For the two daylight cases (clear
and overcast) there is additional PpIX production during the light illumination. For clear con-
ditions during daylight PDT figure 4.6 b demonstrates a large drop in concentration during
the initial 10 J cm 2 for the non-uniform situation. This drop is larger than the drop for the
same light dose for overcast conditions during daylight PDT (non-uniform case), shown in
figure 4.6 c. Due to the difference in irradiance between these two weather conditions, the
time it takes to deliver the same light dose of 10 J cm 2 corresponds to 2 min (clear) and 21
min (overcast). During this time, there is a larger amount of additional PpIX being produced,
for the overcast situation compared to the clear situation. This explains the overall larger PpIX
concentrations during overcast conditions.
The first set of parameters (set 1 in table 4.2) is what is believed to be a reasonable
assumption of the parameters. For this reason this set is the most discussed and explored in
this chapter. The results shown in figure 4.7 indicates treatment depths similar to the uniform
case described in chapter 3, after a delivered light dose of 75Jcm 2 during conventional PDT.
This indicates that these parameters result in realistic treatment depths. For daylight PDT the
overcast treatment depth is larger than for the clear conditions when considering a total light
dose of 75 J cm 2. This feature is consistent for all parameters investigated and is explored in
more detail in Appendix B. However when comparing the same treatment time (2.5 hours),
the clear conditions results in deeper penetration. This is explained by the increased light dose
delivered during 2.5 hours of illumination during clear (370Jcm 2) conditions compared to
overcast (75 J cm 2) conditions. This is graphically demonstrated in figure 4.8.
Even though the treatment depths are varied, the fluorescence signal does not in general
vary as much (table 4.3). When the relaxation time ⌧p, in sets 5 and 6 in table 4.2, is changed
the evolution of the fluorescence signal does not change from the initial set of parameters
(set 1) however there is a change in effective treatment depth. For the situations where the
fluorescence signal carries a closer resemblance to the linear trend, this resulted overall, in
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more superficial treatment depths. The two sets of parameters that were found where the
fluorescence signal favourably correlated to the linear trend (figure 4.11 and 4.12), resulted
in superficial treatment depths as shown in figures 4.13 and 4.14. Even though the applied
toxic threshold is an approximation, the light penetration for these two sets of parameters is
confined to superficial layers. Hence there is reason to believe that these sets of parameters
are not appropriate. In addition the relaxation time ⌧p for set B2 in table 4.4 is approximately
0.5 s. This can be argued to be unreasonable since this would correspond to a faster clearance
of PpIX than has previously been suggested in the literature [188]. Even though there might
be other sets of parameters that match the linear trend as well as results in deeper light
penetration these have not yet been found in the work presented here.
There are several potential explanations to why the set of parameter that matched the
linear trend best, resulted in unreasonably low penetration depths. First of all the model
developed in this chapter might not be sophisticated enough to be able to match the clinical
results with the theoretical models. By simplifying the process of accumulating PpIX in the
tumour, important information might be lost. It has been suggested in the literature that dose
dependent rate equations should be used instead of first order kinetics when considering the
production of PpIX since the conversion is controlled by an enzyme reaction. Due to the rate
limitation of the process of producing PpIX, it is potentially important to include such aspects
within the model [173]. However limited knowledge of these processes in vivo, discourages
the application of such methods within the model presented here. As will be discussed in
chapter 6, there is a possibility that the clinical data was affected by the degree of the surface
preparation. By applying a deep curettage some of the measurements would be affected by
the amount of blood produced as well as by the thin lesions remaining. Surface preparations
are necessary to enable the cream to penetrate however the degree of curettage is varied
between different institutes. Other aspects of the clinical study, might also have affected the
measurements, such as exposure to light every 20 min. Further discussion of these issues may
be found in chapter 6. For this reason alternative trends should not be discarded for future
extended studies.
It is believed that the initial set, set 1 in table 4.2, is the most reasonable set of data
strengthened by reasonable treatment depths. However these are approximations and the
fluorescence signal generated from the models shows in figure 4.10 a steep increase at early
times before plateauing. A possible explanation to the reason why the clinical results and the
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theoretical results do not coincide is the tumour depth. The curettage associated with the
clinical study could result in a shallow tumour depth. If the tumour is very superficial, a set
of parameters resulting in a linear fluorescence trend (set B1 and B2) could be motivated.
See chapter 6 for a further discussion of the level of curettage. Future developments have
to include extension of the theoretical model as well as additional clinical studies where the
level of curettage is considered.
By including a distribution of PpIX which changes both temporally and spatially, a more
accurate theoretical representation of PDT may be obtained. By increasing the appropriate-
ness of the model more accurate information can be gained from the resulting simulations.
However, in the model developed here, several aspects of the PpIX production have not been
considered for the sake of simplicity. It was assumed that the PpIX did not diffuse from the
location where it is produced. It was also assumed that the concentration gradient of MAL
molecules was not affected by the production of PpIX or photobleaching. To include these
processes, a more complex model would be required where more parameters would have
to be assumed and approximated. Additionally it was also assumed that the light penetra-
tion was not affected by the presence of cream on the surface of the lesion. If the optical
properties of the cream were known, a thin layer of cream could be added to the simula-
tion. However, due to lack of this information, it was not included in the model. Future
developments of the model should consider the steps discussed above as well as the permeab-
ility of the cream through the skin. Here the permeability is ignored since it was assumed
that the stratum corneum was broken up with a reduced functionality in the region of the
tumour [53, 65, 174, 175]. It was additionally approximated that there was no difference
between MAL or ALA based creams. Other aspects of the model that have not been included
are the non-uniformity in the lateral direction (along the surface) as well as between different
types of tumour positioned on different locations of the body [69].
The diffusion model presented here is a step towards a more accurate representation of
the different treatment modalities. By adopting reasonable parameters for A, ⌧p, and D in
equation 4.9 such as the ones suggested in set 1 in table 4.2, the model indicates that the
treatment depth is not only limited by the light penetration but also by the drug diffusion and
PpIX production rate. These are important factors to consider when calculating and optimising
PDT dosimetry. The work presented here is a step towards further exploring the limitations
and potential of daylight PDT which can be a useful technique for situations when limited
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resources are in place.
4.6 Conclusion
The incubation time associated with different treatment modalities results in different initial
distributions of the photosensitive molecule PpIX. A non-uniform distribution of PpIX was
investigated where a model was developed which depends on both the distance from the sur-
face as well as the time passed since prodrug application. The main challenges are the limited
knowledge about the cream diffusion and PpIX production which forces several assumptions
and approximations. The work presented here explores the effect that these parameters have
on the distribution of PpIX and the associated treatment depths. By including a non-uniform
distribution of PpIX a more accurate representation of PDT was achieved. The results suggest
that the treatment depths associated with PDT are not only limited by the penetration of the
light but also by the penetration of the prodrug as well as the production of PpIX. Even though
further investigation is required to establish the distribution parameters, the work presented
here is a stepping stone towards more accurate theoretical simulations of PDT during different
treatment conditions. Including a time dependent PpIX production model is key in driving the
theoretical simulations of light based therapies forward.
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5
Light distribution modelling of skin ageing and
different skin types
5.1 Summary
It is important to adopt appropriate optical properties when modelling light distribution
through skin tissue. This chapter discusses the techniques of generating the optical properties
adopted throughout this thesis. By appropriately adjusting the optical properties and compos-
ition of a multi-layered skin phantom, different ages and skin types were represented. The
results demonstrate the effect that different optical properties have on the distribution and
penetration of light. The developed model shows that the light penetration increases with
age and reduces with increasing skin type classification number. The results also indicate that
daylight photodynamic therapy (PDT) is more affected by ageing and level of pigmentation
compared to conventional PDT methods.
The work presented in this chapter contributed to the conference proceeding (Proc. SPIE,
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volume 9531) "3D Monte Carlo radiation transfer modelling of photodynamic therapy" (2015)
[189].
5.2 Introduction
The optical properties in skin tissue are inhomogeneous due to its complex structure and
vary both within individuals as well as between individuals. The structure of the skin has
previously been described in more detail in chapter 1 (section 1.2). In this chapter the optical
properties and the method of how to represent different skin types and conditions will be
discussed. The aim of this chapter is to demonstrate the effects that differences in skin optical
properties and skin composition have on light penetration and PDT treatment outcome. This
shows the importance of correct and appropriate allocation of the optical properties of the
developed skin phantom.
5.2.1 Optical properties
Skin exhibits a wide range of optical properties due in part to the complex structure of skin
and the variability that exists between individuals. Therefore the optical properties are not
homogenous as previously assumed and will change for different people with different skin
types. There are several publications of optical properties for different tissue types, both
human and animal, both in vivo and in vi t ro [111, 112, 156, 190]. However to achieve ap-
propriate optical properties for a large wavelength range and allow the optical properties to
be flexible for representation of different skin compositions, appropriate estimating equations
can be used.
Scattering
Scattering occurs when light interacts with the tissue which results in a change in direction
of propagation. The change in direction is described by the Henyey-Greenstein phase func-
tion (equation 2.21) and the anisotropy factor (chapter 2). When light is scattered from the
direction of a light beam, it reduces the intensity of light within the beam. The scattering is
characterised by the scattering coefficient or the reduced scattering coefficient, both in the
units of cm 1. The reduced scattering coefficient µ0s, corresponds to the scattering corrected
by the anisotropy factor, g (equation 2.22), hence µ0s = µs(1  g). Filamentous proteins, such
as collagen and keratin within the skin tissue dominate the scattering in human skin.
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A common way to compute the reduced scattering properties of skin tissue of a desired
wavelength is by adopting power law functions that have been fitted to experimental data.
Different power-law functions have been suggested in the published literature [112,154,155,
191,192] and in this thesis two different equations have been used to compute the scattering
properties.
In chapters 3 and 4 there was no need to distinguish between the epidermal and dermal
layers. Hence the following equation was applied,
µ0s( ) = C
✓
 
 0
◆ b
(5.1)
where  0 = 1 nm and C and b have been experimentally determined [154,155] to be, b =
1.50 and C = 5.81⇥105 cm 1. However for the chapter presented here a multi-layered model
was developed with distinct epidermal and dermal layers. An extension of the equation 5.1
was applied where both the contributions from Rayleigh and Mie scattering are considered
[112,191],
µ0s( ) = C 0
0B@ fra y Ç   00
å 4
+ (1  fray)
Ç
 
 00
å b01CA (5.2)
Here fray corresponds to the fraction of Rayleigh scattering, hence (1  fray) corresponds
to the fraction of Mie scattering and the reference wavelength  00 = 500 nm. Following the
work by Iglesias-Guitian et al (2015) the values for the parameters in equation 5.2 stated in
table 5.1 were adopted [191,192]. The reduced scattering coefficient for the hypodermis can
be determined using the following equation [190],
µ0s( ) = 1050.60  0.68 (5.3)
In all the above equations the wavelength of light is expressed in the units of nm.
Table 5.1: Table with parameters adopted to compute scattering coefficients for epidermal
and dermal layers (equation 5.2).
Layer C’ (cm 1) fray b’
Epidermis 66.70 0.29 0.69
Dermis 43.60 0.41 0.35
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5.2.2 Anisotropy
All the scattering coefficients presented above are the reduced scattering coefficients. The
anisotropy factor in skin tissue typically ranges between 0.7-0.9 and a recent publication by
Jacques et al summarises current published values for g [112]. The g factor that was used in
the majority of work presented in this thesis was published by Van Gemert et al (1989), where
a wavelength dependent g was suggested such that
g = 0.62+ 0.29 ⇥ 10 3 (5.4)
where   has the units of nm [193].
Absorption
The absorption coefficient in a specific tissue can be expressed as the sum of all the contri-
butions of the absorbing chromophores. It is common to include the main absorbers (blood
and melanin) in combination with a background absorption to compute the total absorp-
tion [154, 155]. This results in a flexible, yet robust expression of the absorption. Chro-
mophores other than blood and melanin tend to have minor contribution and variation and
therefore it is convenient to combine them into this background absorption. By allowing the
manipulation of the volume fraction of the main absorbers, different tissue types and condi-
tions can be efficiently represented.
The two main absorbers within skin tissue that are considered here are as mentioned
above, blood and melanin. However due to the lack of blood in the epidermal layers the sole
main absorber in the epidermis is the melanin. The absorption coefficient for the epidermal
layers can therefore be expressed as,
µa,epidermis( ) = fmelµa,mel( ) + (1  fmel)µa,back( ) (5.5)
Where fmel is the volume fraction of melanin within the epidermis [112], µa,mel is the
absorption coefficient for melanin (cm 1) and µa,back is the background absorption of human
tissue (cm 1), and is given by [154,155],
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µa,back( ) = 7.84⇥ 108  3.255 (5.6)
The dominating absorbing chromophore in the dermal layers is the hemoglobin, since
there is no melanin present in the normal dermis or hypodermis. The absorption coefficient
for the dermal and hypodermis layers is therefore expressed by,
µa,dermis( ) = fbloodµa,blood( ) + (1  fblood)µa,back( ) (5.7)
where fblood is the volume fraction of blood within the modelled tissue and µa,blood is the
absorption coefficient for blood (cm 1) [154,155].
Blood
The main absorber of the dermal layer is as mentioned above the blood. The blood volume
fraction within the dermis typically ranges between 0.2 % and 7 % [154]. The absorption for
hemoglobin consist of both deoxygenated and oxygenated blood where the oxygen saturation
level of the blood, Sox determines the ratio between the two contributions such that
µa,blood( ) = Soxµa,ox( ) + (1  Sox)µa,deox( ) (5.8)
Following the work by Iglesias-Guitian et al [191], Sox is assumed to be 0.75 for the work
presented in this chapter. The blood volume fraction was varied to appropriately represent
different age groups. For the other chapters in this thesis the oxygen saturation was assumed
to be 0.64 and the blood volume fraction 1.01% [154]. The µa,ox and µa,deox in equation
5.8 are the absorption coefficients, in units of cm 1, for the oxygenated and deoxygenate
hemoglobin respectively. The two contributions are graphically shown in figure 5.1 a.
Melanin
Melanin is the main absorber in the epidermal layers and the absorption coefficient for melanin
is shown in figure 5.1 b. As demonstrated in the figure, the melanin has a strong absorption
for shorter wavelengths and therefore provides protection against damaging ultraviolet (UV)
light.
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Figure 5.1: Absorption properties for melanin and blood. a) Absorption properties for
blood within dermal layer. Both oxygenated and deoxygenated blood are displayed where the
oxygen saturation determines the proportion of the two contributions to the total absorption
coefficient b) Absorption coefficient for melanin within the epidermal layers [112,154,194,
195]
5.2.3 Skin ageing and pigmentation
The composition and structure of the skin changes with age and appropriate care of elderly
skin has great medical importance [196]. The ageing of skin is a complex procedure that is
due to both endogenous and exogenous factors. The endogenous factors include physiolo-
gical and chronological changes that affect the skin, as it ages. The exogenous factors that
contribute to ageing include UV radiation, toxins and infectious agents that can lead to struc-
tural skin damage and DNA changes [197]. Due to the medical implications it is important to
understand how ageing changes the response to light based treatment such as PDT. The work
presented here follows on from recently published work by Iglesias-Guitian et al [191] where
the main changes in composition and structure due to ageing are included. The changes that
were considered were thinning of the different skin layers (approximately 6-16 % reduction
per decade [198]) and reduction of the main absorbing components in the skin: melanin
(epidermis, approximately 8 % per decade [199]) and blood (dermis, approximately 6-10 %
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per decade [200]). As well as ageing, different skin types [194] were investigated where the
melanin content was adjusted appropriately.
The level of pigmentation, and thereby the appearance of the skin, varies between indi-
viduals. A higher level of melanin pigmentation results in a higher level of absorption and
therefore higher protection against UV radiation (figure 5.1 b). Different levels of pigment-
ation are typically divided into different skin types [9]. Table 5.2 presents the different skin
types in relation to the appearance of the skin.
Table 5.2: Skin type classification [9] displaying the appearance of the skin and the reaction
to sun exposure. A lower skin type classification is associated with a stronger reaction to sun
exposure, in the form of burning, due to the lack of melanin.
Skin
type
Response to sun exposure Appearance
I Always burns, never tans white skin colour
II Burns often, minimal tanning white skin colour
III Burns sometimes, average tanning white skin colour
IV Slightly burns, more than average tanning light brown skin colour
V Rarely burns, tanned strongly brown skin colour
VI Almost never burns dark brown skin colour
5.3 Method
In this chapter radiation transport was utilised (chapter 2) to investigate the light distribution
for different optical properties. A multi-layered model was developed in an attempt to gener-
ate a more realistic and appropriate skin model. The effect of PDT was compared for different
skin types and different ages by computing the toxicity and applying the same toxic threshold
as in chapters 3 and 4. In the work presented here, the initial distribution of PpIX was as-
sumed to be uniform since the focus on the work is the effect of different optical properties.
The same light sources as in chapter 3 and 4 were simulated and compared. Both the fluence
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rate as well as the photodynamic dose (PDD) was generated for conventional PDT (Aktilite)
as well as daylight PDT. The different skin models generated for different ages and skin types
are discussed below.
5.3.1 Skin models
As previously discussed in chapter 1 (section 1.2) the human skin can be divided into several
different layers with differing structure and optical properties. The model presented here
includes five separate layers of different tissue types. The different layers are presented in
figure 5.2. The outermost layer is the epidermis which was divided into two sub-layers; the
stratum corneum (SC) and the living epidermis (LE). The second main layer is the dermis,
which was divided into two layers: the papillary dermis (PD) and the reticular dermis (RD).
The final layer that was included in the model was the hypodermis, situated below the dermal
layers. [6,196].
Figure 5.2: Figure representing the multi-layered skin phantom included in the theoret-
ical model. The thickness and the blood/melanin content within the layers was adjusted
accordingly to represent ageing and different skin types.
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Table 5.3: Thicknesses of the investigated layers that were included in the skin model to
represent ageing [191].
Thickness (mm)
Skin layer Age (years)
30 55 80
Stratum Corneum 0.02 0.02 0.02
Living Epidermis 0.08 0.07 0.06
Papillary Dermis 0.18 0.15 0.13
Reticular Dermis 1.82 1.55 1.27
Hypodermis 2.90 3.21 3.52
Table 5.4: Input parameters that were used for the melanin and hemoglobin levels for
the Living Epidermis (LE), the Papillary Dermis (PD) and the Reticular Dermis (RD). These
parameters were used to compute the optical properties of the different skin layers to rep-
resent different ages and skin types. The hypodermal layer is assumed to contain 5 % of
hemoglobin. The blood oxygen saturation was assumed to be 75 %. [191]. 30, 55 and 80
corresponds to the age of the patient (in years).
Melanin and hemoglobin volume fraction (%)
Skin type Melanin (LE) Hemoglobin (PD) Hemoglobin (RD)
Age (years) Age (years) Age (years)
30 55 80 30 55 80 30 55 80
I 1 0.8 0.6 6 3.6 1.2 4.5 2.73 0.9
II 3 2.4 1.8 6 3.6 1.2 4.5 2.73 0.9
III 5 4 3 6 3.6 1.2 4.5 2.73 0.9
IV 10 8 6 6 3.6 1.2 4.5 2.73 0.9
V 20 16 12 6 3.6 1.2 4.5 2.73 0.9
VI 30 24 18 6 3.6 1.2 4.5 2.73 0.9
The dimensions of the code were set to be 5mm⇥ 5mm⇥ 5mm. The voxel based grid
was not symmetric since higher resolution was required in the z direction (depth from the
surface). Therefore 100 x 100 x 500 grid cells were adopted for the work presented here.
To represent a semi-infinite tissue slab, repeated boundaries were adopted (chapter 3). The
refractive index between each layer does not vary significantly between the different tissue
layers [191] and due to modelling resolution limitations the refractive index (n =1.38) was
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assumed to be uniform throughout the skin tissue. The boundary between the different layers
were therefore only affected by the different optical properties. The thickness of each layer
for the different skin models are presented in table 5.3. Table 5.4 shows the different input
parameters used to determine the absorption properties (equation 5.5 and 5.7). The scattering
properties for the different layers are shown in figure 5.3 a, where the scattering is assumed
to not be affected by skin type or ageing (equation 5.2). The absorption properties for the
epidermal layers are shown in figure 5.3 b-d, where only skin type I, III and VI are displayed
for three different ages (see appendix C for remaining skin types). The absorption properties
for the dermal and hypodermal layers are shown in figure 5.4 for three different ages (30, 55
and 80 years). It was assumed that these properties did not change with skin type.
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Figure 5.3: Figure showing the optical properties adopted in the MCRT model to represent
different ages and skin types. a) Reduced scattering coefficients for the three main layers.
These are assumed to be the same both for different skin types and different ages. The
absorption properties for the epidermal layers are shown in the figure for three different skin
types: I(black), III (red) and VI (blue) for three different ages b) 30 years, c) 55 years and
d) 80 years.
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Figure 5.4: Figure showing the absorption properties of the dermal and hypodermal layers
adopted in the MCRT model presented. The absorption properties of the dermal and hypo-
dermal layers are assumed to not change with skin type however the effects of ageing are
shown in the figure. The different ages that are compared are: a) 30 years, b) 55 years and
c) 80 years.
5.4 Results
The penetration of light depends strongly upon the illuminating wavelength due to the wavelength
dependency of the optical properties (figures 5.3 and 5.4). To demonstrate this, the fluence
rate was generated for three different wavelengths (405, 540 and 630 nm). The effect of the
light penetration for the different wavelengths for three different skin types and two different
ages are shown in figure 5.5. The remaining skin types can be found in appendix C. The
fluence rate describes the distribution of light within the skin tissue and indicates the effect of
the investigated changes on the penetration depth. The fluence rate reduces with increasing
skin type number and increases with age. The different ’kinks’ in the fluence rate is due to
the light propagation through the different tissue layers. The change in optical properties
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between the different layers result in different propagation properties in the different layers.
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Figure 5.5: Figure showing normalised fluence rate ( / 0) as a function of depth for
different ages and skin types. The normalised fluence rate is defined as the fluence rate
divided by the incident irradiance. Each figure demonstrates fluence rate for a certain age
and skin type where three different wavelengths were investigated: 405 nm (blue), 540 nm
(green) and 630 nm (red). The figures each correspond to the fluence rate for a) skin type
I, age 30, b) skin type III, age 30 c) skin type VI age 30 d) skin type I, age 80, e) skin type
III, age 30 and d) skin type VI age 80.
The effects of ageing and different skin types on PDT are displayed in figure 5.6. Here the
PDD for (only) 75 Jcm 2 is shown, since this is believed to be a common light dose delivered
during conventional PDT. The three different light conditions that are compared is the Aktilite
(conventional PDT) and daylight during two weather conditions, clear and overcast. For
conventional PDT the light dose of 75 J cm 2 corresponds to 15 min of light exposure while the
same light dose for daylight corresponds to 30 min (clear) and 150 min (overcast). Similarly
to the fluence rate the light penetration and therefore treatment depth increases with age and
reduces with skin type classification number. A higher skin type classification corresponds to a
larger amount of melanin and therefore, the resulting treatment depth reduces with skin type.
Both blood and melanin content are reduced with age, which results in an increase of light
penetration. The difference between age 30 and 80 (figures 5.6 a and c) is approximately
0.5 mm for skin type I for daylight PDT (clear), while the same difference in ageing for skin
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type VI corresponds to a difference in treatment depth of over 1 mm (figure 5.6 g and i). The
graphical representation of the excluded skin types can be found in appendix C
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Figure 5.6: Photodynamic dose corresponding to 75 Jcm 2 for the different light sources
at age 30, 55 and 80 and for skin types I, III and VI. Three light sources were compered:
daylight for clear conditions (black), daylight during overcast conditions (blue) and the
artificial light source, Aktilite (red). The results show the change in effective penetration
depth with age and skin type. The horizontal line corresponds to the adopted toxic threshold,
which is the same threshold adopted in previous chapters. The different figures correspond
to: a) skin type I, age 30, b) skin type I, age 55 , c) skin type I, age 80, d) skin type III, age
30, e) skin type III, age 55, f) skin type III, age 80, g) skin type VI, age 30, h) skin type VI,
age 55 and i)skin type VI, age 80.
The different light conditions were compared and the results are summarised in table 5.5.
When comparing the different light sources, the results from the simulation suggest that the
largest effects in terms of treatment depth are associated with the overcast daylight conditions
while the smallest effects are associated with the conventional artificial light source (Aktilite).
This is explained by the different spectral distribution of the different light sources (figure
3.4). Since the daylight covers the blue wavelength range, the reduction due to melanin and
blood affects the penetration of the daylight more strongly compared to the red conventional
light source.
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Table 5.5: Table showing the effective treatment depths generated from the MCRT simu-
lations for different skin types and different ages. The different light conditions that are
compared are: Daylight, during clear conditions (DC), daylight during overcast conditions
(DO) and the Aktilite (A). It is clear from the table that the increase due to age is more sig-
nificant for daylight PDT (DC and DO). The effects due to skin type is also more significant
due to daylight.
Effective treatment depth (mm)
Skin type 30 years 80 years
DC DO A DC DO A
I 1.3 1.0 3.5 1.8 1.5 4.1
VI 0.3 0.1 1.8 1.3 0.7 3.0
5.5 Discussion
The results presented in this chapter, demonstrate the effect on light distribution and toxicity
for different skin tissue types for skin corresponding to different ages. The effective treatment
depth associated with the toxic threshold is shown to increase with age and decrease with
increasing skin type classification number. The deeper treatment depths are associated with
older patients of lighter complexion, which is the most common patient group undergoing
PDT [17]. A lighter complexion contains lower levels of melanin which results in a deeper
light penetration. A higher age corresponds to skin tissue with lower levels of both blood
and melanin, which both contributes to a deeper penetration. The reduction of thickness
of epidermis and dermis also contributes to the deeper penetration associated with this skin
model. The reduction of melanin and blood will have a larger effect on the blue part of the
spectrum and this is the reason why the daylight which covers a large wavelength range is
more strongly affected by ageing and skin pigmentation.
The model presented here only investigates healthy tissue where no tumour structure has
been included. The motivation for this is to show the effect of light penetration through
different tissue types. There is limited knowledge of how the optical properties of tumour
change with skin type and skin age. However future developments of this work should include
confinement of PpIX into restricted areas for application of PDT as well as different surface
conditions associated with ageing. Effects such as dryness, surface roughness and uneven
pigmentations, which are typically associated with skin ageing has not been included in this
work. The work presented here is also applicable to other light based therapies where the
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range of ages and skin types is larger. One such area would be laser hair removal, where it
would be of both interest and relevance to study a larger range of patient groups.
Different lesion locations will be associated with different thicknesses of the different lay-
ers included in the developed model [154,201]. So far no distinction has been made regarding
location, however this is something that would be of interest to study further in future work.
To enable this, accurate information of the thickness at different locations is required. Recent
publications suggests that the rate at which the PpIX is produced in an older age group (65-
85 years) is lower compared to a younger age group (18-54 years) [202]. This has not been
considered in the work here, where the initial distribution of PpIX was assumed to be equal
for all groups of patients.
It is clear from the results presented here that accurate information about the skin compos-
ition is important in combination with accurate allocation of optical properties. Even though
differences will still exist between skin tissue of the same skin type and age, the presented
work attempts to initialise a distinction between different groups of skin tissue with respect
to both age and skin type. This categorisation can be further extended by including other
features such as location, gender, race [201], appearance and tumour type. There will always
be differences between human skin tissue, however this allows for some of the reduction of
the errors associated with assuming a generic tissue structure.
5.6 Conclusion
This chapter discusses the relevance of different optical properties and how these can be
efficiently determined. The optical properties were generated for the skin models in this
way throughout this chapter unless otherwise stated. The importance of different optical
properties have been demonstrated in this chapter by investigating the effects that different
skin ages and skin types have on light penetration. It was found that the deepest effective
treatment depth was associated with older skin groups of lighter complexion. Further studies
should attempt to include more classification parameters to extend the range of investigated
optical properties.
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6
Photodynamic therapy through heterogeneous
tumour tissue
6.1 Summary
The effects of three dimensional (3D) tumour structures on depth dependent fluence rates,
photodynamic doses (PDD) and fluorescence images through Monte Carlo radiation transfer
modelling (MCRT) of photodynamic therapy (PDT) are explored. The aim of this work was
to compare the commonly used uniform tumour densities with non-uniform densities to de-
termine the importance of including 3D models in theoretical investigations. It was found
that fractal 3D models resulted in deeper penetration on average of therapeutic radiation
and deeper treatment. For the fractal structures under investigation, an increase in effective
treatment depth of 1 mm for conventional PDT and closer to 1.5 mm for daylight PDT was
observed, when comparing to the equivalent smooth model. Wide field fluorescence images
were simulated, revealing information about the relationship between tumour structure and
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the appearance of the fluorescence intensity. The different models explored indicate that the
3D tumour structure strongly affects the spatial distribution of therapeutic light, the PDD and
the wide field appearance of surface fluorescence images.
The work presented in this chapter contributed to the publication "Monte Carlo modelling
of photodynamic therapy treatments comparing clustered three dimensional tumour struc-
tures with homogeneous tissue structures" in "Physics in medicine and biology" (2016) [203].
6.2 Introduction
The majority of previously published MCRT models of human tissue assume a uniform ho-
mogeneous density of tissue. Some models assume that the whole simulation region is of a
single homogeneous tissue type [98, 99] while some introduce parallel layers representing
different tissue types. However within these layers the tissue is assumed to have a uniform
density distribution [119,124,204,205]. Theoretical models that consider different tumours
tend to include these in the form of geometrical shapes, such as squares, spheres and cylin-
ders [101, 125, 126]. Geometrical cylindrical shapes have also been included in MCRT mod-
els to represent blood vessels, which has been adopted frequently when studying port wine
stains [123,133,134]. Within these shapes, the density has still been assumed to be uniform.
So far in this thesis, the simulation grids have been represented by different tissue types of
uniform densities. Cylindrical tumours were explored in chapter 3 and 4 and a layered model
was introduced in chapter 5. However within these parallel layers or cylindrical shapes, the
tissue has been assumed to have a uniform density.
There are few studies that include 3D geometries that are not symmetric. Brain tissue
has been explored, where complex 3D brain structures have been included as the propagating
medium [128, 131]. Davis et al introduced a complex vessel network containing different
shapes and sizes of blood vessels with the aim to simulate the depth dependence of vascular
fluorescence in brain tissue. The study showed differences when compared to an equivalent
homogeneous model. It was also shown that to accurately represent the depth dependent
fluorescence, the individual vascularisation should be included [206]. To my knowledge there
has been no investigation of the importance of including 3D structures within skin tissue when
simulating PDT.
In this chapter, 3D effects are included in the form of fractal tumour structures with the
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aim to investigate the effects that these have on the treatment outcome. Histological work
by for example Scheibe et al [207] demonstrating the principle of reconstructing 3D tumour
shapes from individual tumour slices indicates heterogeneous tissue. A typical slice of a nod-
ular basal cell carcinoma (nBCC) is shown in figure 6.1. Additional histological samples have
also demonstrated heterogeneous tumour tissue [208]. Therefore it can be argued that sim-
ulations of tumour tissue should incorporate these heterogeneities to provide more realistic
representations. The aim of this work is to investigate the importance of including such het-
erogeneities. The work presented in this chapter does not adopt real tumour shapes since
the aim is to investigate the effect that heterogeneous tissue has on the light penetration
by investigating different degrees of density redistributions. By generating artificial tumour
structures it is possible to compare heterogeneous models to an equivalent smooth model as
well as to adjust the degree of structure within the heterogeneous simulation in an easy way.
The work presented here is an initial step towards more detailed theoretical simulations of
light interaction with skin tissue.
Figure 6.1: Image of a tumour slice demonstrating the heterogeneous tissue structure of a
nodular basal cell carcinoma (nBCC). The dimension of this slice is 4.4⇥12.7 mm. The slice
of tumour shown in this image comes from a paraffin embedded specimen (of a nBCC). The
6 µm thick slice underwent hematoxylin and eosin (H&E) staining and subsequently digital
image processing. For more detailed information see [207]. Image was received from Patrick
Scheibe as a result of research at TRM Leipzig [207].
6.3 Method
The MCRT code previously described (chapter 2) was adopted in this chapter to simulate light
distribution through skin tissue. The same dimensions of the simulation region as demon-
strated in chapter 3 were adopted, where each side of the simulation volume had the dimen-
sions of 10 mm. In accordance with chapter 3 a cylindrical tumour was added, representing
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the tumour tissue. The diameter of the tumour was assumed to be 6 mm and the depth from
the surface was assumed to be 5 mm (figure 6.2). The tissue surrounding the cylindrical tu-
mour volume was assumed to be uniform and of single (dermis) tissue type. The mass of the
tumour was conserved but for the heterogeneous models the mass was regrouped within the
cylinder to represent different tumour structures (section 6.3.1). The optical properties for
the healthy tissue were assumed to be the same as those adopted in chapter 3. The average
optical properties for the tumour tissue were also assumed to be the same as those previously
adopted (figure 3.1). For the heterogeneous medium the tumour optical properties were as-
sumed to scale linearly with the density such that the total attenuation coefficient was higher
for regions of higher density. The concentration and distribution of the photosensitive mo-
lecule protoporphyrin IX (PpIX) was assumed to be proportional to that of the tumour tissue
and was assumed to be restricted to the cylindrical region. The average number density of
the PpIX was assumed to be 7.84⇥ 1013 cm 3 (identical to the uniform case investigated in
chapter 3).
Figure 6.2: Drawing of the MCRT simulation region containing 100⇥ 100⇥ 100 grid cells
with the dimensions 10 mm on a side. The tumour was assumed to be centrally placed with
a diameter of 6 mm and a depth of 5 mm from the surface. Photons where assumed to
normally illuminate the surface of the grid.
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6.3.1 Tumour models
Representations of non-uniformities within the tumour were introduced by adopting 3D fractal
clustered structures. By regrouping the mass of the tumour into clusters in a fractal manner,
a 3D structure was formed. The average density over the tumour region was consistent with
a smooth equivalent model with a uniform density. The structures were generated following
algorithms presented by Elmegreen [209] and is illustrated for a 2D case in figure 6.3. To
determine the density of the new tumour models, separate hierarchical levels are set-up. For
the first level, N1 points are cast randomly within a 3D Cartesian grid with the x, y and z
coordinates all taking values in the range (0,1). At each subsequent level H, NH points are
cast around each point generated at level (H-1), resulting in a clustered fractal model. The
distance between the points at level H and (H-1) decreases with increasing hierarchical level.
The maximum distance from the previous level is expressed by,
± 0.5 1 H (6.1)
where H is the hierarchal level and   is the dimensionless casting length which is determined
through the fractal dimension such that,
fdim = log10NH/llogmathrm10  (6.2)
where NH is the number of points cast at level H. Figure 6.3 demonstrates the basics of the
fractal structure that is built up through this routine in 2D. The points that are cast outside
of the grid of unit dimensions are instead cast on the other side of the grid. If, for example a
point is cast at x = 1+ ", that point is instead given the x co-ordinate ", since the x-boundary
is set to be 1. The resulting density is proportional to the total number of points at the final
hierarchical level cast in each voxel. In figure 6.3 the number of levels is three, hence the
resulting density is proportional to the number of plus signs in each pixel (here a 5⇥ 5 grid
system). The 3D grid of unit dimensions is thereafter mapped to the desired density grid such
that the dimensions correspond to the simulated grid. In the case described here the clustered
grid system is mapped onto a grid system containing 100⇥ 100⇥ 100 voxels. The clustered
structure is further restricted to the cylindrical tumour region (figure 3.2 a) by eliminating
points located outside of this volume. The density within the cylinder is scaled to ensure that
the total mass of the tumour is conserved.
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Figure 6.3: Demonstration of the clustered fractal model in two dimensions (2D). Three
levels are generate for illustrative purposes. The first level (red squares) cast four random
points within the 2D plane. The subsequent level (blue triangles) randomly cast four points
around each point generated at the previous level, hence generating 16 new points. The
third level (black pluses) cast four points around each point generated at the second level,
hence generating 64 new points. Only the points cast at the final level contribute to the
resulting density grid, hence only the number of pluses within each pixel (dashed lines) are
considered [210].
A fraction, fsmooth determines the minimum density within each voxel and represented the
density that cannot be resolved within the grid. The remaining fraction is distributed within
the clustered fractal model. Hence fsmooth determines the minimum relative density present
within the tumour region. This ensures that no voxels within the tumour region contains no
mass (zero density) and thereby creating a void in the simulation region. For this reason the
average density for a 100% smooth/uniform model (i.e. no mass redistribution) and for a
model with a proportion of its mass redistributed is equal.
Six different tumour models were compared with the aim to investigate the importance of
3D effects as it changes for different degrees of clustering. For the work presented here both
fsmooth and fdim are varied to represent different degrees of heterogeneous behaviour. A larger
fdim results in a wider spread of the points cast at the final level of the fractal model. A smaller
fdim results in a tighter fractal structure containing smaller regions of higher densities. For this
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reason, values for fdim were chosen to be between 2 and 3. A large fsmooth results in a smaller
variation in density between the clusters and the surrounding smooth component while a
smaller fsmooth results in a larger difference. If fsmooth is high, the density distribution would be
close to uniform. Conversely, if fsmooth is low then regions closer to zero density would appear.
For this reason fsmooth values between 0.25 and 0.50 were chosen. The different parameters
associated with the fractal models are summarised in table 6.1. The motivation for choosing
these specific values is to allow for different degrees of heterogeneity to be investigated.
Table 6.1: Parameters used to generate different density structures representing different
tumour structures. These values were only chosen to represent different degrees of hetero-
geneity.
Fractal model tumour depth fsmooth H fdim Ni
(mm)
1 5 25 % 5 3 (16,32,32,32,32)
2 5 25 % 5 2.5 (16,32,32,32,32)
3 5 25 % 5 2 (16,32,32,32,32)
4 5 50% 5 3 (16,32,32,32,32)
5 5 50 % 5 2.5 (16,32,32,32,32)
6 5 50 % 5 2 (16,32,32,32,32)
To localise the tumour structure into the cylindrical region the first level of the fractal
model was forced to only cast points within this restricted region. The first locations (x1, y1, z1)
were therefore determined as follows
x1 = 0.3+ 0.4⇠1 (6.3)
y1 = 0.3+ 0.4⇠2 (6.4)
z1 = 0.5+ 0.5⇠3 (6.5)
Where ⇠1, ⇠2 and ⇠3 are different random numbers drawn from a uniform distribution, in
the range (0,1). This concentrated the redistribution of the density to a cuboid within the
cylinder which can be argued to be a more realistic representation than a model where the
points at the first level are randomly cast within the entire Cartesian grid.
For the different fractal density structures that are generated to represent different degrees
of heterogeneities both the fluence rate for different wavelengths as well as the PDD was
generated. To enable comparison with previous chapters in this thesis, both conventional PDT
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(Aktilite) and daylight PDT (for clear and cloudy conditions) have been explored.
The fluorescence generated by the PpIX as a result of light illumination was simulated
as previously described in chapters 2 and 4. In this chapter the wide field fluorescence was
simulated, where a uniform illumination of 405 nm was assumed. The fluorescence photons
were isotropically emitted from the absorption locations and allocated a wavelength from
the PpIX fluorescence spectrum (figure 4.2). Fluorescence photons exiting the surface of the
grid were recorded and binned according to location of exit. A numerical aperture of 0.22
was implemented allowing only photons exiting the simulation grid within a certain cone to
be included within the resulting fluorescence grid. In chapters 2 and 4 only photons within
a certain area corresponding to the fibre probe were collected. In the work presented here
the wide field fluorescence is simulated, hence photons from the whole simulation region are
included. By simulating the wide field fluorescence the intensity variation over the tumour
structure can be investigated.
6.4 Results
Figure 6.4 shows cross-sections in both the vertical plane and the top slice of density structures
1 - 3 in the horizontal plane. Figure 6.5 show the same cross-sections for density structures
4 - 6. Figure 6.6 shows the density histograms for the different density structures. The
histograms demonstrate the distribution of different densities over the whole tumour region.
The bin size for each histogram is set to be 1 to ensure easy comparison. The minimum density
within the allocated area is equal to fsmooth (table 6.1). The proportion of the voxels with a
relative tumour density equal to this smooth component vary for the different structures.
The density distributions demonstrated by the histograms are more affected by a changing
fractal dimension (fdim) compared to a varying smooth component (fsmooth). However a higher
smooth component leaves a smaller amount of remaining mass to be distributed within the
clustered features. A lower value for the fractal dimension (fdim) results in tighter clusters
and hence a large number of voxels are occupied by the smooth component. However a
larger proportion of voxels contain higher densities compared to the more open structure
associated with higher values for fdim.
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Figure 6.4: Figure demonstrating the density distribution of the different tumour models
that are explored. The left column represents a slice in the x-z plane in the middle of the
density grid. The right column represents a slice in the x-y plane at the top of the grid. The
difference in the tightness of the clusters is cause by the variation of the fractal dimension
such that a) fdim = 3, b) fdim = 2.5 and c) fdim = 2. For all the structures in this figure
fsmooth = 0.25 which corresponds to the minimum density in the tumour model and the
amount of mass that is uniformly distributed through the tumour region. As the fractal
dimension, fdim, reduces the clustered structure becomes tighter with smaller areas of higher
densities.
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Figure 6.5: Figure demonstrating the density distribution of the different tumour models
that are explored. The left column represents a slice in the x-z plane in the middle of the
density grid. The right column represents a slice in the x-y plane at the top of the grid. The
difference in the tightness of the clusters is cause by the variation of the fractal dimension
such that a) fdim = 3, b) fdim = 2.5 and c) fdim = 2. For all the structures in this figure
fsmooth = 0.5. Compared to the density structures in figure 6.4 the minimum density in these
structures is higher and therefore a smaller amount of the total mass is redistributed within
the clustered features.
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Figure 6.6: Figure demonstrating the density distribution of the different tumour models
that are explored. The density was binned to demonstrate the distribution of different dens-
ities within the different tumour structures. Figure a - c corresponds to fractal structures 1 -
3 and d - f corresponds to fractal structures 4 - 6 such that a) fdim = 3 and fsmooth = 0.25,
b) fdim = 2.5 and fsmooth = 0.25, c) fdim = 2 and fsmooth = 0.25, d) fdim = 3 and fsmooth
= 0.5, e) fdim = 2.5, and fsmooth = 0.5 and f) fdim = 2 and fsmooth = 0.5.
The fluence rate was generated in the 3D grid for three different wavelengths: 405 nm,
540 nm and 630 nm. The average fluence rate through the tumour tissue is displayed in
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figure 6.7. All six tumour structures are included and compared to the equivalent smooth
model (where the tumour tissue is assumed to have a uniform distribution). All fractal mod-
els demonstrate an increase in the average fluence rate compared to the smooth model. The
difference reduces with increasing wavelength and with increased fractal dimension (fdim).
This is explained by the difference in density distribution, which is demonstrated by the histo-
grams in figure 6.6. At shorter wavelengths the optical properties of tumour tissue are more
highly affected by change in density compared to longer wavelengths (figure 3.1). A cross
sectional representation of the fluence rate, demonstrating the variation across the tumour
tissue is displayed in figures 6.8 and 6.9. The images only demonstrate a single pixel wide
slice of the tumour to illustrate the variation of fluence rate across the tumour. There will be
a 3D variation of the fluence rate across the tumour region due to the density variation.
The PDD for the different fractal models (table 6.1) as well as the corresponding smooth
model using the Aktilite as the illuminating light source is shown in figure 6.10. The smooth
model assumed an initial uniform distribution of the tumour/PpIX corresponding to the av-
erage density of the fractal models. The figures both show the average for the fractal models
(solid lines) as well as individual vertical sample sections demonstrating the range of treat-
ment depth through different parts of the tumour (grey dotted lines). From the results it
is clear that fractal structure 3 (figure 6.10 c) demonstrates the largest difference in treat-
ment depth. For this structure an additional average treatment depth of approximately 1 mm
was gained compared to the corresponding smooth model. However, this fractal model is
also associated with the largest spread when considering vertical sample sections. Here the
smoothing factor fsmooth starts to dominate since the redistributed mass is concentrated to
smaller volumes, resulting in deeper light penetration through the lower density regions. Fig-
ure 6.10 a, on the other hand corresponds to a fractal model where the smooth part does not
make-up as large a part of the mass distribution. This results in an average PDD as a function
of depth that does not differ as much from the corresponding smooth model. The vertical
sample sections for this fractal model demonstrate the range of treatment depths achieved
across the tumour region. Hence even though the average PDD is not significantly different
from the smooth model, a large fraction of the individual sample sections penetrate deeper
into the skin. Conversely a large fraction also penetrates to a shallower depth (figure 6.10
a). For fractal structures with a higher smooth fraction (fractal models 4 - 6) the difference
between the smooth and the fractal PDD is not as significant. This is due to the differences
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between higher and lower density regions is not as significant compared to fractal structures
1 - 3.
The PDD for the different fractal models for daylight PDT during clear conditions is shown
in figure 6.11 and for overcast conditions in figure 6.12. There is a larger difference between
the smooth and the fractal models for daylight PDT compared to conventional PDT (figure
6.10). This is explained by the wavelength dependence of the optical properties of the tu-
mour tissue (figure 3.1). Tumour tissue absorbs more light in the shorter wavelength range,
hence the change in experienced absorption due to the redistribution of mass for shorter
wavelengths is more significant compared to longer wavelengths. The daylight spectrum (fig-
ure 3.4) contains a large fraction of shorter wavelengths which therefore results in higher
sensitivity to changes in tumour densities. The difference between the fractal model (solid)
and the smooth model (dashed) for fractal structure 3 (table 6.1) is close to 1.5 mm for day-
light PDT for both clear and overcast conditions (figures 6.11 c and 6.12 c). The grey lines in
figures 6.11 - 6.12 corresponds to vertical sample sections through the tumour volume sim-
ilar to figure 6.10. This is also due to the increased sensitivity to density variation at shorter
wavelengths. To additionally demonstrate the variation of PDD over the tumour region, pixel
wide cross sections of the PDD are displayed in figure 6.13 and 6.14. The PDD for a total
delivered light dose of 75 Jcm 2 is displayed for the three different light conditions.
The simulated wide field fluorescence for the different fractal structures under investiga-
tion is shown in figure 6.15. The relative fluorescence intensity is displayed and the image
comprises fluorescence photons generated throughout the tumour that have escaped the sim-
ulated region via scattering. The fluorescence signal appears more uniform than the cross
section of the tumour density shown in figures 6.4 and 6.5. The wide field fluorescence also
demonstrates the variation that might occur when using a small probe to measure the fluor-
escence signal. The intensity of the fluorescence signal varies significantly over sub-mm size
scales. The higher smooth component in figure 6.15 d - f results in a smoother fluorescence
signal across the surface, although variations still occur.
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Figure 6.7: Average fluence rate for the different fractal structures under investigation
compared with the equivalent smooth model (dashed). Three different wavelengths are com-
pared: 405 nm (a & d), 540 nm (b & e) and 630 nm (c & f). The kink in the fluence rate
at 5 mm in figures b, c, e and f corresponds to the boundary between the tumour and the
surrounding skin tissue.
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Figure 6.8: Pixel wide cross sectional slices through the tumour tissue representing the
fluence rate for tumour density structures a) 1 b) 2 and c) 3 (table 6.1). The left column
represents 405 nm light, the middle column 540 nm light and the column to the right
represents 630 nm light.
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Figure 6.9: Pixel wide cross sectional slices through the tumour tissue representing the
fluence rate for tumour density structures a) 4 b) 5 and c) 6 (table 6.1). The left column
represents 405 nm light, the middle column 540 nm light and the column to the right
represents 630 nm light.
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Figure 6.10: Photodynamic dose (PDD) for fractal structures a ) 1 b) 2 , c) 3, d) 4, e) 5
and f) 6 for the case when the Aktilite is used as the illuminating source. Both the average
of the fractal models (solid) and the equivalent smooth model (dashed) are included. The
grey lines corresponds to the different vertical sample sections and demonstrate the range
of PDD across the tumour volume. The average PDD for the fractal model is comparatively
noisy in figure c due to the larger change in density in the vertical direction associated with
this density structure (figure 6.4 c). Only the total light dose of 75 J cm 2 is plotted in the
figure, since this is believed to be a typical light dose delivered during light treatment. For
fractal dimension equal to two (c and f) there is a kink in the data which is explained by
redistribution of the tumour mass which is more prominent for a lower fractal dimension.
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Figure 6.11: Photodynamic dose (PDD) for fractal structures a ) 1 b) 2 , c) 3, d) 4, e)
5 and f) 6 for the case of daylight PDT during clear conditions. Both the average of the
fractal models (solid) and the equivalent smooth model (dashed) are included. The grey
lines corresponds to the different vertical sample sections and demonstrate the range of PDD
across the tumour volume. Only the total light dose of 75 J cm 2 is plotted in the figure,
since this is believed to be a typical light dose delivered during light treatment.
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Figure 6.12: Photodynamic dose (PDD) for fractal structures a ) 1 b) 2 , c) 3, d) 4, e) 5
and f) 6 for the case of daylight PDT during overcast conditions. Both the average of the
fractal models (solid) and the equivalent smooth model (dashed) are included. The grey
lines corresponds to the different vertical sample sections and demonstrate the range of PDD
across the tumour volume. Only the total light dose of 75 J cm 2 is plotted in the figure,
since this is believed to be a typical light dose delivered during light treatment.
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Figure 6.13: Demonstrating the photodynamic dose (PDD) through a pixel wide slice
through the tumour tissue after a total delivered light dose of 75 J cm 2. Three different
light conditions were simulated. The left column corresponds to illumination by the Aktilite
(conventional PDT), the middle column corresponds to illumination by daylight during clear
conditions and the right column corresponds to illumination by daylight during overcast
conditions. The different tumour structures that are compared (table 6.1) are a) 1 b) 2 and
c) 3.
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Figure 6.14: Demonstrating the photodynamic dose (PDD) through a pixel wide slice
through the tumour tissue after a total delivered light dose of 75 J cm 2. Three different
light conditions were simulated. The left column corresponds to illumination by the Aktilite
(conventional PDT), the middle column corresponds to illumination by daylight during clear
conditions and the right column corresponds to illumination by daylight during overcast
conditions. The different tumour structures that are compared (table 6.1) are a) 4 b) 5 and
c) 6.
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Figure 6.15: Figure demonstrating the simulated wide field fluorescence for fractal struc-
tures a) 1 ( fdim = 3 and fsmooth = 0.25), b) 2 ( fdim = 2.5 and fsmooth = 0.25), c) 3 ( fdim
= 2 and fsmooth = 0.25) , d) 4 ( fdim = 3 and fsmooth = 0.5), e) 5 ( fdim = 2.5 and fsmooth
= 0.5) and f) 6 ( fdim = 2 and fsmooth = 0.5). The image shows both a more uniform fluor-
escence signal compared to the cross section of the density (figures 6.4 and 6.5) as well as a
variation in fluorescence over small distances. The image dimensions are 1 cm on a side.
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6.5 Discussion
The work presented here explores the importance of including 3D tumour structures within
theoretical simulations of PDT. Most existing models only consider uniform densities of differ-
ent tissue types, however it is shown that tissue with a non-uniform distribution significantly
affects the light penetration in tissue. Different degrees of redistribution of the tumour mass
were compared but the average density over the whole tumour region was the same for all
models. The results presented in this work suggest that if there are non-uniformities within
tissue, 3D effects should be considered in theoretical models. From the different models
compared in this chapter it is evident that when simulating daylight PDT it is especially im-
portant to consider 3D effects. The results show that the significance of including 3D effects
is considerably larger when shorter wavelengths are included. This is further demonstrated
by the difference in fluence rate at different wavelengths (figure 6.7) as well as by the PDD
for different treatment conditions.
The different vertical sample sections in figures 6.10 - 6.12 demonstrate the range of
the penetration through different parts of the tumour. The spread increases as the smooth
component, fsmooth becomes more dominant. For a structure where the mass redistribution
forms tight clusters with high density, the majority of the volume is made up of the smooth
component. Hence the majority of the propagating photons will experience a medium of lower
opacity which results in larger average fluence rates deeper in the tissue. The resulting regions
of lower density of PpIX results in an insufficient PDD in these regions, since there are not
enough absorption events possible to reach the estimated threshold. There is more absorption
in regions of higher density on the other hand and consequently a higher PDD. This explains
the larger spread in PDD associated with the vertical sample sections from fractal structures 3
and 6 compared to fractal structures 1 and 4, where the density difference between regions is
lower (figure 6.6). When studying the vertical sample sections a trend becomes obvious which
demonstrates the PDD in tissue where the photons only experience the smooth component.
The PDD at the surface will therefore not be lower than the PDD caused by tissue with density
corresponding to the smooth component (fsmooth).
The work presented here assumed that the PpIX distribution mimics that of the tumour
tissue. Therefore the initial distribution of PpIX was assumed to be the same for the different
light conditions that were considered. The topical application of the pro-drug for different
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occlusive treatment times were not considered. Extending this chapter would include the
PpIX production method developed in chapter 4.
The presented models do not consider a density dependent toxic threshold. The threshold
that is introduced is consistent with previous chapters in this thesis. When the density of
tumour tissue is lower, fewer absorbed photons might be required to result in efficient tissue
destruction. The threshold that is adopted here is what is believed to be an approximation
of the average number of required absorption events. The cross sectional images figures 6.13
and 6.14 do not indicate voids where the tumour density is too high to allow photons to
penetrate through. Enough light has to be able to reach regions of high density to efficiently
destroy the tumour cells. Such a density dependent toxic threshold is not considered in the
presented model and should be considered in future work. In addition, the difference in PpIX
production in regions of varied density is not considered.
The wide field fluorescence images (figure 6.15) comprise fluorescence light emitted not
only from the surface but also contributions from the tumour below the surface. The increas-
ing inhomogeneity of the images varies as expected between the different fractal structures.
Point measurements will vary over small distances due to the clusters of higher densities. This
could be one of the reason why the clinical measurements presented in chapter 7 show a large
spread. Measurements using a probe with a small collection region can be different at two
positions close to each other.
The work presented here is to my knowledge the first to consider the effects of 3D tis-
sue structure on light distributions during PDT. Even though the structures considered are
constructed from mathematical algorithms they illustrate the effects of a non-uniform distri-
bution on the light penetration. The method of using these algorithms also allows for easy
comparison to the equivalent smooth model to assess the importance of 3D affects. Future
work should include more realistic tumour models perhaps based on histological samples.
6.6 Conclusion
3D tumour structures were introduced with the purpose of theoretically studying topical PDT.
The effects of non-uniformities within the tissue were explored by including fractal clustered
tumour models. By changing the fractal dimensions of the density structures, different degrees
of redistributions were investigated. It was found that light penetration is strongly affected by
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the distribution of tissue and encourages continued usage of 3D MCRT models when studying
light propagation through skin tissue.
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7
A quantitative study of in vivo protoporphyrin IX
fluorescence build-up during occlusive treatment
phases
7.1 Summary
Protoporphyrin IX (PpIX) is a strongly fluorescing molecule. Fluorescence measurements can
therefore be used as an indicator of the amount of PpIX present within the tissue. In this
chapter a clinical study is presented where the fluorescence measurements were used to in-
vestigate the build-up of PpIX within the tumour tissue during the 3 hour long occlusive treat-
ment prior to irradiation. The data was explored using statistical frameworks to appropriately
consider the nature of the data. The predictive models suggest that there is a significant dif-
ference in PpIX production between lesion location. However no difference is demonstrated
between different lesion types. The study presented includes 40 lesions from 40 individual
patients where the majority of the lesions were actinic keratosis and basal cell carcinoma.
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7.2 Introduction
During topical photodynamic therapy (PDT), the prodrug is applied to the skin in the form of
a cream containing aminolevulinic acid (ALA) or methyl aminolevulinate (MAL). The lesion
is then covered with an occlusive dressing which blocks out any ambient light. During this
occlusive treatment (with a typical duration of three hours) the cream diffuses through the
skin and is converted to the photosensitive molecule protoporphyrin IX (PpIX) in the tumour
cells [58]. PpIX is a naturally occurring molecule which is produced in the mitochondria as
part of the heme biosynthesis. When precursors to PpIX are added to the tumour cells, rate
limiting steps are bypassed and an excess amount of PpIX is selectively accumulated in the
tumour cells. For a more detailed description see chapter 1 (section 1.5).
Many skin properties change when removed from the body. Therefore, in vivo data is
important for accurate representations of skin dynamics. Clinical studies are for this reason
vital for development of the PDT treatment as well as determination of skin properties to
allow accurate theoretical simulations. In PDT the in vivo data acquisition is mostly lim-
ited to surface measurements, due to the non-invasive nature of the treatment. Due to the
strong fluorescence characteristics of the PpIX, the level of fluorescence indicates the amount
of PpIX in tissue [211]. The decay in fluorescence can, for example, be used to determine
PpIX photobleaching properties during illumination [100]. In the present study the fluores-
cence observations were used to measure the production of PpIX prior to the exposure to the
light source. The study presented here compares different lesion characteristics where the
fluorescence signal was measured every 20 minutes for a full 3 hours. The primary objective
for the study was to determine how the PpIX fluorescence signal changed with time from the
application of the prodrug and how this was affected by the patient and lesion characterist-
ics. The secondary objective was to combine the clinical data with theoretical models to gain
more knowledge about the characteristics of the PpIX production. The secondary objective
has already been discussed in chapter 4 where the clinical study was replicated theoretically
in an attempt to gain more knowledge about the PpIX production.
The measurements were performed at Hospital Amaral Carvalho, Jaú, Brazil. The data
collected in Jaú was part of an initial collaboration with the University of São Paulo. The
hospital is the centre for cancer and PDT, which covers an area approximately 500 km in
diameter and closely collaborates with the University of São Paulo. The patients that are
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treated in the hospital are typically from rural areas and have spent a majority of their working
lives outside without using any sun protection. From observations, the sun damage in many
patients was extensive and a wide spread problem throughout the country [212]. Figure 7.1
shows a patient with a large area of the arms covered with actinic keratosis (AK), a type of
precancerous lesion. The high throughput of patients as well as the opportunity of sharing
knowledge made Brazil a good study site.
All measurements were recorded by me, during my time in Brazil.
Figure 7.1: Patient with extensive Aktinic Keratosis (AK) on both arms.
7.3 Method
The majority of the lesions included in the study were basal cell carcinoma (BCC) (26) and
actinic keratoses (AK) (11) however a few Bowen’s disease (BD) and squamous cell carcino-
mas (SCCs) were determined from the biopsy. These lesions were still included within the
study however when a comparison of the lesion type was investigated only AK and BCCs were
included.
Many patients presented with more than one lesion, and a maximum of 4 lesions per
patient was recorded. However, only one lesion per person was included in the analysis
of the data presented here. Most patients returned for a second treatment, one week after
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the initial treatment. When appropriate, both the first and second sessions were recorded.
The measurements from the first treatment and the second treatment are not statistically
independent data sets. For the purposes of the work presented here the two treatments were
independently analysed and compared. All statistical modelling was done using R [213].
The study was conducted in compliance with the regulations and standards of good clinical
practice (GCP). The study was conducted under the ethical approval accepted by the ethics
committee at Hospital Amaral Carvalho (CEPFHAC-140/11). All supporting documents can
be found in appendix D.
7.3.1 Study design
Appropriate lesions were examined and selected for the study by a qualified dermatologist.
Before the cream was added to the lesion, the lesion was lightly scraped removing the surface
crust using a sharp blade. This removed some of the potential interference associated with
the prodrug diffusion. After this routine surface preparations (curettage), a cream containing
20% MAL (PDTPharma LTDA., Carvinhos-SP, Brazil) was applied to the lesion of interest. The
biopsy that was removed during the curettage was sent away for analysis which allowed for
a specification of the lesion type. After the cream application, the lesion was covered with
a plastic film and a compress, which was secured with surgical tape. The occlusive dressing
was applied for a total of three hours and ensured that the interaction with ambient light
was minimised. During this occlusive treatment period the fluorescence signal was recor-
ded at a regular time interval. At each measurement point the dressing was removed, any
excess cream was removed and the fluorescence signal was recorded from the lesion. Five
repeated measurements (from approximately the same area) were recorded before the cream
and dressing was reapplied. This was repeated every 20 min for a total of 3 hours. When
required, additional cream was added to the lesion to ensure that there was always an excess
amount of cream present on the lesion. The fluorescence signal was additionally recorded
prior to the surface preparation, after the surface preparations (before cream application) as
well as directly after the completed illumination.
The fluorescence measurements were recorded using an optical biopsy system (OBS),
which houses a blue, 405 nm laser diode. Section 2.5.1 (chapter 2) describes the OBS in
more detail. The probe was placed perpendicular in contact with the skin lesion, and the
measurements were performed in a darkened environment. Due to a significant amount of
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ambient light in the treatment room, a black-out cap was designed. The cap was placed over
the probe to reduce the disturbance from the ambient light (figure 7.2).
Figure 7.2: A black out cap was designed to remove artefacts from ambient light. The cap
was placed on top of the probe before each measurement.
Following the occlusive treatment the lesion was treated using the therapeutic light source
for 20 minutes. In the case presented here the LINCE was used, which is a red LED array based
light source with an irradiance of 125 mWcm 2 [212]. Figure 7.3 shows a patient undergoing
PDT where the LINCE was adopted.
Figure 7.3: Patient undergoing PDT using the LINCE developed in Brazil. Here three differ-
ent lesions are treated with three individual light sources.
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7.3.2 Study population
40 lesions were included in the analysis presented here. Only one lesion per patient was in-
cluded to ensure that the different lesions were independent. The lesion that was included
within the study was randomly selected for each patient presenting multiple lesions. In addi-
tion, the lesions that were excluded were those demonstrating a negative fluorescence signal
since this indicates inaccurate measurements.
7.3.3 Statistical model development
The observations were normalised by subtracting the background signal (measurement be-
fore cream application) from each observation, removing the effects of autofluorescence. By
doing this some of the differences in the optical properties were corrected for and the relative
increase of the fluorescence due to PpIX production could be determined [214]. This was car-
ried out for each individual patient and session individually since the autofluorescence will be
different for different subjects and potentially may also vary day to day. To analyse the data,
the characteristic peak fluorescence signal at ⇠ 635 nm was recorded for each measurement
to investigate how the peak changed with time from cream application.
The aim was to generate a statistical model that accurately predicts the fluorescence sig-
nal as it changes with time for different patient conditions such as different skin types and
lesion types. The easiest and most straight forward approach to relating the fluorescence sig-
nal (response) to the time (explanatory variable) is by applying a simple linear regression.
This framework can be further extended to include other features of the data set, such as
correlation, which are important to gain more accurate information. Here the conditions for a
simple linear regression will be described followed by a discussion of where this model breaks
down for the data set in question. Expansions and developments of this model will thereafter
be discussed and explored, and the benefits and limitations will be considered.
A simple linear regression assumes normality, homogeneity and independence [215]. If
a simple linear regression is adopted, these assumptions should be verified. The data is nor-
mally distributed if the data points have a Gaussian distribution at all x values (here time).
The homogeneity applies if the data displays equal variance for all values of x. Independ-
ence assumes that there is no dependence between different data points. Violation of the
independence assumption can lead to over fitted models and can lead to misleading results.
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For simple linear regression one assumes that the observations Yi have a normal distribution
(normal distribution of the unexpected differences between the observations and the model)
with mean
E(Yi) =  +↵X i (7.1)
For i=1,....,n, where n is the total number of observations. Here Xi is the explanatory vari-
able, Yi is the response and ↵ and   are the parameters explaining the relationship between
the response and the variable.   represents the intercept in the model and ↵ represents the
slope. The goal is to determine the parameters to be able to explain the response as accur-
ately as possible. This is commonly done through maximum likelihood estimations, based on
finding the parameter values that are most probable, given the observations and the given
model [216,217].
Model diagnostics are crucial when justifying a particular model and help to validate the
accuracy of the applied model. The residuals are defined as the observed values minus the
predicted values by the model and the shape of the residuals usually reveals a lot about the
appropriateness of the applied model. If the residuals are plotted as a function of the fitted
values the homogeneity can also be explored. If no trends or shapes are obvious through the
residuals, the applied model is supported. Therefore it is not only important to observe the fit
of the data, but also the residuals should be investigated.
If in the data set acquired the assumptions about independence, homogeneity and nor-
mality are violated, alternative frameworks have to be applied. A simple linear regression
assumes a normal distribution of the observations. To generalise and allow for a non-normal
error distribution, generalised linear models (GLM) are adopted. This introduces transform-
ations of the linear model to allow for the different distributions of the error component.
Below, the nature of the data will be discussed followed by a description and motivation for
the frame work that is adopted.
Nature of the data
The data in question is clearly correlated. The amount of PpIX present in a tumour after
60 min depends on the amount of PpIX after 40 min. This results in a correlation of the
fluorescence measurements. Typically a longitudinal data set such as the one discussed here,
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is autocorrelated, where the dependence decreases exponentially with time. For this reason
the data points cannot be assumed to be independent and a simple linear regression such
as the one above, is possibly not appropriate [217]. Previous studies show an initial linear
increase which eventually levels off. An initial analysis of the data showed that the data
supports the linear trend previously published [218,219]. For this reason the adopted model
was assumed to follow a positive linear trend. Negative fluorescence signals should not be
possible, therefore the data is positive and the slope of the linear trend should also be positive.
Since all data points were normalised by the measurements before the cream was applied at
time zero, the intercept was forced to be zero. The skewness of the residuals in combination
with the requirements of a positive model indicates a Gamma distribution of the observations,
where the variance increases quadratically with expectations [217,220].
Generalized Linear Mixed Effects Model (GLMM)
A common and convenient way of modelling variation between individuals within a data set
is by adopting random effects. The random effects represents the variation not explained
by the covariates (fixed effects). The difference in for example genetic make-up associated
with different individuals results in slightly different PpIX production rates. This effect is
not considered within the fixed effects model. The additional noise that is not explained by
the fixed effects, can be further explained by the addition of random effects. This is also
an attempt to gain more understanding of the population as a whole. The collected data
represents a small subsection of the wider population. Hence by including the random effects
associated with the individual and explaining the associated noise, the information gained
from the estimated model can be applied to the wider population and not only the small
subset of patients included in the study [217].
GLMM requires probability distributions that are conditional on the random effects. GLMM
models introduce effects that are not only fixed but also randomly allocated, which makes the
likelihood function complicated. The resulting function can, for the majority of the cases,
not be solved analytically and therefore different numerical approaches are required. For this
reason statistical programs are useful for generating solutions and here R [213] was chosen
to assist in the estimation of parameters and associated standard errors [216,217,220].
The model of interest should initially include all the different covariates of interest such as
gender, location, skin type and lesion type. The model proposed is a multiplicative model to
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ensure a positive slope with an intercept of zero. The observations are assumed to be gamma
distributed, as a result of which the variation increases as a function of expected value. The
conditional mean, i.e. the mean value of Yijk is conditional on the value ↵i, can be expressed
as,
E(Yijk|↵i) = ↵iX j gi li sti ti (7.2)
Here Yijk is the observation k at time j for patient i. ↵i is the slope associated with each
patient from the simple linear regression. The simple linear regression has been extended
to include  gi which is the contribution from the gender,  li that corresponds to the location
of the lesion,  sti the skin type of lesion and  ti that corresponds to the type of lesion. To
determine the different contributions from the fixed effects gender, location, skin type and
lesion type and the significant relevance, the observation is divided by the time Xj and the log
transform is applied to the remaining expression,
log(E(
Yijk
X j
|↵i)) = log↵i+ log gi+ log li+ log sti+ log ti = a+ bg+ bl+ bst+ bt (7.3)
This is a linear model similar to the simple linear regression described above (equation
7.1). However here the combination of the different contributions becomes the slope of the
model describing the relationship between the observation and the time. The final slope
will be expressed as ea+bg+bl+bst+bt . Combining the log transform and the skewness of the
data a gamma log link function GLMM was applied to the model, where the observations are
assumed to have a gamma distribution. The GLMM allows for the repeated measurements to
be included where the within-subject correlation is considered within the developed model.
Only the explanatory variables that showed a significant difference, i.e. with a p-value below
0.05, were kept in the model. Other covariates were dropped from the model.
The different treatment sessions (1 and 2) were analysed independently. The two sessions
were also compared to investigate significant effects in the fluorescence signal between the
two sessions.
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7.4 Results
Figure 7.4 shows a patient with multiple lesions with typical characteristics for the study.
This figure corresponds to two superficial BCC lesions on the shoulder/back. The size of the
lesions were approximately 2 cm (left) and 1.5 cm (right). Only one of the lesions (right)
was included within the study and is in the figure magnified. The characteristic fluorescence
signal generated from the PpIX within the lesion tissue is shown in figure 7.5. In the figure
the characteristic peaks at 635 nm and 705 nm are shown. The work presented here focuses
on the peak at 635 nm since this is the most prominent peak.
All the peak observations (⇠ 635nm) during the first for all patients, subtracted by the
autofluorescence, including all the repeated measurements are shown in figure 7.6. The x-
axis shows the occlusive treatment time, where the measurements are repeated every 20
minutes. A jitter was added to the plot to spread out the data points at each time point (x-
axis) to more clearly show the density. For an easier representation of the data, the averages
of the repeated measurements for each patient are displayed in figure 7.7. In this figure
a linear trend within the data can be noted, however a large variability is also displayed,
the median standard deviation between patients was determined to be 108% over all time
points. The individual representation of the patients included in the study can be found in
appendix E. A random selection of five patients was generated and the repeated measurements
were plotted in figure 7.8 (first session). The median standard deviation for the repeated
measurements, i.e. the intra-variation, including all patients, was determined to be 59%. For
the second session, the data are shown in figure 7.9 (repeated observations) and 7.10 (average
observations). When applying a simple linear regression (equation 7.1), the resulting fitted
model with associated 95% confidence intervals is displayed graphically in figure 7.11 (first
session) and 7.13 (second session). For the simple regression models only the average of the
repeated measurements are included. This was motivated by a need to reduce the level of
correlation. However there are still correlations present within the data set which have to be
further considered.
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Figure 7.4: Image of typical lesions included within the study. Two superficial BCCs are
displayed in the image. Only the lesion to the right (magnified) was included within the
study.
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Figure 7.5: Figure showing a typical fluorescence signal (arbitrary units (a.u.) ) observed
from one of the patients included within the study. The fluorescence signal is generated
when the PpIX is exposed to blue, 405 nm, light. The fluorescence spectrum displays two
characteristic peaks at 635 nm and 705 nm. In the analysis presented here, the focus lies
within the peak at 635 nm.
159
Chapter 7. A quantitative study of in vivo protoporphyrin IX fluorescence build-up during
occlusive treatment phases
0 50 100 150
0
20
0
60
0
Time (min)
Fl
uo
re
sc
en
ce
 (a
.u
.)
Figure 7.6: Figure showing the data for the repeated measurements for the first treatment
session. All observations are normalised by the observation prior to cream application. This
corrects for different optical properties and autofluorescence.
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Figure 7.7: Figure showing the average of the repeated measurements for the first treatment
session. The observation prior to cream application (time = 0 min) have been subtracted
for each individual at each time point to normalise the observations. This introduces the
restriction of a zero intercept model.
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Figure 7.8: Figure showing the data associate with five randomly sampled patients from the
total data set of patients. The repeated measurements of the fluorescence signal (arbitrary
units, a.u.) are included within the plot and the different colours corresponds to the five
different patients. To see all the measurements for the first session, see appendix E.
The resulting residuals from the simple linear regression for both session one and two are
shown in figure 7.12 and 7.14. The residuals show that both the assumption of normality
and the homogeneity are violated. Therefore a more complex framework is required for the
correct analysis of the data where both increase of the variance with time as well as correlation
and skewness is considered.
As previously discussed, a more appropriate statistical framework to apply is a GLMM. The
GLMM suggested (equation 7.3) indicates a significant difference (p<0.05) between lesion
location during the first session. The model showed a difference between lesions located
on the face compared to other lesion locations. Originally the locations were divided into
three groups: face, arms or back/chest. As the effects were not significant, the arms and
back/chest lesions were grouped together and were compared to the lesions located on the
face. The observations from the face showed a steeper slope and therefore an overall higher
fluorescence signal, indicating a faster production of PpIX. Other properties such as lesion
type, skin type and gender did not show any significant difference and were therefore dropped
from the model. Figure 7.15 shows the predicted model for the data corresponding to the first
session with the different lesion locations. The 95% confidence intervals are included in the
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figure to demonstrate the uncertainty in the estimates.
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Figure 7.9: Figure showing the data for the repeated measurements for the second treatment
session. All observations are normalised by the observation prior to cream application. This
corrects for different optical properties and autofluorescence.
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Figure 7.10: Figure showing the average of the repeated measurements for the second
treatment session. The observation prior to cream application (time = 0 min) have been
subtracted for each individual at each time point to normalise the observations.
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Figure 7.11: Figure showing a simple linear regression (first session) where the solid line
corresponds to the predicted model with confidence intervals represented with dashed lines.
The circles represents the average of the repeated measurements. The average of the repeated
measurements were assumed in this model to be the absolute value to reduce correlation
within the observations.
0 50 100 150 200−
20
0
0
20
0
40
0
Fitted values
Re
sid
ua
ls
Figure 7.12: Residuals as a function of the fitted values (first session). The residuals give
us an indication of the normality of the data set. The residuals for the simple linear re-
gression shows a skewness that indicates that the data is neither normally distributed nor
homogeneous. In addition, no trend is observed which supports the linear assumption.
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Figure 7.13: Figure showing a simple linear regression for the second session where the solid
line corresponds to the predicted model with confidence intervals represented with dashed
lines. The circles represents the average of the repeated measurements. The average of
the repeated measurements were assumed in this model to be the absolute value to reduce
correlation within the observations.
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Figure 7.14: Residuals as a function of the fitted values. The residuals give us an indication
of the normality of the data set. The residuals for the simple linear regression shows a
skewness that indicates that the data is neither normally distributed nor heterogeneous.
The appropriate residual representation is displayed in figure 7.16 since this considers the
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non-normal distribution of the observations. This can be compared to figure 7.12, where the
residuals associated with the GLMM indicates a better fit.
When the second session was investigated no significance was demonstrated for lesion
location, lesion type, gender or skin type. However a significant difference (p<0.05) between
the different sessions was demonstrated when comparing the data for both sessions. The
second session resulted in a steeper slope parameter compared to the observations for the first
session. The predicted GLMMmodel for the different locations (ignoring all other explanatory
variables) is shown in figure 7.17.
The results were generated using the ’glmmPQL’ function in the ’MASS’ package in R,
however the ’glmer’ function in the ’lme4’ package gave approximately the same results. The
different functions uses different approaches to solving the maximum likelihood, however the
results are equivalent therefore only the results from the glmmPQL function are displayed.
The different slope parameters estimated by the different models discussed are summarised
and presented in table 7.1. The boundaries for the GLMM models reported in table 7.1 are
not uniform due to the exponential nature of the model. Therefore the upper and lower limits
are presented in the table to present the deviance of the slope.
Table 7.1: Table showing the different parameters estimated from the different models ex-
plored. Upper and lower boundaries are represented in terms of ±1.96  where   represen-
ted the standard error. Here ↵ is the slope of the parameter where Y= ↵X.
Model Slope Lower boundary Upper boundary
↵ ↵ -1.96   ↵ + 1.96  
Simple linear regression
session 1 1.050 0.976 1.124
session 2 1.387 1.334 1.440
GLMM location
session 1
Face 1.072 0.685 1.678
Other locations 0.628 0.467 0.846
GLMM session
session 1 0.835 0.705 0.989
session 2 1.129 1.078 1.183
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Figure 7.15: Figure showing the linear trend between the fluorescence signal (arbitrary
units, a.u.) and time (minutes) for the first treatment. The predicted model was generated
using a Generalized Linear Mixed Effects Model (GLMM) where the results demonstrate a
significant difference (p < 0.05) between lesions located on the face compared to other body
sites. The fluorescence was shown to be higher for lesions located on the face (red). The circles
show observations, where the repeated measurements were averaged to reduce clutter on the
graph. However all repeated (five) measurements were used to fit the model. The black
circles represents lesions located on other body sites other than the face and the red circles
corresponds to observations from lesions on the face. The confidence intervals (dashed) are
included for the different situations. Note that the lower confidence interval for the face
group (red) overlaps with the upper confidence interval for the other locations (black).
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Figure 7.16: Figure showing the residuals for the GLMM model. The residuals indicates
that the model is a considerably better fit compared to the simple linear regression
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Figure 7.17: Figure showing the comparison between session 1 (black) and session 2 (red).
The two treatments are typically spaced one week apart. The applied model only compared
the effect of different treatment session where the results indicates a higher fluorescence
signal for the second treatment (p < 0.05).
7.5 Discussion
The aim of the clinical study was to quantify the increase of PpIX during the occlusive treat-
ment time with the intention of investigating the effect that different lesion characteristics
have on the amount of PpIX present within the tissue. As an indication of the amount of
PpIX, the fluorescence signal produced by the PpIX was measured every 20 min during the
full three hour long occlusive period. The resulting study suggested that the strength of the
fluorescence signal was affected by the location of the lesion which supports previous find-
ings [221]. However this significance was only indicated for the first (of two) treatment
sessions. Other characteristics such as lesion type, gender and skin type did not show any
significant difference to either treatment sessions. The lack of effect of gender and skin type
can be explained by the fact that these factors should not have any effect on the lesion itself. A
more significant difference between lesion type (comparing AK and BCC) was expected both
due to potential anatomical and physiological variation between lesion types as well as pre-
vious published results [218]. However this significant difference was not found within the
data.
The linear trend that was deduced to be the most appropriate is supported by previous
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studies [218, 219], however there is no way of determining the shape after the three hours
that were measured. It can be argued that the linear trend would flatten out if the occlusive
treatment was extended due to the saturation of the PpIX. To measure this, subjects would
have to stay in the clinic for a longer period of time and would not be able to undergo PDT
during the same day. This study would therefore be considerably less convenient for the
patients and would introduce additional visits to the hospital which is not desirable. The
study performed here is not believed to affect the underlying PDT treatment and therefore no
information beyond the three hours can be deduced. Only the linear increase in fluorescence
and thereby PpIX production during the initial three hours can be successfully determined.
There are several issues associated with the study presented. Due to the location of the
study (Brazil), the surface preparations were not carried out according to the standard pro-
tocol established in the UK which was impossible to establish prior to the start of the study.
The curettage performed is clearly depending on the institute and the training of the staff.
At Hospital Amaral Carvhalo in Jaú the curettage was very deep which resulted in a lot of
blood production. Two issues arise from this. First of all is the possibility of the fluorescence
measurements being affected by blood due to the strong absorption properties of blood. Even
though attempts to reduce the blood effects, there are high probabilities that some measure-
ments, especially the background readings, could be affected by blood. The second effect that
arises from the deep curettage is the removal of lesion. A lot of the lesion is removed during
this deep curettage which means that the PpIX is limited to superficial layers and therefore the
linear trend could be explained by the theoretical model developed in chapter 4. If a majority
of the lesion is removed, the PpIX will only be produced to shallow depths. This is then in
agreement with the theoretical model developed in chapter 4. To investigate the effect that
the curettage had on the measurements and the PpIX production a study on a different study
site should be carried out. This would allow the level of curettage to be investigated as well
as support the study performed in Brazil.
The stability of the measurements could have been affected by the instability in the energy
supply as well as the heat and humidity associated with the conditions within the hospital.
The black out cap was produced to block out as much ambient light as possible, however it
was not possible to explore the effects that this addition had on the measurements. Since
the background autofluorescence measurements were performed with the black out cap, it
could however be argued that the effect from the cap was considered within the normal-
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isation (subtraction of background from subsequent measurements). It was assumed that no
ambient light interacted with the already produced PpIX during the measurements. The meas-
urements were performed as fast as possible, and the resulting photobleaching should not be
significant. However measurement techniques where the removal of the dressing and the
cream are avoided would be preferable since this would remove any possibilities of additional
unwanted photobleaching.
The intra-subject variability could be explained by an inhomogeneous distribution of the
PpIX in the horizontal plane. Even though the same area was targeted, due to the potential
inhomogeneous nature of tumours this could explain the large variability displayed within an
individual. There is also a large variability between individuals, as is displayed in the raw
data (figure 7.6). This could be explained by the difference between the genetic make-up
between patients which is the motivation behind the mixed effects model. Chapter 6 explored
the fluorescence signal from heterogeneous tumour tissue which suggested large variability in
the resulting signal on the sub-mm size scale.
Future work should include a quantification of the OBS to relate the fluorescence signal
to an amount of PpIX. This could be done in a phantom of known optical properties with a
known amount of PpIX. Other improvements involve, as previously mentioned, an additional
study where the curettage is under better monitoring to establish effects associated with the
level of curettage and the outcome of the treatment and the PpIX production.
Even though the study presented here is associated with some instabilities, the observa-
tions suggests a linear trend where only lesion location had a significant effect on the fluor-
escence signal. The complex statistical framework that was developed is appropriate for this
study as well as other similar clinical studies and should be considered as a potential frame
work for future studies. The data collected extends previous knowledge where the frequency
of measurements have been extended as well as the comparison between more explanatory
variables has not previously been performed.
7.6 Conclusion
The PpIX fluorescence signal from patients presented with superficial skin lesions was meas-
ured at a regular time interval during the three hour long occlusive treatment phase. Due
to the strong fluorescence characteristics associated with the PpIX, the fluorescence measure-
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ments are useful for indication of the amount of PpIX present within the region of interest
during a particular time. It was found that the PpIX increased linearly during the first three
hours of the occlusive phase where results indicate a larger overall amount of PpIX for le-
sions located on the face compared to other lesion locations. No significance was found when
comparing gender, lesion type and skin type. Even though the results show a large variability
both intra- and inter-subject, the linear trend supports previously published results. The data
was analysed using a generalised linear mixed effects model which appropriately considers
the nature of the data. The resulting trend has been utilised in chapter 4 in an attempt to
gain more information about the in homogenous distribution in the vertical direction of the
produced PpIX.
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Concluding remarks and future prospects
8.1 Summary
The main aim of this project was to improve existing theoretical models of topical photo-
dynamic therapy (PDT) to better understand different aspects of light propagation through
skin tissue during treatment. In a theoretical model, the accuracy of the outcome is highly
dependent on the accuracy of the input parameters. Therefore it is important to include em-
pirical data derived from the clinical environment and from experimental set-ups. The work
presented here highlights both the potential and limitations of adopting theoretical models.
This chapter provides a short summary of each analytic chapter and discusses the primary
results of the project in the context of future work.
8.1.1 Theoretical modelling of photodynamic therapy
Chapter 2 described the theory and details of the Mont Carlo radiation transfer (MCRT) model
developed for this project. In this chapter the code was both experimentally and theoretically
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validated prior to further investigation of PDT. The theoretical validation included reproduc-
tion of results generated from another MCRT model published in the literature [97]. The
model provides a flexible and robust technique where many different aspects of PDT can be
accurately represented. The main limitation is the requirement of knowledge of input para-
meters such as optical properties and photobleaching dynamics.
The code was then used in chapter 3 to simulate daylight PDT. This is the first known the-
oretical investigation of daylight PDT [127]. The depth dependent photo-toxicity for different
weather conditions was generated and compared to conventional PDT. The results support
the usage of daylight PDT for treating superficial skin lesions to a depth of over 2 mm. This
chapter also highlights the variability caused by different input parameters such as initial
distribution of the photosensitive molecule protoporphyrin IX (PpIX) and illumination angle.
This improves on knowledge of the treatment conditions during PDT and demonstrates the
importance of including accurate parameters. The code allows for these parameters to be
investigated in a way that is impossible in the clinical environment and demonstrates the
potential range in treatment depth associated with different treatment conditions.
To consider the different treatment protocols associated with daylight PDT and conven-
tional PDT, chapter 4 incorporated a model where the distribution of PpIX varies both spatially
and temporally. This allowed for the topical application of the pro-drug for different occlus-
ive treatment times to be considered, resulting in a more accurate representation of different
treatment modalities. The main challenge within this chapter was the allocation of appro-
priate PpIX production parameters. This was addressed by combining the model developed
in this chapter with the clinical data collected in chapter 7. The results in chapter 4 suggest
that treatment depth is not only limited by light penetration but also by the distribution and
accumulation of PpIX molecules. A more complex model would introduce further parameters
and would require detailed exploration of the production and accumulation of PpIX within
human tumour tissue to ensure an accurate representation.
As discussed above, the accuracy of the modelled outcome is dependent on appropriately
representing the skin tissue. Only when relevant optical properties are adopted within the
MCRT model, accurate and useful information about the light propagation and energy depos-
ition within the skin tissue can be generated. There is no such thing as a generic patient and
the literature shows a large variability in optical properties between individuals [112]. For
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this reason it is important to consider different patient characteristics to further individualise
treatment parameters. In chapter 5 a range of optical properties were discussed and explored.
This is the first known theoretical investigation of light penetration and treatment outcome
which compares different patient characteristics such as age and skin type. The results show
that older patients with a light complexion are associated with a deeper effective treatment.
Chapter 5 only considered two properties that cause variation in the optical properties. If the
data were available further development of this would include characteristics such as lesion
location, lesion type and patient gender. Most patients are treated twice, the second treatment
typically one week after the initial treatment. The histology of the skin and tumour tissue will
potentially change between these two treatment locations. By investigating this, further treat-
ment categorisation would be achieved and the importance of multiple treatments would be
explored.
In chapter 6, the three dimensional properties of the model were developed to include
non-homogeneous tumour tissue. This is believed to be the first theoretical investigation that
includes heterogeneous skin tissue when exploring PDT. By adopting artificial tumour struc-
tures, comparison with uniform tumour models was possible. Different degrees of heterogen-
eity were explored to investigate the effect that these three dimensional heterogeneities have
on the treatment outcome. The results show that heterogeneous tissue should be considered
within future models since this has an effect on the simulated treatment depth. The wide field
fluorescence light as a result of these heterogeneous tumour tissues was additionally simu-
lated. The results suggest that fluorescence light not only from the top layer of the tumour,
but also tumour tissue from lower layers contribute to the fluorescence signal exiting the sur-
face of the tumour. The fluorescence simulations also show large variations over sub-mm size
scales which could explain measurement variations experienced in chapter 7. Future work
would include real tumour structures and would compare different tumour types at different
growth stages. However the reason why this has not been done at this stage, is due to the
limitations in available data.
Chapters 2 - 6 describe code developments and implementations in different situations,
which have increased our understanding of light interaction with skin tissue for different
treatment conditions of PDT. However to further improve and develop the model to achieve
even more realistic and complex skin models additional issues must be considered. These
include blood vessels and real tumour structures as well as other tissue characteristics. When
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including finer structures within the simulation region an improved resolution is required.
This can be achieved by increasing the number of grid cells or introducing a mesh based
grid system. A mesh based grid system introduces a finer grid system only in regions where
increased resolution is required. This technique makes it easier to consider curved surfaces
[131] and allows details like surface roughness and small capillaries to be included in the skin
model. The drawback with this is the increase in simulation time although more advanced
computation techniques including parallelisation should mitigate these problems.
Oxygen depletion during PDT continues to be poorly understood. The level of oxygen
is reduced due to the production of singlet oxygen molecules; simultaneously new oxygen
is introduced to the tumour through vascularity. During the simulations presented in this
thesis the oxygen levels have not been considered and it has been assumed that the oxygen
availability has been unlimited. With a reduced oxygen availability, fewer singlet oxygen
molecules can be produced which consequently results in a reduced photodynamic effect
[69, 102, 222] and this will be important to consider in future developments of theoretical
simulations of PDT.
Oxygen levels and thermal effects change the optical properties as a result of light ex-
posure [223] resulting in changes in penetration and treatment depth. By including this in
the model, treatment conditions would be explored that could be utilised to further optimise
treatment parameters.
During daylight PDT, sunscreen is applied to exposed areas (including the tumour region).
This results in a spectral filter which blocks some harmful wavelengths [83]. The motivation
for not including this in the presented work is the small amount of overlap between the optical
filter provided by common sunscreen lotions and the daylight spectrum. However different
sunscreen lotions might block different wavelengths and therefore this should be considered
when developing future models for daylight PDT.
8.1.2 Clinical data collection
Through in vivo measurements increased knowledge about appropriate model parameters
can be achieved. In chapter 7 the build-up of PpIX was investigated by measuring the increase
of the fluorescence signal from the PpIX during the occlusive treatment phase within the
clinical environment. Since PpIX is associated with a characteristic fluorescence signal it is
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thought to be a good indication of the amount of PpIX present within the skin tissue. Both
Aktinic Keratosis (AK) and Basal Cell Carcinoma (BCC) lesions were studied and a total of
40 patients were included. The resulting data suggest that the fluorescence signal increases
linearly during the initial three hours of occlusive treatment. Different lesion characteristics
were compared and it was found that the fluorescence signal increased faster in lesions located
on the face compared to other locations. The data were associated with large variability which
can potentially be explained by the non-uniformity in the fluorescence signal over sub-mm size
scales which is demonstrated in chapter 6. It is believed that the level of curettage could affect
the resulting data and an additional study would be able to investigate this. By extending the
study to a different institute where the level of curettage is different the resulting trend of the
fluorescence signal could be compared and the affect caused by the level of curettage could
be explored.
8.2 Future prospects
The work that is presented in this thesis provides new knowledge about light interaction with
skin tissue. The developed code provides a flexible and robust technique of exploring light
penetration through a medium. There are aspects of PDT and especially daylight PDT which
can be further explored using the developed code. However there are also other areas where
the developed model can be applied by appropriately adjusting the simulation parameters.
Some of these future application will be discussed below.
8.2.1 Further investigation of PDT
As previously mentioned, the change in concentration of oxygen during treatment is some-
thing important to consider for further improvements. When this is considered it will be
possible to study fractionated PDT where the levels of oxygen is allowed to recover between
intervals of light treatment [69, 70]. By theoretically simulating fractionated PDT the aim
would be to investigate the potential and limitations of this treatment method further. This
would allow for comparison with other treatment modalities and exploration of optimal treat-
ment parameters during the fractionation. This includes the length of both the individual light
bursts as well as the length of the ’dark’ periods in-between bursts.
One of the main limitations of daylight PDT is the weather dependency. The number of
days when daylight PDT is possible, is both limited and hard to predict, especially in places
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in temperate and boreal latitudes. This results in difficulties in treatment planning and last-
minute cancellations of treatments. Patient choice in treatment is now recognised as import-
ant, and, in this respect, it should be noted that daylight PDT is generally the preferred choice
compared to conventional PDT [78]. However, patients who have made arrangements for
daylight PDT should not have to reschedule due to bad weather. For this reason it seems
reasonable to develop indoor facilitates where patients can be treated irrespective of outdoor
conditions all year round. By creating an environment which mimics daylight illumination
this could be achieved. This would require the exploration of the suitability of different light
sources and the arrangement of light within the room. The required total irradiance from
the light sources experienced by the lesion at different places within the room has to be con-
sidered. An environment where patients can move around freely and comfortably would be
the ideal situation, but to achieve this the light illumination across the allocated room has to
be considered. The MCRT model developed in this thesis can assist the comparison of different
light sources to establish the most appropriate light source to implement.
Further investigations of daylight PDT that could be considered include the possibility
of treating skin lesions through a glass window, for example in a conservatory. This would
eliminate the minimum temperature restriction and might improve the comfort of patients.
To achieve this, a glass layer and its associated parameters have to be included within the
model.
Additionally, daylight PDT for different locations around the world should be considered.
The irradiance of the daylight and the ratio between the direct and diffuse component will
change for different locations and this could be explored using the model by adjusting the
daylight spectra used to simulated daylight PDT.
The current photobleaching equation adopts a single exponential to estimate the pho-
tobleaching of PpIX during light illumination. However, recent work in our group suggests
that the photobleaching equation could be better represented by a double exponential. This is
motivated by a fast photobleaching during the initial illumination which subsequently slows
down. Depending on the ratio between the two different photobleaching constants, deeper
treatment than originally estimated could be achieved. The model has the potential to incor-
porate such changes in the photobleaching equation and also include investigations of altern-
ative photobleaching equations. However the limitations lie within the available supporting
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data required for efficient representation of the process.
8.2.2 Areas where MCRT can be adopted for light based treatments
Even though MCRT modelling has proven to be a useful tool for investigations of PDT, it is
not the only area of research where it can be adopted. Other light based therapies such as
port wine stains, acne treatment, hair removal and tattoo removal can adopt this simulation
technique to further explore the interaction between skin tissue and light. Even thought
many of these research areas have already adopted MCRT modelling [123, 224, 225] further
development can be made by incorporating techniques discussed in this thesis.
PDT and photodiagnosis is not only adopted for topical applications of skin tissue. It has
also been proven to be a useful tool in other areas of medicine such as brain tumours [226]
and disorders in the urinary tracts [227]. In brain tumours the selective accumulation of PpIX
within brain tumours tissue can be used to assist the surgery. The fluorescence signal produced
by the PpIX allows for tumour segments to be identified that would otherwise easily be missed.
PDT can also be adopted to selectively treat small tumour segments which are otherwise
difficult to remove using surgery [228,229]. MCRT modelling would assist the development
of these treatment regimes since it is important to understand the penetration of light through
the tissue during both the photodiagnosis and PDT. Determining where the fluorescence light
comes from and the possible treatment depth would allow further exploration of the potential
role that light could take during surgery. To accurately simulate this, both optical properties
and tissue structures have to be established.
8.2.3 Further experimental and clinical explorations
Accurate input parameters are based on experimentally and clinically determined data. One of
the main limitations throughout this thesis has been to determine appropriate tissue paramet-
ers. Further determination of in vivo optical properties of different tissue types is required to
extend and improve the existing models. For example, to be able to compare different tumour
types, the optical properties of these have to be determined over the required wavelength
range.
In a similar way to methods described in chapter 7 it is common to use fluorescence meas-
urements to monitor treatment progress. PpIX fluorescence is most commonly measured as a
result of excitation using blue light. Since the characteristic red fluorescence light is spectrally
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very different from the illuminating blue light source it is easy to develop optical instruments
for this situation. One limitation with using this approach is the shallow penetrated depth
associated with blue light. This has the consequence of only fluorescence light from the most
superficial layers being recorded. An alternative approach would be to adopt a red light source
which would achieve deeper penetration. With appropriate filters to block out the excitation
wavelengths, it would be possible to record fluorescence light from deeper situated tissue
segments. It would also be of interest to explore the wide field fluorescence properties to
investigate the distribution of fluorescence light across the tumour tissue [230].
8.3 Conclusion
Even though PDT is widely used for treating NMSC, there are still treatment parameters that
are not yet optimised. This thesis has focused on theoretical simulations of PDT using MCRT
modelling in an attempt to further explore different treatment parameters. By exploring dif-
ferent treatment conditions knowledge about light interaction with skin tissue during PDT
has increased. This thesis has also explored daylight as an alternative light source for treating
superficial skin lesions, the temporal and spatial dependence of PpIX production as well as
different tissue structures. The main issue with theoretical simulation of skin tissue is that
there is no such thing as a generic or average patient. Tumour and skin properties will vary
between people which makes standardising treatment protocols difficult. For this reason the
future focuses should lie in individualising treatments according to patient characteristics. By
combining theoretical simulations with data from the clinical environment further improve-
ment and developments can be made to achieve better treatment outcomes for individual
patients.
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Appendix: Monte Carlo radiation transfer
modelling, code set-up and validation
A.1 Path length summation
To improve the signal to noise ratio, a path length summation approximation was adopted.
This was first introduced by Lucy in 1999 [141]. The two quantities in section 2.4.1 that were
considered, fluence rate and absorption rate are described in further detail here.
A.1.1 Absorption rate
The absorption rate is defined as the amount of energy absorbed per cubic centimetre per
unit time. Instead of counting each individual absorption event, the energy from each photon
multiplied by the probability of being absorbed within a grid cell is considered. This way,
the contribution from photons that do not interact within a grid cell is still considered. This
therefore results in an improved signal to noise. Hence for each grid cell the energy from a
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single photon packet can be expressed by,
Eprop = Eiµal (A.1)
Where Ei is the energy of a single photon packet, µa is the absorption coefficient within
the grid cell and l is the distance travelled within the grid cell. The absorption coefficient
corresponds to the probability of a photon being absorbed, and µal is therefore the probability
of a photon being absorbed over the travelled distance l. Hence, Eprop is the proportion of
energy from that energy packet which contribute to the total absorbed energy within that
grid cell. By dividing by the voxel volume,  V and the total time of the illumination  t and
summing for all photon contributions within the grid cell, the energy absorption rate per cubic
centimetre is determined,
Q =
Ei
 V t
X
i
µal =
IA
N V
X
i
µal (A.2)
Here the sum,
P
i corresponds to the summation of all contribution within the grid cell. A
corresponds to the illumination region and I corresponds to the irradiance or the light source.
The calculation is performed for all the grid cell in the simulated region.
A.1.2 Fluence rate
The fluence rate is defined as the energy flow per unit area per unit time regardless of the flow
direction. The energy density ue (J cm 3) is defined as the optical energy per unit volume and
is obtained by,
ue =
 
c
(A.3)
Where c is the speed of light in the medium. To determine the energy volume density the
following steps can be applied. The time each photon packet spends within each grid cell is
defined as  t = l/c, where l is the propagating distance within the grid cell. From this the
energy contribution from the energy to the grid cell is,
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Econtr = Ei
 t
 t
=
Ei
 t
l
c
(A.4)
Where Ei is the energy of a photon packet. If the contributions from all the photo packets
propagating through the grid cell, the energy volume density is obtained,
ue =
P
i Econtr
 V
=
P
i Eil
 t V c
=
IA t
N
1
 t V c
X
i
l =
IA
 VNc
X
i
l (A.5)
Hence the fluence rate can be expressed using the following path length summation
 =
IA
 VN
X
i
l (A.6)
The absorption rate is defined as the absorbed energy from the propagating photons and
can therefore be expressed as Q= µa , which is clear from equation A.2 and A.6.
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Appendix: Theoretical determination of
continuous protoporphyrin IX production
The toxicity, concentration profile and fluorescence signal for sets 1-8 in table 4.2 were gener-
ated using the MCRT model developed in chapter 4. Different weather conditions (clear and
overcast) during daylight PDT as well as conventional PDT, where the Aktilite was simulated,
were compared. The motivation for exploring all the sets of parameters suggested in table 4.2
was to determine the effect that the different parameters had on the concentration, toxicity
as well as fluorescence signal during the incubation time. The graphical representation of
the different sets for the toxicity/photodynamic dose (PDD) as well as the fluorescence is dis-
played in this appendix. From the results, a discussion of the effect the different parameters
had on the treatment depths and fluorescence was carried out and summarised in table 4.3 in
chapter 4.
As a comparison the PDD (figure B.1) as well as the fluorescence (figure B.2) for set 1
(table 4.2) are displayed in the appendix as well as in chapter 4.
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The second set of parameters (set 2, table 4.2) were taken from the literature [181])
although argued to not be reasonable due to the short clearance rate. However this set of
parameters, shown in figure B.3, generated treatment depths similar to that of the first set
of parameters. Even though the clearance rate is fast, the initial concentration was high and
the conversion rate from MAL to PpIX was slow. From equation 4.8, this generated a PpIX
distribution that is similar to the one suggested by the initial set of parameters. The results are
displayed in figure 4.4. However it is important to also consider the relevance of the values of
the parameters. Since the PpIX distribution was comparable the evolution of the fluorescence
signal with time during the incubation period was also comparable and displayed in figure
B.4, which also shows similar trend as set 1.
For the third set of parameters, the parameter A was reduced compared to the initial set.
This is equivalent to a reduced initial concentration, a reduced yield or a slower conversion
rate from MAL to PpIX. This resulted in a lower concentration of PpIX and due to the nature
of equation 4.9 has the same shape as set 1, however with a lower absolute value. Under-
standably this also resulted in more shallow light penetration, as shown in figure B.5. Due
to the lower distribution of PpIX the fluorescence signal gradually increased in a more linear
fashion, displayed in figure B.6, compared to sets 1 and 2. When adopting set 4, parameter A
was instead increased which resulted in a higher PpIX concentration where the PpIX reached
into deeper levels. Consequently this resulted in deeper treatment depths, indicated in figure
B.7. The fluorescence signal resulted in an instantaneous increase in strength, where this level
was then maintained throughout the following 170 min. Hence even though the distribution
of PpIX builds up within the tissue, only the fluorescence signal from superficial layers will be
detected through the surface observations. When the relaxation time determining the rate at
which PpIX was cleared from the tissue ( ⌧p) was increased and reduced by a factor of 100,
there was not a significant change of the fluorescence signal indicated in figures B.10 and
B.12, from the model however there was a larger difference in treatment depth as demon-
strated in figure B.9 and B.11. The concentration profile for these two sets of parameters
are illustrated in figure 4.4 and indicates a large difference in PpIX distribution, which is not
carried through to the fluorescence signal. However when the relaxation time was reduced
even further (set B2, table 4.4) the fluorescence signal displayed a more linear trend (figure
4.12).
When the diffusivity was reduced or alternatively increased the distribution of PpIX was
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reduced and increased accordingly. A higher diffusion coefficient allows the prodrug to dif-
fuse quicker into the skin. Following previous arguments this resulted in a fast increase of
the fluorescence signal due to the high concentration of PpIX at superficial layers seen in
figure B.14. The opposite effect occurred when the diffusivity was lower which resulted in
a significantly different change in fluorescence signal with time, as demonstrated in figure
B.16. Similarly set B1 hosts a low diffusion coefficient and therefore also resulted in a linear
increase in the fluorescence signal (figure 4.11).
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Figure B.1: Figure showing the PDD for set 1 of the parameters in table 4.2 where A =
3.47⇥ 1015 m 3 s 1, ⌧p = 4680s and D = 0.69⇥ 10 10 m2 s 1.
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Figure B.2: Figure showing how the fluorescence signal changes with time during the oc-
clusive treatment phase. This figure corresponds to set 2 of the parameters in table 4.2
where A = 3.47⇥ 1015 m 3 s 1, ⌧p = 4680s and D = 0.69⇥ 10 10 m2 s 1. The linear
line (black) corresponds to the trend determined from the clinical data in chapter 6 and the
fluorescence signal for set 3 (red) is compared to the fluorescence signal for set 1 (dashed).
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Figure B.3: Figure showing the PDD for set 2 of the parameters in table 4.2 where A =
3.47⇥ 1015 m 3 s 1, ⌧p = 84ms and D = 0.69⇥ 10 10 m2 s 1.
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Figure B.4: Figure showing how the fluorescence signal changes with time during the oc-
clusive treatment phase. This figure corresponds to set 2 of the parameters in table 4.2
where A = 3.47⇥ 1015 m 3 s 1, ⌧p = 84ms and D = 0.69⇥ 10 10 m2 s 1. The linear
line (black) corresponds to the trend determined from the clinical data in chapter 6 and the
fluorescence signal for set 3 (red) is compared to the fluorescence signal for set 1 (dashed).
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Figure B.5: Figure showing the PDD for set 3 of the parameters in table 4.2 where A =
3.47⇥ 1010 m 3 s 1, ⌧p = 4680s and D = 0.69⇥ 10 10 m2 s 1.
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Figure B.6: Figure showing how the fluorescence signal changes with time during the oc-
clusive treatment phase. This figure corresponds to set 3 of the parameters in table 4.2
where A = 3.47⇥ 1010 m 3 s 1, ⌧p = 4680s and D = 0.69⇥ 10 10 m2 s 1. The linear
line (black) corresponds to the trend determined from the clinical data in chapter 6 and the
fluorescence signal for set 3 (red) is compared to the fluorescence signal for set 1 (dashed).
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Figure B.7: Figure showing the PDD for set 4 of the parameters in table 4.2 where A =
3.47⇥ 1014 m 3 s 1, ⌧p = 4680s and D = 0.69⇥ 10 10 m2 s 1.
Clinical result
Theoretical result
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Figure B.8: Figure showing how the fluorescence signal changes with time during the oc-
clusive treatment phase. This figure corresponds to set 4 of the parameters in table 4.2
where A = 3.47⇥ 1014 m 3 s 1, ⌧p = 4680s and D = 0.69⇥ 10 10 m2 s 1. The linear
line (black) corresponds to the trend determined from the clinical data in chapter 6 and the
fluorescence signal for set 4 (red) is compared to the fluorescence signal for set 1 (dashed).
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Figure B.9: Figure showing the PDD for set 5 of the parameters in table 4.2 where A =
3.47⇥ 1012 m 3 s 1, ⌧p = 46.80 s and D = 0.69⇥ 10 10 m2 s 1.
Clinical result
Theoretical result
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Figure B.10: Figure showing how the fluorescence signal changes with time during the
occlusive treatment phase. This figure corresponds to set 5 of the parameters in table 4.2
where A = 3.47⇥ 1012 m 3 s 1, ⌧p = 46.80 s and D = 0.69⇥ 10 10 m2 s 1. The linear
line (black) corresponds to the trend determined from the clinical data in chapter 6 and the
fluorescence signal for set 5 (red) is compared to the fluorescence signal for set 1 (dashed).
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Figure B.11: Figure showing the PDD for set 6 of the parameters in table 4.2 where A =
3.47⇥ 1012 m 3 s 1, ⌧p = 468000s and D = 0.69⇥ 10 10 m2 s 1.
Clinical result
Theoretical result
Set 1
0 50 100 150
Time [min]
0.0
0.2
0.4
0.6
0.8
1.0
No
rm
ali
se
d 
Fl
uo
re
sc
en
ce
Figure B.12: Figure showing how the fluorescence signal changes with time during the
occlusive treatment phase. This figure corresponds to set 6 of the parameters in table 4.2
where A = 3.47⇥ 1012 m 3 s 1, ⌧p = 468000s and D = 0.69⇥ 10 10 m2 s 1. The linear
line (black) corresponds to the trend determined from the clinical data in chapter 6 and the
fluorescence signal for set 6 (red) is compared to the fluorescence signal for set 1 (dashed).
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Figure B.13: Figure showing the PDD for set 7 of the parameters in table 4.2 where A =
3.47⇥ 1012 m 3 s 1, ⌧p = 4680s and D = 1⇥ 10 12 m2 s 1.
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Figure B.14: Figure showing how the fluorescence signal changes with time during the
occlusive treatment phase. This figure corresponds to set 7 of the parameters in table 4.2
where A = 3.47⇥ 1012 m 3 s 1, ⌧p = 4680s and D = 1⇥ 10 12 m2 s 1. The linear line
(black) corresponds to the trend determined from the clinical data in chapter 6 and the
fluorescence signal for set 7 (red) is compared to the fluorescence signal for set 1 (dashed).
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Figure B.15: Figure showing the PDD for set 8 of the parameters in table 4.2 where A =
3.47⇥ 1012 m 3 s 1, ⌧p = 4680s and D = 1⇥ 10 8 m2 s 1.
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Figure B.16: Figure showing how the fluorescence signal changes with time during the
occlusive treatment phase. This figure corresponds to set 8 of the parameters in table 4.2
where A = 3.47⇥ 1012 m 3 s 1, ⌧p = 4680s and D = 1⇥ 10 8 m2 s 1. The linear line
(black) corresponds to the trend determined from the clinical data in chapter 6 and the
fluorescence signal for set 8 (red) is compared to the fluorescence signal for set 1 (dashed).
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C
Appendix: Light distribution modelling of skin
ageing and different skin types
The absorption properties for the epidermal layers not shown in chapter 5 are shown in figure
C.1. The absorption properties for skin type II, IV and V are graphically represented for ages
30, 55 and 80 years.
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Figure C.1: Figure showing the optical properties adopted in the MCRT model to represent
different ages and skin types. The absorption properties for the epidermal layers are shown
in the figure for three different skin types: II(black), IV (red) and V(blue) for three different
ages a) 30 years, b) 55 years and c) 80 years.
Figure C.2 shows the normalised fluence rate for two different ages for skin types II, IV
and V. The normalised fluence rate is defined as the fluence rate divided by the irradiance
of the incident light. Three different wavelengths were simulated using the Monte Carlo
radiation transfer (MCRT) code developed and described in chapter 5. The wavelengths that
were simulated were 405 nm, 540 nm and 630 nm.
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Figure C.2: Figure showing normalised fluence rate as a function of depth for different ages
and skin types. Each figure demonstrates fluence rate for a certain age and skin type where
three different wavelengths were investigated: 405 nm (blue), 540 nm (green) and 630 nm
(red). The figures each correspond to the fluence rate for a) skin type II, age 30, b) skin type
IV, age 30 c) skin type V age 30 d) skin type I, age 80, e) skin type IV, age 30 and d) skin
type V age 80.
Figure C.3 shows the photodynamic dose (PDD) for three different light conditions, day-
light (clear conditions), daylight (overcast conditions) as well as the Aktilite. Where the
figure shows the results generated after a total delivered light dose of 75 J cm 2. The total
irradiance for the different light sources were assumed to be: dayligth, clear: 41 mW/, cm2,
daylight, overcast: 8 mWcm 2 and the Aktilite: 82 mWcm 2. Hence the same light dose
corresponds to different treatment times. Figure C.3 shows the PDD for three different ages
(30, 55 and 80 years) for three different skin types (II, IV and V). The results supports the
results found in chapter 5, where the treatment depth increases with age but reduces with
skin type classification number.
197
Appendix C. Appendix: Light distribution modelling of skin ageing and different skin types
AktiliteDaylight (clear)Daylight (overcast)
0 1 2 3 4 5
Depth [mm]
0.1
1.0
10.0
Ph
ot
od
yn
am
ic 
Do
se
 [1
01
8  p
ho
to
ns
/cm
3 ]
0 1 2 3 4 5
Depth [mm]
0.1
1.0
10.0
Ph
ot
od
yn
am
ic 
Do
se
 [1
01
8  p
ho
to
ns
/cm
3 ]
0 1 2 3 4 5
Depth [mm]
0.1
1.0
10.0
Ph
ot
od
yn
am
ic 
Do
se
 [1
01
8  p
ho
to
ns
/cm
3 ]
0 1 2 3 4 5
Depth [mm]
0.1
1.0
10.0
Ph
ot
od
yn
am
ic 
Do
se
 [1
01
8  p
ho
to
ns
/cm
3 ]
0 1 2 3 4 5
Depth [mm]
0.1
1.0
10.0
Ph
ot
od
yn
am
ic 
Do
se
 [1
01
8  p
ho
to
ns
/cm
3 ]
0 1 2 3 4 5
Depth [mm]
0.1
1.0
10.0
Ph
ot
od
yn
am
ic 
Do
se
 [1
01
8  p
ho
to
ns
/cm
3 ]
0 1 2 3 4 5
Depth [mm]
0.1
1.0
10.0
Ph
ot
od
yn
am
ic 
Do
se
 [1
01
8  p
ho
to
ns
/cm
3 ]
0 1 2 3 4 5
Depth [mm]
0.1
1.0
10.0
Ph
ot
od
yn
am
ic 
Do
se
 [1
01
8  p
ho
to
ns
/cm
3 ]
0 1 2 3 4 5
Depth [mm]
0.1
1.0
10.0
Ph
ot
od
yn
am
ic 
Do
se
 [1
01
8  p
ho
to
ns
/cm
3 ]
a b c
d e f
g h i
Skin type I
Skin type III
Skin type VI
Age 30 Age 55 Age 80
Figure C.3: Photodynamic dose corresponding to 75 Jcm 2 for the different light sources
at age 30, 55 and 80 and for skin types II, IV and V. Three light sources were compered:
daylight for clear conditions (black), daylight during overcast (blue) and the artificial light
source, Aktilite (red). The results show the change in effective penetration depth with age
and skin type. The horizontal line corresponds to the adopted toxic threshold, which is the
same threshold adopted in previous chapters. The different figures correspond to: a) skin
type II, age 30, b) skin type II, age 55 , c) skin type II, age 80, d) skin ape IV, age 30, e) skin
type IV, age 55, f) skin type IV, age 80, g) skin type V, age 30, h) skin type V, age 55 and
i)skin type V, age 80.
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E
Appendix: A quantitative study of in vivo
protoporphyrin IX fluorescence build up during
occlusive treatment phases: individual patient
measurements
The data collected in the clinical study presented in chapter 7 for each individual patient is
shown below (during the first session). The measurements have been corrected for by the
autofluorescence from each individual patient and the line through the data corresponds to
the mean of the repeated data points. Each individual plot corresponds to a single patient
where the different data points corresponds to the repeated measurements for that patient.
The plotted line corresponds a line that is drawn through the average fluorescence signal
at each time point which is measured, for each patient. The overall analysis of the data is
described and presented in chapter 7.
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F
Appendix: A quantitative study of in vivo
protoporphyrin IX fluorescence build-up during
occlusive treatment phases: pain during
treatment
During the light treatment the pain experienced by individual subjects was recorded. In this
section the pain was compared to different patient characteristics such as gender, age and
lesion location. The pain was also compared to the fluorescence signal measured during
the study presented in chapter 6. It was found that male patients experiences a statistically
significant higher level of pain and lesions located on the face also showed a higher level of
experienced pain compared to other lesion locations.
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F.1 Method
After the three hour long occlusive treatment discussed in chapter 6, the lesions included
within the study were exposed to a light source for 20 min. During this light treatment, the
pain score was recorded every 3 min. The patients were asked to state the level of experienced
pain on a scale of 0 - 10, where 10 was the highest imaginable pain and 0 was no experienced
pain. The question of pain experienced was repeated every 3 min during the full treatment.
In this analysis only the patients with pain scoring were adopted and only people treated
with the standard 20 min irradiation was included. 26 recordings for treatment session 1 and
39 recordings for treatment session 2 were included in the study. The average pain scoring
during the treatment was compared for size of the lesion, age of the patient, gender of the
patient, location of the lesion, session as well as the fluorescence signal after 3 hours of
occlusive treatment.
The statistical analysis that was adopted was independent Student’s t-test as well as simple
linear regression. The aim was to only compare different groups of patients to investigate the
effect that different characteristics had on the level of experienced pain.
F.2 Results
The pain experienced during the first and the second session was compared where the record-
ings from the same individual was assumed to be independent. This analysis showed that
there was no significant difference in the mean recorded pain during the irradiation. Figure
F.1 shows a box plot of the average recorded pain score for session one and two demonstrating
the insignificance between the different sessions.
The size of the lesion was recorded prior to the cream application. The average recorded
pain score in relation to the size (diameter) of the lesion is shown in figure F.2.
The patients included in the study presented here were between 43 and 92 years old. The
average age was 68 (±11) years with a median age of 72 years. No relationship was found
between the age of the patients and the level of pain experienced.
The relationship between pain and the fluorescence signal after 180 min of occlusive treat-
ment was explored. Figure F.3 shows the fluorescence signal vs. recorded pain, and no signi-
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ficant relationship was found between the two variables.
When the gender was investigated a significant difference in experienced pain was recor-
ded where the females recorded a significantly lower pain score (p < 0.05). This is displayed
in the box plot in figure F.4.
It was found from the analysis that lesions located on the face was experienced to be
significantly (p <0.05) more painful compared to the lesions located on other body sites. The
plot displaying the distribution in the different categories are shown in in figure F.5.
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Figure F.1: Figure showing box plot of the average recorded pain ( 0 - 10) during the first
and the second treatment session. The different treatment sessions were most commonly
spaced 7 days apart. the number of observations for session one was 26 and for session two,
38. No significant difference was found between the two groups of observations (p >0.05)
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Figure F.2: Figure showing box plot of the average recorded pain (0 - 10) for different sizes
of the lesion. No relationship was found between the two parameters.
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Figure F.3: Figure shown the scatterplot of the fluorescence signal prior to the light irra-
diance and the corresponding average recorded pain score. No significant relationship was
found between the signal and the experienced pain.
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Figure F.4: Boxplot of the experienced pain for males and females. It was found that males
reports a significantly higher experienced pain score (p < 0.05) compared to the females
where 18 male observations (both sessions) and 44 female observations (both sessions) were
included within the analysis.
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Figure F.5: Boxplot of the experienced pain for different lesion locations. The only significant
body location was lesions located on the face, which was found to be associated with a higher
experience pain compared to other lesion locations.
F.3 Discussion
Pain is a big disadvantage of (conventional) PDT where some patients find the treatment
extremely painful [231].This chapter discusses the level of pain experienced by the patients
included within the study presented in chapter 7. The only significant difference was found
between different genders and locations of the lesion. The model does not combine the dif-
ferent explored parameters, but looks at each aspect individually.
It has previously been found that pain is both size and gender dependent while no effect
has been suggested for skin type (table 5.2) or dose. Different published results indicate
different levels of significance between the pain and the fluorescence intensity [79,152,231].
In agreement with previous publication the lesions on the face region was found here to be
associated with a higher level of pain. The gender dependency found in this work also agrees
with previous findings. However no significance was found between the level of fluorescence
intensity prior to the illumination (after 3 hours of occlusive treatment).
Pain is a difficult quantity to measure since the experienced pain will significantly vary
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between individuals and can be subjective. This should always be considered when comparing
the pain experienced between different patients. Even so, it is important to investigate pain,
since an ideal treatment method would be associated with lower pain levels or no pain at all.
Methods that have been associated with lower experienced pain is daylight PDT or ambulatory
PDT [76,77,80].
F.4 Conclusion
The work presented here compares the pain experienced during PDT treatment for the pa-
tients included in the clinical study presented in chapter 7. It was found that the highest
level of pain was associated with lesions on the face, where male patients overall experienced
higher levels of pain, supporting previously published results. Other parameters such as skin
type, lesion size and fluorescence intensity did not indicate a correlation with the experienced
level of pain.
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